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Immunoglobulin G (IgG) antibodies represent important analytical targets both 
for their therapeutic properties and for their critical role in the adaptive immune response. 
While much of the primary structure is conserved across the IgG class, subtle changes in 
amino acid sequence and the presence or absence of post-translational modifications can 
have a profound effect on the function and therapeutic potential of a given antibody. As 
such, there remains a high demand for versatile analytical tools capable of both 
identification and complete structural characterization of IgGs. The work presented in 
this dissertation largely focuses on the development of mass spectrometry-based methods 
for the improved analysis of antibodies. This was accomplished using strategic enzymatic 
Brodbeltselectivity for regions of particular diagnostic value or to facilitate 
comprehensive structural characterization.  
A method based on chromophore-mediated 351 nm UVPD was developed as a 
means to streamline the identification of antibodies in mixtures by enhancing selectively 
for the third complementarity determining region of the IgG heavy chain (CDR-H3). The 
hypervariable sequences within this region serve as the primary determinant of antigen 
binding specificity and thus provide a molecular signature by which to differentiate 
 viii 
unique antibodies. To accomplish this, a highly conserved cysteine residue located in the 
framework preceding the CDR-H3 region was exploited for selective tagging with an 
Alexa Fluor 350 (AF350) thiol-selective maleimide. This site-specific tagging combined 
with strategic enzymatic digestion and 351 nm UVPD allowed selective dissociation of 
only AF350-labeled peptides for facile discrimination of CDR-H3 sequences within a 
high-throughput liquid chromatography-tandem mass spectrometry (LC-MS/MS) based 
workflow. 
Two variations of middle-down mass spectrometry based on either restricted Lys-
C proteolysis or hinge-selective IdeS digestion combined with 193 nm UVPD were used 
for the characterization of monoclonal antibodies. Both strategies yielded considerably 
greater diagnostic sequence information when benchmarked against conventional 
collision- and electron-based activation methods. The Lys-C proteolysis method was 
found to have considerable implications for the analysis of serological antibody 
repertoires owing to its facile implementation into high-throughput proteomic workflows 
and ability to unambiguously differentiate unique CDR-H3 sequences. 
The development and implementation of a front-end dual spray reactor for high-
throughput ion/ion-mediated bioconjugation is demonstrated for the enhanced structural 
characterization of unmodified and post-translationally modified peptide cations by 193 
nm UVPD and CID. The ability to generate ion/ion complexes in real-time followed by 
efficient covalent conversion allowed integration of the dual spray reactor into a high-
throughput LC-MSn workflow for rapid derivatization of peptide mixtures.   
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Chapter 1  
Introduction 
 
1.1  MOTIVATION AND SCOPE OF RESEARCH  
Antibodies, whether generated through an immune response or administered 
therapeutically, function to selectively engage a specific target (antigen) and initiate 
critical effector mechanisms that confer protective immunity to a host. Monoclonal 
antibodies (mAbs) have emerged as one of the most effective and rapidly advancing 
therapeutic modalities used for the treatment of oncogenic, infectious and autoimmune 
disease. The success of mAb-based biologics arises from their high specificity, favorable 
pharmacokinetics, and targeted modes of action;1,2 however, these properties rely 
critically on antibody structural integrity, both in terms of sequence composition and 
post-translational modifications (PTMs).3,4 Despite tremendous inroads in manufacturing 
and engineering technologies, large scale bioproduction results in heterogeneous 
molecular compositions that require comprehensive characterization to ensure therapeutic 
safety and efficacy.5,6 Alternatively, methods that enable facile differentiation of unique 
antibodies in highly diverse serum repertoires remain critical for the evolving field of 
immunoproteomics, which seeks to understand and therapeutically leverage antibody-
mediated immunity at the protein level.7 This objective has be aided by recent 
developments in next-generation sequencing of immunoglobulin genes (Ig-seq) combined 
with high-throughput bottom-up mass spectrometry (MS) to identify antibodies elicited 
during an immune response at functionally relevant concentrations.8,9 Despite these 
advances, a number of analytical challenges arising from the intrinsic features of 
antibodies, such as their high degree of sequence homology, limit the utility of 
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conventional bottom-up MS approaches for highly complex antibody mixtures and 
greatly complicate subsequent bioinformatic interpretation.10  
The work presented in this dissertation focuses on the development of bottom-up 
and middle-down mass spectrometric methods for the analysis of antibodies using 
variations of ultraviolet photodissociation (UVPD). Herein, UVPD is advanced as a 
powerful analytical tool for the comprehensive structural characterization of therapeutic 
monoclonal antibodies. Furthermore, the utility of combining UVPD and strategic 
enzymatic digestion is demonstrated for the unambiguous identification of unique 
antibodies via improved coverage of peptides derived from their diagnostic antigen-
binding domains. While not directly applied to highly complex immunoproteomic 
mixtures at the current stage of development, the latter proof-of-principle studies provide 
a strong justification for integrating UVPD into future MS based antibody repertoire 
analyses.  
  
1.2  IMMUNITY AND THE PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODIES 
The mammalian immune system employs two primary defense mechanisms, the 
innate and adaptive response, that act in concert to detect, neutralize and clear foreign 
pathogens.11 The innate system serves as the first line of defense and mounts a rapid, but 
non-specific response that broadly recognizes a conserved set of Pathogen-Associated 
Molecular Patterns (PAMPs) that are distinct from those expressed by host cells.12,13 
These molecules include bacterial lipopolysaccharides (LPS) and lipopeptides, as well as 
viral strands of RNA and DNA.12,13 Once cells of the innate system recognize pathogen 
invasion, signaling cascades occur that stimulate pro-inflammatory responses, cell-death, 
and antigen presentation.14 The latter is responsible for initiating the highly specific 
adaptive immune response. 
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The adaptive immune system is further divided into a T cell-mediated cellular 
component and a B cell-mediated humoral component.11,15 T cells and B cells each 
possesses specific receptors (TCRs and BCRs, respectively) that are unique to each 
clonal population and confer antigen specificity as a result of genetic rearrangements of 
receptor genes that occur during individual cell development.15 In B cells, these receptors 
are membrane-bound immunoglobulins (Ig) that serve as the precursors to secreted 
antibodies.16  
During B cell development, Ig variable (V), diversity (D) and joining (J) germline 
gene segments undergo somatic V(D)J recombination to form the BRCs expressed on 
naïve, or pre-antigen stimulated B cells.8,15 Following antigen exposure, naive B cells 
displaying antigen-recognizing BCRs become activated and undergo clonal expansion 
and somatic hypermutation within their variable Ig domains to fine-tune antigen 
specificity in a process referred to as affinity maturation.8,15 Mature antigen-specific B 
cells subsequently undergo differentiation into long-lived memory B cells that mount a 
rapid protective response upon re-exposure to the cognate antigen,17,18 or into antibody-
secreting plasma cells.8,19 The resulting antigen-specific antibodies released into plasma 
and extracellular fluids confer protection against cognate antigen through three effector 
mechanisms: neutralization, opsonization, and complement activation.20 Neutralization 
occurs through direct antibody-binding to epitopes of the pathogen to effectively block 
access to host cells.20 Alternatively, during opsonization antibodies recruit effector cells 
to the bound pathogen to initiate functions including antibody-dependent cell-mediated 
cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP).21,22 
Finally, complement activation occurs when antigen-bound antibodies interact with 
complement protein C1, which in turn activates the complement cascade that ultimately 
results in the pathogen surface being coated with complement defense proteins that mark 
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it for destruction via phagocytosis in a process referred to as complement-dependent 
cytotoxicity (CDC).23,24  
 
1.3 ANTIBODY STRUCTURE AND FUNCTION 
Secreted immunoglobulins, or antibodies, are composed of two identical heavy 
chain and two identical light chain polypeptides that form a characteristic “Y” shaped 
protein structure that is held together by a series of intra- and intermolecular disulfide 
bonds.25 Each component chain is further divided into N-terminal variable (VH and VL) 
regions that are responsible for antigen recognition and C-terminal constant (CH and CL) 
regions that interact with effectors cells. Human antibodies are divided into five classes, 
or isotypes: IgA, IgD, IgE, IgG and IgM, which are distinguished by the structure of their 
constant regions (α, δ, ε, γ, and μ, respectively) and ultimately their functional role within 
the immune response.25,20 Among these, IgG is the predominant isotype produced during 
B cell activation and constitutes approximately 75% of total serum antibodies in 
circulation.25 Moreover, IgG is further divided into four subclasses, IgG1, IgG2, IgG3, 
and IgG4, that vary slightly in amino acid composition (although they remain >95% 
homologous), as well as inter-chain disulfide number and connectivity. These structural 
differences ultimately determine which effector mechanisms are activated, as well as the 
stability of each IgG subclass. Consequently, the relative abundance, high antigen-
specificity, and critical role in nearly all effector mechanisms employed during adaptive 
immunity make IgG the critical target for mass spectrometry-based analysis of antigen-
specific antibody repertoires,26–29 and currently the only antibody isotype used 
therapeutically. As such, the remainder of the discussion presented herein will focus on 
IgG. 
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Figure 1.1 The immunoglobulin G (IgG) structure is composed of two identical light 
chains (orange) and two identical heavy chains (blue) that are further 
divided into variable (V) and constant (C) regions. The variable regions of 
each chain contain hypervariable complementarity determining regions 
(shown in green and purple for the heavy and light chains, respectively). 
The molecule possesses two functional domains: the antigen-binding 
fragment (Fab) and the glycosylated crystallizable fragment (Fc).  
 
As demonstrated in Figure 1.1, the heavy chains of IgG contain one variable 
region (VH) and three constant regions (CH, CH2 and CH3), whereas the light chains contain 
one variable (VL) and one constant (CL) region. The IgG monomer is divided into 
functional units consisting of two identical fragment antigen-binding (Fab) domains and a 
single glycosylated fragment crystallizable (Fc) domain, which are responsible for 
antigen binding and initiation of effector mechanisms, respectively. The variable regions 
of the Fab contain V, D, and J germline gene segments, which undergo V(D)J 
recombination in addition to somatic hypermutation,30 as previously discussed within the 
context of B cell development. Importantly, the human genome encodes for many V, D, 
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and J gene segments that can recombined, in theory, to form an incredible number (>1013) 
of clonally unique antibodies.20,31 The light chain CDR-L3 is formed in a similar manner, 
with the exception that only V and J gene segments undergo recombination, thereby 
significantly limiting its diversity relative to CDR-H3.30 Conversely, the CDR1 and 
CDR2 loops of each chain are encoded within the VH and VL gene segments and therefore 
exhibit lower sequence diversity compared to CDRs formed through genetic 
recombination. However, somatic hypermutation within these regions affords a 
mechanism by which antigen specificity is fine-tuned through various sequence 
mutations.20 
 Whereas the variable Fab domain facilitates antigen recognition, the glycosylated 
Fc domain, composed of the CH2 and CH3 constant regions, provides a direct link between 
the adaptive and innate immune systems, as well as the humoral and cellular components 
of the adaptive immune response.22 This is mediated by interactions with either Fc 
gamma receptors (FcγR) expressed on the surface of innate immune effector cells that 
initiate critical pathogen clearance mechanisms, or with complement protein C1q to 
initiate the complement pathway. These binding interactions are critically dependent on 
both the presence and composition of a highly conserved N-linked glycosylation site at 
asparagine-297 (Asn297) within the CH2 constant region.22         
  
1.4  THERAPEUTIC ANTIBODIES 
Over the past three decades monoclonal antibodies (mAb) have emerged as one of 
the fastest growing classes of therapeutic modalities within the biopharmaceutical 
industry. Currently, there are approximately 50 mAb-based products approved in the 
United State and European Union (EU), most of which possess therapeutic indications for 
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oncogenic, autoimmune and infectious disease treatment;32 with many other candidates 
currently in the clinical development stages.33 In 2013 alone, the world-wide sales of 
mAb-based products generated approximately $75 billion in revenue. At the current 
approval rate these figures are expected to exceed $125 billion in sales by the year 
2020.33,34 The success of mAb-based therapeutics is due to their high target specificity, 
favorable pharmacokinetic properties and ability to elicit or modulate a desired immune 
response. This has largely been driven by advances in antibody production and 
engineering technologies, which has led to more potent therapies with fewer 
immunogenic side effects. 
 In theory, antibodies produced from a single B cell clone should possess 
homogenous structural compositions; however, therapeutic mAbs produced from 
recombinant DNA technologies are generally complex, heterogeneous and subject to 
numerous enzymatic and chemical modification during expression, purification and 
storage that can profoundly influence therapeutic safety and efficacy. Sequence variants 
are commonly detected in recombinant proteins produced in cell culture, which can arise 
from mutations at the DNA level, amino acid misincorporation during protein assembly, 
or miscleavage during post-translational processing.35,36 Importantly, point mutations 
within the CDRs have been shown to significantly modulate antigen binding affinity and 
specificity.37,38 Other common modifications that can occur during production and storage 
include variations in the Fc glycan structure, C-terminal processing of the heavy chain, 
pyroglutamic acid formation, oxidation, and deamidation.39  These modifications can alter 
pharmacokinetic properties, reduce therapeutic potency and stimulated deleterious 
immunogenic responses to varying degrees.5,6 The potential for adverse effects arising 
from heterogeneities introduced throughout all stages of production highlight the need for 
sensitive analytical tools capable of comprehensive mAb structural characterization.  
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Figure 1.2 Typical mass spectrometry based workflows for IgG analysis.   
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1.5  MASS SPECTROMETRY FOR ANTIBODY ANALYSIS 
 Mass spectrometry (MS) has emerged as an essential analytical tool for the 
structural characterization of therapeutic monoclonal antibodies,40–42 and more recently 
for the molecular level deconvolution of antigen-specific antibody repertoires expressed 
in serum.9,10,27,26 Advances in MS instrumentation and ion activation methods facilitate 
detailed and sensitive analysis of antibody amino acid sequence, post-translational 
modifications, and higher-order structure. As demonstrated in Figure 1.2, MS-based 
strategies for antibody analysis fall into three general categories: bottom-up, middle-
down, and top-down.  
 
1.5.1 Bottom-Up MS Analysis 
Conventional bottom-up mass spectrometry, which relies on the identification and 
characterization of antibodies via the analysis of their peptide surrogates, remains the 
method of choice for the structural characterization of therapeutic mAbs40,43 and is to date 
the only strategy employed for MS-based serum antibody proteomics.10,26,27,29 The utility 
of the bottom-up workflow largely arises from the fact that peptides are more easily 
separated, ionized and fragmented using established liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) based techniques than their intact counterparts.      
In the bottom-up approach, antibodies are subjected to enzymatic digestion with 
trypsin, or a combination of enzymes, to produce small (≤2.5 kDa) proteolytic peptides. 
The resulting peptide mixture is separated using reverse phase liquid chromatography and 
the eluting peptides are then analyzed by tandem mass spectrometry (MS/MS) to obtain 
peptide mass and fragmentation information. The resulting MS/MS data is then used to 
identify the resulting peptides, as well as characterize any modifications that may be 
present. This typically involves the use of in silico database search algorithms that 
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compare experimentally obtained MS/MS data with theoretical spectra generated from a 
candidate sequence database. This approach has proven highly effective for therapeutic 
IgGs of known primary sequence, but poses a significant technical hurdle for complex 
mixtures of antibodies derived from serum, for which no a priori sequence database is 
available. This arises from the fact that antibody genes are not encoded in the germline, 
but are assembled through somatic recombination and hypermutation. Several groups 
have recently addressed this limitation through the use of high-throughput next-
generation DNA sequencing of B cell immunoglobulin variable domains (V genes), or 
Ig-seq, to generate a sample-specific antibody sequence database for the interpretation of 
antibody-derived MS/MS data.26–29 While this paired Ig-seq/bottom-up MS approach has 
made great strides in terms of handling the complexity of serum antibody repertoires, the 
high degree of homology intrinsic to the antibody sequence poses a formidable challenge 
for unambiguous Ig identification using standard decoy-based error modeling employed 
by most in silico algorithms.10 De novo sequencing has also been explored as an 
alternative approach for mass spectral interpretation of serum-derived antibody mixtures, 
which overcomes the need for a reference database;44–46 however, continued development 
is necessary before these methods can be routinely employed for complex and highly 
homologous repertoire samples. 
While bottom-up methods remain popular, they suffer from several key 
limitations, particularly with regard to comprehensive structural characterization of 
mAbs. Sample preparations required for bottom-up analysis tend to be time-consuming 
and labor-intensive. Moreover, extensive sample handling and proteolysis often 
introduces artifactual heterogeneities that can obscure intrinsic or manufacturing-related 
modifications.40,47   Lastly, incomplete peptide sampling is a common problem owing to 
the complexity of peptide mixtures generated by proteolytic digestion.40,47    
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1.5.2 Top-Down MS Analysis 
The top-down approach omits proteolysis (or chemical reduction) prior to 
analysis. Structural characterization is therefore accomplished based on accurate mass 
measurements and MS/MS fragmentation of the intact antibody. This approach is 
particularly desirable due to the lack of sample preparation required, which maintains 
high structural integrity, as well as its ability to yield immediate feedback on sequence 
fidelity and proteoform abundance.48,49 Despite considerable advances in both ion 
activation methodologies and high performance MS instrumentation that have increased 
the scope of top-down strategies in recent years,49–51 these methods remain non-trivial for 
the characterization of intact antibodies owing to their size (~150 kDa), structural 
complexity, and high degree of sequence homology. To date, electron-transfer 
dissociation (ETD) and electron-capture dissociation (ECD) performed on Orbitrap and 
FTICR mass spectrometers have shown the greatest promise for top-down sequencing of 
intact antibodies; however, these methods remain limited to the interrogation of 
approximately 30-35% of the antibody structure, due to the number of disulfide protected 
regions within each antibody domain.52–54 These important structural features currently 
preclude top-down analysis as a standalone approach for antibody characterization.   
 
1.5.3 Middle-Down MS Analysis 
Middle-down mass spectrometry has emerged as a promising intermediate 
between top-down and bottom-up strategies. This approach typically involves restricted 
proteolysis with enzymes that target less frequent amino acids to generate peptides within 
a mass range of 3–20 kDa.55–59 The larger size of the resulting peptide mixture results in 
reduced complexity and thus improved MS/MS sampling efficiency. Moreover, restricted 
digestion generates peptides with more unique sequence character, which can be 
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exploited for improved differentiation of highly homologous antibody mixtures, or to 
increase the probability of localizing PTMs or point mutations.56    
A common variation of the middle-down approach for the analysis of monoclonal 
antibodies involves the reduction of intermolecular disulfides to produce free heavy 
chains (~50 kDa) and free light chains (~25 kDa). This strategy can be combined with 
hinge-selective digestion using proteases such as papain or immunoglobulin G-degrading 
enzyme from Streptococcus pyogenes (IdeS) to generate three distinct subunits (~25 kDa) 
consisting of the free light chain (Lc), the variable domain fragment of the heavy chain 
(Fd), and the reduced heavy chain Fc domain (Fc/2).40,55,60–64 While better adapted to LC-
MS/MS analysis compared to intact antibodies, comprehensive characterization of 
antibodies subunits remains challenging due to inherent limitations in speed and 
sensitivity of high resolution measurements required for large (≥ 25 kDa), highly charged 
species within narrow chromatographic elution windows.65–67  
 
1.5.4 Polypeptide Fragmentation Nomenclature 
The success of mass spectrometric methods for IgG characterization and the 
differentiation of unique clonotypic antibodies in complex immune mixtures rely on the 
ability to generate and interpret sequence-specific information from the heavy and light 
polypeptide chains. Owing to the high degree of sequence homology intrinsic to the IgG 
scaffold, differentiation of unique antibodies often requires complete sequencing of their 
hypervariable CDR sequences, of which the CDR-H3 exhibits the greatest sequence 
diversity and is thus the most diagnostic. As with any tandem mass spectrometry 
(MS/MS) based protein or peptide sequencing application, this requires controlled 
fragmentation of the polypeptide backbone. To accomplish this, ion activation methods 
have been developed that restrict fragmentation to specific bonds along the polypeptide 
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backbone,68 for which a systematic nomenclature has been developed to categorize the 
resulting fragment ions.69,70 A graphical illustration of this nomenclature and 
representative product ion formation is shown in Figure 1.3. 
 
 
 
 
 
Figure 1.3 Polypeptide fragmentation nomenclature as proposed by Roepstorff et al. 
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Each product ion is defined by the type and location of the bond cleavage across 
the polypeptide backbone, as well as the terminus (N or C) that is retained. Product ions 
originating from the N-terminal end of the polypeptide are as classified as a, b and c-type 
ions, whereas those retaining the C-terminal end are x, y and z-type ions. The two ions 
produced by cleavage of the same bond are referred to as complementary pairs and 
include a/x, b/y, and c/z ions. Slow-heating or threshold based activation methods, such 
as collisional induced dissociation (CID) and some types of photodissociation, result in 
predominant cleavage at the C–N amide bonds of the polypeptide backbone producing b- 
and y-type ions. In contrast, c- and z-type ions generated from cleavage of the N–Cα bond 
are characteristic of radical-directed mechanisms. Higher energy activation, such as 157 
nm and 193 nm ultraviolet photodissociation (UVPD), also produce a- and x-type ions 
arising from Cα–C bond cleavage in addition to b/y and c/z ions.  
 
1.5.5 Collisional Dissociation 
Collision induced dissociation (CID) is the most established and widely utilized 
ion activation method owing to its robust performance and implementation on virtually 
all commercial mass spectrometers. CID, as employed in ion trap instruments, is 
accomplished through resonant excitation using a supplemental AC waveform at the 
secular frequency of the precursor ion.71,72 This excitation frequency accelerates the 
precursor to higher kinetic energy allowing multiple inelastic collisions with inert bath 
gas molecules present in the trap. Each collision causes conversion of kinetic energy into 
internal vibrational energy until the dissociation threshold of the precursor is exceeded 
and fragmentation occurs.71,72  
The stepwise nature of the activation process restricts CID fragmentation to the 
lowest energy pathways, which for protonated peptides and proteins is generally observed 
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as cleavage of the C–N amide bond to produce b and y-type product ions. However, a 
number of well-defined variables, including the amino acid composition, charge state and 
the presence of post-translational modifications can dramatically influence the 
dissociation behavior of the precursor ion. The mobile proton model, derived from 
extensive mechanistic studies, provides a qualitative framework by which collision-
induced fragmentation can be rationalized.73,74 This theory posits that ionizing protons are 
initially localized at the basic sites of the peptide, including the N-terminus or side-chains 
of arginine, lysine, and histidine. Upon activation, protons become ‘mobilized’ and can 
migrate to less-basic sites along the backbone to initiate charge-directed fragmentation. 
Under sufficiently mobile conditions, N-protonation of the amide bond facilitates 
sequence-informative cleavage. This pathway is modulated in the presence of proline due 
to the higher proton affinity of its amide bond, resulting in highly favorable N-terminal to 
the proline cleavage.73–76 Alternatively, under proton deficient conditions, fragmentation 
is governed by charge-remote pathways that lead to preferential cleavage C-terminal to 
aspartic and glutamic acid residues.77–79 Collectively, preferential sequence-specific 
cleavages restrict the utility of CID for characterization peptides and proteins containing 
these residues. Another shortcoming of CID arises from the slow heating mechanism that 
governs the activation process, which promotes preferential cleavage of labile PTMs, 
such as phosphorylation. Chapter 7 of this dissertation directly addresses the latter 
shortcoming of CID for phosphopeptide analysis using a novel gas-phase bioconjugation 
technique that stabilizes the labile phosphate group during collisional activation to 
promote greater sequence informative fragmentation and phosphosite localization. 
On the basis of its aforementioned merits, including efficient and predictable 
fragmentation of proteolytic peptides, CID remains the most commonly employed ion 
activation method used for the analysis of antibodies in bottom-up workflows. While CID 
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maintains stable modifications, such as oxidation, deamidation, and N-terminal 
pyroglutamate, a severe limitation arises from its preferential cleavage of labile 
modifications that are critical for antibody characterization, such as glycosylation.80 Of 
the PTMs commonly found in IgG, the highly conserved N-glycosylation at Asn-297 is 
generally considered among the most important owing to its critical role in antibody 
effector functions, stability, and immunogenicity. CID spectra arising from peptides 
containing this important glycosylation site are often dominated by labile glycosidic bond 
cleavages that preclude peptide identification.40,42 To overcome this limitation, CID is 
often paired with complementary fragmentation techniques, such as electron-based 
activation, that preserve labile modifications and preferentially cleave the peptide 
backbone.81    
 
1.5.6 Ultraviolet Photodissociation (UVPD) 
A laser was first coupled to a mass spectrometer for the purposes of 
photodissociation of gas phase ions over four decades ago,82,83 and has since evolved into 
a powerful and versatile tool for the structural characterization of biological molecules, 
most notably peptides and proteins.68,84,85 The photoactivation process relies on energy 
accumulation and subsequent dissociation through photon absorption, which can occur 
either non-specifically or in a highly selective chromophore-mediated manner.68,84,85 The 
type of UVPD experiment (i.e., non-specific versus chromophore-mediated) is largely 
dictated by the wavelength selection and the photoabsorption properties of the gas phase 
ions being interrogated. The most common wavelengths used for UVPD correspond to 
those generated from pulsed excimer and Nd:YAG lasers, which include 157 nm, 193 
nm, 266 nm, 351 nm, and 355 nm (7.9 eV, 6.4 eV, 4.7 eV, and 3.5 eV per photon, 
respectively).68,84,85 
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UVPD using 157 nm and 193 nm photons has proven highly effective for the 
comprehensive structural characterization of peptides86–90 and proteins91–97 owing to the 
strong absorption of the polyamide backbone at these wavelengths.98  The high energy 
deposition of photons at 157 nm and 193 nm (7.9 eV and 6.4 eV, respectively) promotes 
electronic excitation, allowing access to new and diverse dissociation pathways that lead 
to the formation of a, b, c, x, y and z ions.99–102 Additionally, radical a and x-ions (a• and 
x•) are observed as a result of homolytic Cα–C bond cleavage, which can undergo 
hydrogen elimination to form a and x ions or partial loss of amino acid side chains 
through secondary dissociation to form v, d, and w ions (Figure 1.4), which have proven 
to be useful for the differentiation of isobaric leucine and isoleucine residues.99 In 
addition to extensive fragmentation of the polypeptide backbone, UVPD has also been 
shown to maintain labile modifications, making it well-suited for the identification and 
localization of biologically relevant post-translational modifications.89,90,103 These 
performance attributes prompted our efforts to pursue 193 nm UVPD for the detailed 
characterization of antibodies as described in Chapters 4 and 5.  
 
 
 
Figure 1.4 Generation of side-chain losses from radical precursor ions (adapted from 
Reference 98). R’ indicates partial loss of side-chain.  
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As an alternative to the comprehensive and indiscriminant fragmentation 
observed with 157 nm and 193 nm photodissociation, chromophore-mediated UVPD at 
wavelengths near 350 nm provide a unique strategy for introducing selectivity into 
proteomic workflows. In principle, the native polypeptide backbone does not absorb near 
350 nm, therefore incorporation of chromogenic moieties that confer photoabsorptivity 
within this wavelength regime are critical for UVPD. This affords an effective means by 
which to discriminate chromophore-labeled versus unlabeled peptides within complex 
mixtures. Several recent applications have demonstrated the utility of site-selective 
chromophore labeling combined with 351 nm UVPD (XeF excimer laser, 3.5 eV per 
pulse) for streamlined proteomic analysis. For example, Aponte et al. reported a method 
for targeting tyrosine (Tyr) and histidine (His) containing peptides via a diazonium 
labeling reaction. Following site-selective derivatization only peptides containing 
modified Tyr/His residues generated diagnostic fragmentation patterns when analyzed by 
LC-MS/UVPD. These highly selective MS/MS datasets combined with the low 
frequency of Tyr and His residues throughout the human proteome vastly diminished the 
redundancy of in silico database searches. Selective chromophore-tagging coupled with 
351 nm UVPD has also been exploited for monitoring protein conformational changes 
based on the relative accessibility of lysine side-chains to an amine-reactive chromogenic 
probe. Selective dissociation provided a facile means by which to track changes in 
modified, or solvent exposed residues across ligand-bound and unbound states.104 
Recently, chromophore-mediated UVPD was demonstrated as a powerful tool for high-
throughput de novo sequencing via spectral simplification. To accomplish this, 
proteolytic peptides were tagged at their N-termini with a 351 nm active AMCA 
chromophore and subsequently irradiated with successive laser pulses to eliminate the N-
terminal chromophore-containing ions. The resulting MS/MS spectra contained a clean 
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series of y ions for which a novel software platform, UVnovo, was developed to 
interpret.105,106 In this dissertation, the development of a selective 351 nm UVPD approach 
for the discrimination of antigen-binding regions from IgG fragments is described.   
 
1.5.7 Electron Transfer Dissociation (ETD) 
Electron-based dissociation methods, such as electron capture dissociation 
(ECD)107 and electron transfer dissociation (ETD),108 have gained traction as powerful 
alternatives to conventional collisional activation due to their ability to generate more 
extensive and randomized cleavage of the polypeptide backbone, while also maintaining 
labile PTMs.48,109–111 Electron capture dissociation entails the irradiation of multiply 
charged peptide or protein cations with low-energy electrons, leading to exothermic 
electron capture and non-ergodic fragmentation of the polypeptide backbone.112,113 ECD is 
typically restricted to Fourier transform ion cyclotron resonance (FT-ICR) mass 
spectrometers, which facilitate simultaneous trapping of electrons and analyte cations 
within their magnetic fields. Electron transfer dissociation was developed as an ion/ion 
analogue of ECD that has greatly extended the utility of electron-based activation owning 
to its facile implementation on ion trap instruments and various hybrid MS platforms.114 
This process involves the transfer of an electron to a multiply charged polypeptide cation 
via reaction with a radical anion reagent (i.e., fluoranthene, anthracene, azulene). 
Exothermic electron transfer subsequently initiates backbone cleavage at N-Cα bonds 
through hydrogen radical migration.108,113,115 A primary advantage of ECD and ETD is the 
formation of odd-electron radical species that undergo non-ergodic fragmentation prior to 
vibrational energy redistribution. This dissociation mechanism overcomes the challenges 
associated with preferential cleavages and loss of labile PTMs as observed in collisional 
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activation.109,116 However, both ECD and ETD exhibit a strong dependency on precursor 
charge density, which limits their effectiveness as precursor mass-to-charge values 
increase. Under instances of low charge density, the phenomenon of non-dissociative 
electron capture/transfer (ECnoD/ETnoD) has been widely reported, in which resulting 
product ions are held together by non-covalent interactions that impede sequence-
informative fragmentation.117–119 
Recently, electron-based activation methods have gained traction for the middle-
down and top-down structural characterization of antibodies.52–54,59,60,120 Comparable 
sequence coverages approaching 35% of intact IgG1 have been reported for ETD on an 
Orbitrap53 and ECD on a 9.4 T FTICR instrument.54 While insufficient for complete 
characterization, these methods far exceed the ~10% total sequence coverage of reduced 
IgG2 chains obtained with CID on an Orbitrap.121 Despite the improved fragmentation 
efficiency of electron-based methods at the intact protein level, the considerable number 
of disulfide protected regions throughout the antibody structure currently limits their 
utility for top-down analysis. To overcome this shortcoming, an alternative middle-down 
approach was recently introduced that relies on the hinge-selective IdeS (immunoglobulin 
G-degrading enzyme of Streptococcus pyogenes) digestion and chemical reduction of 
disulfide bonds to generate ~25 kDa IgG subunits. Targeted ETD analysis of the resulting 
subunits resulted in up to 68% sequence coverage when transients were averaged from 
multiple LC-MS/MS runs collected with varied ETD reaction times.60  
 
1.6 OVERVIEW OF CHAPTERS: 
The critical role of antibodies, both as therapeutic modalities and as the primary 
constituents of the humoral immune response, has prompted the development of 
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analytical methods capable of their detailed characterization. While mass spectrometry-
based approaches have led to tremendous progress for both the comprehensive structural 
characterization of therapeutic mAbs and the differentiation of unique antibodies in 
complex serological mixtures, there remain opportunities for continued development. The 
research presented in this dissertation is aimed at improving the versatility and tunability 
of MS/MS methods for antibody identification and characterization by combining 
strategic sample preparation with variations of ultraviolet photodissociation.  
In Chapter 3, a high-throughput chromophore-mediated 351 nm UVPD method is 
described to selectively interrogate cysteine-containing peptides as a means to streamline 
the identification of unique IgGs in homologous antibody mixtures. To accomplish this, a 
highly conserved cysteine residue located in the framework preceding the CDR-H3 
region is exploited for selective derivatization with an Alexa Fluor 350 (AF350) thiol-
selective maleimide. When combined with strategic enzymatic digestion and 351 nm 
UVPD, selective dissociation of AF350-labeled peptides is accomplished for facile 
discrimination of CDR-H3 sequences. 
A middle-down strategy for the improved characterization and differentiation of 
unique monoclonal antibodies using restricted Lys-C proteolysis and 193 nm UVPD is 
presented in Chapter 4. The selection of enzymatic digestion using Lys-C is based on its 
ability to generate peptides spanning the entire length of the diagnostic CDR-H3 region, 
as demonstrated both experimentally and using in silico methods. The merits of this 
strategy were assessed in the context of a middle-down proteomics experiment combined 
with next-generation V-gene database searching for the analysis of a simple mixture of 
anti-influenza monoclonal antibodies. 
In Chapter 5, a targeted middle-down UVPD method is demonstrated for the 
detailed primary sequence analysis and post-translational site localization of therapeutic 
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monoclonal antibody subunits generated by hinge-selective enzymatic digestion with 
recombinant immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS) 
followed by chemical reduction. Under optimized conditions, approximately 60% of the 
IgG sequence is interrogated, in addition to unambiguous glycosylation site localization 
and extensive coverage of the antigen-binding domains within a single targeted LC-
MS/MS experiment. UVPD exhibits improved performance metrics when benchmarked 
against more conventional ETD activation; however, both methods yield complementary 
information that is combined to facilitate greater overall subunit characterization.   
The development and implementation of a front-end dual spray reactor for high-
throughput ion/ion-mediated gas-phase bioconjugation of peptide cations is described in 
Chapter 6. To demonstrate the utility of the dual spray reactor, peptide cations are 
subjected to front-end ion/ion reactions with chromogenic 4-formyl-1,3-
benezenedisulfonic acid (FBDSA) anions. Subsequent collisional activation of the 
resulting ion/ion intermediate promotes covalent Schiff base reactions between primary 
amine sites in the peptide cation and the aldehyde moiety of the FBDSA anion. Resulting 
Schiff base modified peptides exhibit enhanced 193 nm UVPD efficiencies relative to 
their unmodified counterparts and yield greater primary sequence information when 
compared to conventional CID. Moreover, due to the efficiency of the bioconjugation 
process and its ease-of-integration with liquid chromatography platforms, this strategy is 
implemented into a LC-MSn workflow for the rapid derivatization of peptide mixtures. 
Chapter 7 extends the dual source methodology presented in Chapter 6 to enhance 
the collision-induced dissociation of phosphopeptides via rapid Schiff base derivatization 
with FBDSA. This strategy exploits the strong electrostatic interactions between 
sulfonate moieties of FBDSA and basic sites within the peptide to facilitate gas-phase 
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bioconjugation, reduce charge sequestration, and increase the yield of phosphate-
retaining sequence ions upon CID.  
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Chapter 2 
Experimental Methods 
 
2.1 OVERVIEW 
The methods described herein are aimed at extending the throughput and 
versatility of tandem mass spectrometric analysis of antibodies through various 
combinations of strategic enzymatic digestion, site-selective derivatization, and 
ultraviolet photodissociation. These methods were designed for either extensive 
fragmentation for improved structural characterization, or to selectively discriminate 
diagnostic sequence information from a greater pool of uninformative background 
peptides within the context of a high throughput liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) based workflow. 
 
2.2  MASS SPECTROMETRIC INSTRUMENTATION 
All experiments described herein were performed using a linear quadrupole ion 
trap (LIT) mass spectrometer or a Fourier Transform (FT) hybrid linear ion trap-Orbitrap 
mass spectrometer. Both instruments were equipped with electrospray ionization (ESI) 
sources, or customized variations thereof, and modified to enable photodissociation. 
 
2.2.1 Electrospray Ionization (ESI)    
The gas-phase conversion and ionization of analytes represents the sine qua non 
of mass spectrometry. While a wide variety of techniques have been introduced to 
generate ions of various forms, the advent of soft ionization methods capable of inducing 
charging effects while maintaining the integrity of the molecule has revolutionized the 
field of biological mass spectrometry. Electrospray ionization (ESI)1,2 is among the most 
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transformative and widely utilized soft ionization methods owing to its ability to generate 
multiply charged ions and its ease of integration with orthogonal solution-phase front-end 
separations (such a liquid chromatography and capillary electrophoresis), making it 
amenable to high throughput applications using a variety of MS platforms. 
  The ESI process can be likened to a controlled current electrolytic cell, as 
demonstrated in Figure 2.1. Charge is accumulated at the liquid surface under the 
influence of an electric field and can also be aided by the addition of solution phase 
additives (i.e., 0.1-1% formic acid or ammonium hydroxide) that act as proton donors 
(positive mode) or proton acceptors (negative mode). At sufficiently high voltage 
conditions (~2-5 kV) a Taylor cone forms at the solution interface that ejects highly 
charged droplets. These droplets subsequently undergo rapid evaporation that induces 
numerous fission events driven by Coulombic repulsion in the shrinking droplet. This 
process continues until desolvated gas-phase ions are formed that can enter the mass 
spectrometer for detection. Electrospray ionization (ESI) and nano ESI (nESI) were 
utilized for all experiments described herein using voltages of 1.8–2.0 kV and 3.5–5.0 kV 
respectively.    
 
 
Figure 2.1 Schematic representation of an electrospray ionization process (adapted 
from Reference 3).      
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2.2.2 Dual Source Reactor    
A dual source reactor was developed in-house to facilitate frontend ion/ion 
reactions. As illustrated in Figure 2.2, the reactor was equipped with two ESI sources 
(Prosolia Inc., Indianapolis, IN), as described in the previous section 2.2.1, that are 
coupled to the frontend of the mass spectrometer via a U-shaped railing system that 
surrounded the MS inlet. The position of each source could be independently adjusted in 
the x, y and z dimensions relative to the MS inlet. One source was completely integrated 
with the MS, allowing direct control of polarity and spray voltage through the instrument 
control software. The spray voltage of the second source was supplied by an external 5 
kV high voltage power supply (Stanford Research Systems Inc., Sunnyvale, CA) 
operated in negative polarity. Nebulizing sheath gas was introduced using an external 
nitrogen line equipped with a tee fitting and adjustable metering valve to evenly split the 
gas flow to both sources and allow manipulation of gas flow rates, respectively. The 
source was use in direct infusion mode or coupled directly to a capillary LC system for 
high-throughput bioconjugation reactions.  
 
 
 
Figure 2.2 Schematic representation of a dual ESI reactor for front-end ion/ion 
reactions. 
-kV
Anion Source
Cation Source
+kV
MS front-end
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2.2.3 Linear Ion Trap (LIT) 
A linear ion trap mass analyzer generally consists of a quadrupole with static lens 
elements placed at the terminal ends of the rods. Opposite RF voltages applied the two 
pairs of quadrupole rods confine ion motion in the radial direction, whereas DC potentials 
applied to the terminal ends of the trap confine ions in the axial direction and gate the 
flow of ions into the trap.4  Auxiliary AC and broadband waveforms are applied to one 
pair of rods for ion isolation and activation in a secular frequency dependent manner. 
Mass analysis is accomplished via sequential ion ejection from the trap using an RF 
voltage ramp, also referred to as a mass selective instability scan.   
All bottom-up analysis and online ion/ion-mediated bioconjugation experiments 
described herein were performed on a Velos Pro dual linear ion trap mass spectrometer 
(Thermo Fisher Scientific, San Jose, CA) equipped for CID, HCD and UVPD. The dual 
LIT configuration consists of a high pressure cell operated at a bath gas (He) pressure of 
approximately 5 mTorr for high trapping and CID efficiency, and a low pressure cell 
operated at nominally 0.3 mTorr for mass analysis.  
 
2.2.4 Orbitrap Mass Analyzer 
Orbitrap technology was first introduced by Makarov in 20005 and has since 
become a powerful FT-based alternative to Fourier transform ion cyclotron resonance 
(FT-ICR) mass spectrometry owing to its high performance (i.e., resolving power and 
mass accuracy) and short acquisition times without the need for an expensive 
superconducting magnet.6 The analyzer consists of an outer barrel-shaped electrode and 
an inner spindle-like center electrode. Under the influence of a quadrologarithmic field, 
ions undergo harmonic oscillations along the axis of spindle electrode at a frequency 
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proportional to (m/z)-1/2, which is detected as image current induced on the barrel 
electrode.5 
Middle-down LC-MS/MS analyses from several variations of IgG digests were 
performed on a modified hybrid linear ion trap Orbitrap Elite mass spectrometer (Thermo 
Fisher Scientific, Bremen, Germany)7,8 equipped with CID, HCD, ETD and UVPD 
capabilities. To enhance the transfer and detection of large ions, the HCD collision gas 
pressure in the vacuum chamber containing the Orbitrap mass analyzed was reduce from 
10 mTorr to ~5-7 mTorr depending on empirically defined spectral quality. The 
instrument was modified to enable UVPD in the HCD collision cell as described in 
greater detail in section 2.3.2. 
 
2.3  ION ACTIVATION 
 Multiple activation methods were employed for the research presented herein, 
including 193 nm UVPD, 351 nm UVPD, CID, HCD, and ETD. The set-up, acquisition 
strategies and relevant parameters for each activation method are detailed in the 
subsequent sections. Unless otherwise stated, MS1 full scan spectra were acquired from 
m/z 400–2000 and MS2 product ion spectra were collected from m/z 200–2000 (note that 
the low m/z cutoff (LMCO) varied for CID based on precursor m/z) for all LC-MS/MS 
analyses. 
 
2.3.1  Collisional Activation 
Normalized collision energies (NCE) between 25-35% were used for CID and 
HCD based peptide fragmentation. CID was employed for all collisional activation 
experiments performed on the Velos Pro dual LIT, whereas HCD was used for all 
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collisional activation experiments performed on the Orbitrap Elite owing to its superior 
speed (0.1 ms vs. 10 ms per activation step) and broader m/z trapping range. For online 
bioconjugation experiments, collision-induced covalent conversion of peptide/FBDSA 
complexes formed during front-end ion/ion reactions was typically performed under 
“gentle” CID conditions using NCE values ≤18%. 
 
2.3.2  Ultraviolet Photodissociation (UVPD) 
Both mass spectrometer platforms used in this work were modified to enable 
photodissociation as previously described.7–9 To allow UVPD on the Velos Pro dual 
linear ion trap, the back flange of the vacuum manifold of the instrument was replaced 
with a customized viewport flange designed to hold a CaF2 or fused silica window for 
transmission of radiation at 193 nm and 351 nm, respectively. An unfocused beam was 
elevated and aligned coaxially with the dual pressure ion trap using an optical periscope 
consisting of two 45° mirrors and subsequently passed through a 1.8 mm aperture 
mounted to the viewport flange followed by a 2 mm aperture on the exit lens of the ion 
trap. The instrument firmware was modified to allow activation and mass analysis in the 
low pressure cell in order to minimize beam divergence and maximize the photon flux 
experienced by the ion cloud. For implementation of UVPD on the Orbitrap Elite the 
vacuum manifold was modified via the addition of a CaF2 optical window coaxial to the 
dedicated HCD collision cell. Additionally, the rods of the ETD reagent ion transfer bent 
quadrupole were rotated 45° to allow transmission of the laser beam into the HCD cell. 
The instrument firmware was adjusted to allow simultaneous trapping of the ion cloud 
and pulse triggering within the HCD cell for a user defined activation period. Coherent 
ExciStar XS 500 pulsed excimer lasers (Santa Clara, CA) operated at either 193 nm 
(ArF) or 351 nm (XeF) were used for all experiments and coupled to the mass 
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spectrometers as described. The maximum repetition rate (500 Hz) was used for all 
experiments to generate one pulse (5 ns pulse duration) every 2 ms. An external trigger 
supplied through the auxiliary interface port gated a pulse generator (Berkley Nucleonics 
Corp., San Rafael, CA) which triggered the laser during the activation period of the 
instrument scam function.     
On the Velos Pro dual linear ion trap, the instrument firmware was modified to 
enable pulse triggering when the CID NCE was set to zero. The activation time was 
adjusted in 2 ms intervals to control the number of pulses based on the repetition rate of 
the laser. Activation q-values ranging between 0.1 and 0.125 were used to reduce the 
low-mass cutoff (LMCO) of the trap. Chromophore selective 351 nm UVPD (3.5 eV per 
photon) was carried out using ten 3 mJ pulses. Alternatively, 193 nm UVPD (6.4 eV per 
photon) of Schiff base modified peptides subjected to online on/ion-mediated 
bioconjugation was performed using one pulse at 2 mJ.  
For 193 nm UVPD experiments performed on the Orbitrap Elite mass 
spectrometer, the instrument firmware was modified to enable UVPD in the HCD cell via 
a custom UVPD flag. Ions were transferred into the HCD cell using 1% NCE, which 
allowed efficient ion transfer without sufficient energy to cause undesired fragmentation. 
All experiments were performed using 1-2 pulses at 2-3 mJ.  
 
2.3.3  Electron Transfer Dissociation (ETD) 
Electron transfer dissociation (ETD) experiments were performed on an ETD-
enabled hybrid linear-ion trap Orbitrap Elite mass spectrometer. Fluoranthene radical 
anions generated via a backend chemical ionization source were introduced as the 
electron-transfer reagent to induce fragmentation of either IgG peptides produced by 
restricted Lys-C proteolysis or IgG subunits produced by IdeS digestion and chemical 
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reduction. ETD analysis of IgG subunits was carried out using two variations of targeted 
acquisition for pre-established precursor ions based on a preceding LC-MS survey scan. 
For the first approached, the most abundant charge state was isolated using a 20 m/z 
window and continuously activated across the elution profile for each subunit. 
Alternatively, for the second approach, approximately 3 or 4 less abundant, but more 
highly charged (greater charge density) precursors were co-isolated using a 150 m/z 
isolation window for targeted broadband ETD acquisition. In both cases, a reaction time 
of 5 ms was used with a reagent AGC target of 7.5 x 105. To enhance detection of low 
abundance and large product ions, the pressure in the Orbitrap detector region was 
reduced so that the change in pressure (∆p) equaled 0.1 x 10-10 (~5 mTorr).   
For IgG peptides generated by Lys-C proteolysis, ETD product ion spectra were 
acquired in a data-dependent manner for the top five most abundant precursors identified 
in an MS1 survey scan. ETD was performed with the charge-stated dependent reaction 
time feature enabled and the reagent AGC target set to 5 x 105. For optimal performance, 
ETD was only carried out for ions possessing charge states of 4+ or higher.  
 
2.4  LIQUID CHROMATOGRAPHY (LC) 
The quality control of therapeutic antibodies using bottom-up or middle-down 
mass spectrometry requires the complete sampling of all peptides produced upon 
enzymatic digestion. This relies critically on front-end separations to facilitate the 
independent interrogation of each peptide. Similarly, effective separation of digests 
arising from highly homologous IgG mixtures increases the potential for sampling 
diagnostic peptides from the variable signatures of clonally unique antibodies. Separation 
of such mixtures is most commonly accomplished using reserve phase liquid 
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chromatography (RP-LC), which is readily coupled with ESI-MS/MS instrumentation. 
Reverse phase resins commonly used for bottom-up and middle-down/top-down 
separations include C18 (for bottom-up) and C8 or C4 (for middle- or top-down), 
respectively. The LC systems, stationary phases and parameters used for the work 
described in this dissertation are detailed below.   
       
2.4.1 Dionex Ultimate 3000 Nano/Capillary RSLC System 
Separations of tryptic and chymotryptic peptide mixtures were carried out on a 
Dionex Ultimate 3000 nano LC system configured for preconcentration. The system was 
equipped with a self-packed New Objective (Woburn, MA) Integrafrit trap column (3.5 
cm x 100 μm) and Picofrit nanobore analytical column (15 cm x 75 μm) containing 3 μm 
Michrom Magic (Auburn, CA) C18 stationary phase. Eluent A was 0.1% formic acid in 
water and eluent B was 0.1% formic acid in acetonitrile. Peptides were preconcentrated 
on the trap column with 2% acetonitrile for 5 min at a flow rate of 5 μL/min. For elution 
of peptides, a linear gradient from 3% to 40% eluent B was used over 70 min for tryptic 
bovine serum albumin (BSA) digests and 120 min for chymotryptic single-chain antibody 
fragment (scAb) digests at a flow rate of 0.3 μL/min. 
Separation of a model peptide mixture for subsequent front-end ion/ion reactions 
was accomplished using a Dionex Ultimate 3000 capillary flow system coupled with a 
homebuilt front-end dual spray reactor (described in section 2.2.2). Peptides were 
separated on an Agilent ZORBAX 300 Extend-C18 column (0.3 x 150 mm, 3.5 μm 
particle size) held at a constant temperature of 30°C. Eluent A was 0.1% aqueous formic 
acid and eluent B was 0.1% formic acid in acetonitrile. A linear gradient was employed 
from 3% B to 35% B over 30 min at a flow ate 4 μL/min.  
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2.4.2 Dionex Ultimate 3000 Microbore LC System 
Separation of IgG subunits (~25 kDa) produced by IdeS digestion and chemical 
reduction was accomplished using a Dionex Ultimate 3000 microbore LC system 
equipped with a Waters XBridge Protein BEH300 C4 column (2.1 x 250 mm, 3.5 μm 
particle size) held at a constant temperature of 65°C. Eluent A was 0.1% aqueous formic 
acid and eluent B was 39.9% isopropanol, 60% acetonitrile, and 0.1% formic acid (v/v/v). 
Two μg of digest was injected directly on column and separated using a steep linear ramp 
from 5% to 20% B over 2 min followed by a shallow gradient from 20% to 40% B over 
28 min at a flow rate of 250 μL/min.         
 
2.4.3 Eksigent 2D Plus NanoLC 
Digests of clinical grade IgG1 and a mixture of influenza monoclonal antibodies 
produced by restricted Lys-C proteolysis were carried out on an Eksigent nano flow LC 
system configured for preconcentration. The system was equipped with a self-packed 
New Objective Integrafrit trap column (3 cm x 100 μm) and Picofrit nanobore analytical 
column (20 cm x 75 μm) containing 5 μm Michrom Magic C8 stationary phase. Eluent A 
was 0.1% formic acid in water and eluent B was 0.1% formic acid in acetonitrile. 
Peptides were loaded onto the trap column and preconcentrated for 5 min with 2% 
acetonitrile containing 0.1% formic acid at a flow rate of 5 μL/min. For separation of 
single IgG digests, a linear ramp from 4% to 10% B over five minutes and then 10% to 
40% B over 55 min was employed at a flow rate of 0.3 μL/min. Separation of digests 
derived from influenza IgG mixtures was performed under the same gradient conditions, 
with the exception that the length of separation was doubled to increase the probability of 
sampling diagnostic variable region peptides required for IgG differentiation. 
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2.5  MATERIALS AND REAGENTS 
Peptides KMVELVHFL, KLVANNTRL, RPPGFSPFR, ASHLGLAR, 
DRVYIHPFHLVIHN, DAEFRHDSGYQVHHQK, as well as phosphopeptides 
RQpSVELHSPQSLPR, GGGPApTPKKAKKL, and KKALRRQEpTVDAL were 
purchased from AnaSpec (Fremont, CA). CDPGYIGSR, AGCKNFFWKTFTSC, 
SYSMEHFRWG and RRLIEDAEpYAARG-NH2 were obtained from American Peptide 
Company (Sunnyvale, CA). DRVYIHPFHL and bovine serum albumin (BSA) were 
obtained from Sigma-Aldrich (St. Louis, MO). Clinical grade Trastuzumab (Herceptin) 
IgG1 monoclonal antibody was obtained from Genentech (San Francisco, CA), and 
Adalimumab (Humira) IgG1 monoclonal antibody was obtained >97% purity from BOC 
Science (Shirley, NY). Reagents used for site-specific bioconjugation, including 4-
formyl-1,3-benzenedisulfonic acid (FBDSA) and AlexaFluor 350 C5 maleimide were 
obtained from Sigma-Aldrich and Life Technologies (Grand Island, NY), respectively.        
Proteases including trypsin, Lys-C and chymotrypsin were purchased from 
Promega (Madison, WI). Recombinant immunoglobulin G-degrading enzyme from 
Streptococcus pyogenes (IdeS/FabRICATOR, Genovis) was obtained from Bulldog Bio, 
Inc. (Portsmouth, NH). All other solvents, chemicals and reagents were obtained from 
Sigma-Aldrich, Thermo Fisher Scientific or EMD Millipore (Temecula, CA).  
 
2.6  SAMPLE PREPARATION 
2.6.1 Single-Chain Antibody Fragment (scAb) Expression and Purification 
Single-chain antibody fragments were prepared are previously described by Rani 
et al.10 with the following modifications: antibody fragments were expressed as scAbs by 
inserting single-chain variable fragment (scFv)-encoding genes of 2 anti-HA33 [HA33 
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(33 kDa), part of the botulinum neurotoxin complex11] variants (#3 and #4) into 
pMopac16 vector, a pAK400 derivative12 in which the scFv was fused in frame to a C-
terminal human kappa light chain constant domain and hexahistidine tag. Antibody 
fragments were expressed in Escherichia coli BL21. Individual colonies were inoculated 
into 4 mL TB media with 50 μg/mL ampicillin and 2% glucose and were grown 
overnight at 37°C. Overnight cultures were used to inoculate 400 mL TB media with 50 
μg/mL ampicillin, and cells were grown at 37°C until an o.d.600 of 0.6 was reached. 
Cultures were brought to 25°C and protein expression was induced with 1 mM IPTG. 
After 5 h incubation at 25°C, cells were collected by centrifugation, and the protein was 
purified from osmotic shock fraction, as previously described.10,13 The purity of isolated 
scAb was verified by gel electrophoresis on a 4-20% SDS-PAGE gel (NuSep, 
Lawrenceville, GA) stained with Coomassie blue. 
 
2.6.2  Selective Derivatization and Sample Processing 
Protein-level modification of cysteine residues in BSA and scAb samples was 
accomplished by first reducing disulfide bonds in the presence of excess tris(2-
carboxyethyl)phosphine (TCEP) at 55°C for 60 min. Free thiols were then reacted in the 
presence of 45 mM Alexa Fluor 350 maleimide for 3 h, or with 15 mM iodoacetamide 
(IAM) for 45 min. Alkylation reactions were carried out at room temperature in the dark. 
Modified BSA and scAbs were then digested overnight at 37°C using a 20:1 ratio of 
protein to trypsin or chymotrypsin, respectively.     
Phosphopeptides were subjected to N-terminal derivatization via 4-sulfophenyl 
isothiocyanate (SPITC) and carbamylation. SPITC reactions were carried out by reacting 
20 μL of reagent stock solution prepared by dissolving 1 mg of SPITC in 100 μL of 1x 
PBS (pH 7.4) with 10 nmol of peptide for 30 minutes at 55°C. N-terminal carbamylation 
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was accomplished via incubation of 10 nmol of peptide with 8 M urea in 50 mM Tris-
HCl (pH 8) at 80°C for 4 h. The reaction products were immediately desalted on C18 to 
terminate further reaction. 
 
2.6.3 Ion/Ion Reaction-Mediated Peptide Bioconjugation 
Peptide cations were subjected to front-end ion/ion reactions with 4-formyl-1,3-
benezenedisulfonic acid (FBDSA) anions using the dual source reactor detailed in section 
2.2.2. To accomplish this peptide cations were produced either from direct infusion or LC 
separation at flow rates of 1.5-4 μL/min using spray voltage of 1.5-1.75 kV. Reagent 
anions were simultaneously generated by direct infusion of 1-2 mM FBDSA at 3 μL/min 
produced using spray voltages ranging between -2 and -3 kV. Peptide/FBDSA complexes 
formed by ion/ion reaction were then isolated and subjected to low energy CID (NCE 
≤18%) for conversion to covalent Schiff base modified forms. 
 
2.6.4 Middle-Down IgG Samples Prepared by Restricted Lys-C Proteolysis 
IgG samples were prepared in 50 mM Tris-HCl (pH 8) containing 2M urea and 
digested at 37°C with Lys-C for two hours using a 1:75 enzyme-to-substrate ratio. 
Digestion was carried out prior to reduction and alkylation to promote the formation of 
larger peptides (i.e., a greater number of missed cleavages). The resulting digests were 
diluted to a final urea concentration of 0.5 M in Tris-HCl and sequentially reduced in the 
presence of 5 mM DTT for 30 min at 37°C and alkylated with 25 mM IAM at room 
temperature, in the dark, for 30 min. Immediately following alkylation, IgG digests were 
acidified with 0.5% formic acid and desalted on a solid phase extraction (SPE) column 
containing C8 resin. 
 43 
2.6.5 Middle-Down IgG Samples Prepared by IdeS Digestion 
Acetone-precipitated monoclonal IgG1 antibodies were resuspended at 5 μg/μL in 
IdeS cleavage buffer (50 mM sodium phosphate, 150 mM NaCl, pH 6.6) and 
subsequently digested with one unit of IdeS per microgram of IgG at 37˚C for 30 
minutes. Following digestion, IgGs were denatured with 4 M urea and reduced in the 
presence of 30 mM TCEP for 30 minutes at room temperature. To quench the reaction 
and prevent disulfide bond reformation, the sample was acidified with 1% formic acid 
(FA). Immediately prior to analysis the sample was diluted to 1 μg/μL in 0.1% FA.  
 
2.7 AUTOMATED TANDEM MASS SPECTROMETRY DATA INTERPRETATION 
LC-MS/MS experiments often generate thousands of mass spectra within a single 
dataset, of which only a fraction can be meaningfully correlated to proteolytic peptides. 
The most common approach for interpreting large volumes of MS/MS spectra in a time 
and computationally effective manner is through comparison with in-silico generated 
theoretical fragmentation patterns generated from candidate protein sequence databases. 
Once potential spectral matches are identified, they can then be validated through 
rigorous statistical measures to facilitate confident identifications based on precursor 
mass and fragmentation ion data. The strength of these searches is therefore largely 
dependent on mass accuracy, sequence coverage across the peptide backbone, and the 
ability of the algorithm to interpret the resulting spectra. In silico searching has proven 
extremely effective for conventional proteomics; however, these methods are limited to 
the interpretation of datasets for which a priori genome data is readily available. Until 
recently, this limitation precluded the use of in silico algorithms to interpret mass spectral 
data arising from antibody repertoires, for which there is little germline data available due 
to incredible sequence diversity of immunoglobulins generated by somatic recombination 
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and hypermutation. This has been partially circumvented with the advent of Ig-seq 
technology, which enables the generation of an individualized database of 
immunoglobulin variable gene (V-gene) sequences constructed by next-generation DNA 
sequencing of mature B cells. In section 2.7.2 an Ig-seq donor V-gene database was used 
in combination with the ProSightPC search algorithm for the identification of middle-
down sized peptides arising from influenza monoclonal antibodies. Additionally, all 
search algorithms and search parameters used for MS/MS data interpretation are detailed 
in the subsequent sections.   
 
2.7.1 MassMatrix 
The MassMatrix database search algorithm (version 2.4.0) was used for in silico 
interpretation of CID and 351 nm UVPD fragmentation datasets arising from tryptic BSA 
and chymotryptic scAb digestions. Searches were performed against forward and reverse 
candidate sequences generated from a bovine proteome FASTA database (UniProtKB) 
modified to include single-chain antibody fragment (scAb) sequences. Peptide matching 
was based on b- and y-type product ions. All data was collected on an LIT mass 
spectrometer and therefore searched using default low resolution parameters including a 
precursor ion tolerance of ±1.8 Da and a fragment ion tolerance of ±0.8 Da. Peptide hits 
were filtered by pp and pp2 thresholds of 5 and a pptag threshold of 2.0.  
 
2.7.2 ProSightPC 
Automated database searching of middle-down LC-MS/MS data derived from 
Lys-C digested IgGs was performed using ProSightPC 4.0 (Thermo Fisher Scientific) 
equipped with UVPD searching functionalities to account for 9 ion types: a, a+1, b, c, x, 
x+1, y, y-1 and z. Spectra were converted to neutral monoisotopic masses using the Xtract 
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algorithm (Thermo Fisher Scientific) using precursor and fragment ion signal-to-noise 
thresholds of 7 and 3, respectively. Data derived from single monoclonal IgGs was 
searched against a custom database containing ten closely related therapeutic IgG 
sequences obtained from the DrugBank resource database (http://www.drugbank.ca/). 
Alternatively, UVPD data from a mixture of anti-influenza IgGs discovered in post-
vaccinated donor serum was searched against a custom V-gene database consisting of 17 
VL and 14,499 VH sequences constructed from next generation sequencing of VL and VH 
genes from B cells of the same donor. Searches were performed in absolute mass mode 
with a precursor mass tolerance of 2.2 Da and a strict fragment ion tolerance of 5 ppm.     
 
2.7.3 ProSight Lite 
All scans collected for a given precursor or group of precursors during targeted 
LC-MS/MS analysis of IgG subunits were combined to generate an averaged 
Thermo.RAW file for each subunit. The averaged UVPD spectra were deconvolved using 
the Xtract algorithm (Thermo Fisher Scientific) using a fragment ion signal-to-noise 
threshold of 3 and searched using ProSight Lite with UVPD searching enabled.  
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Chapt1er 3 
Selective 351 nm Photodissociation of Cysteine-Containing Peptides for 
Discrimination of Antigen-Binding Regions of IgG Fragments in  
Bottom-Up LC-MS/MS Workflows
*
 
 
3.1 OVERVIEW 
Despite tremendous inroads in the development of more sensitive LC-MS/MS 
strategies for mass spectrometry-based proteomics, there remains a significant need for 
enhancing the selectivity of MS/MS-based workflows for streamlined analysis of 
complex biological mixtures. Here, a novel LC-MS/MS platform based on 351 nm 
ultraviolet photodissociation (UVPD) is presented for the selective analysis of cysteine-
peptide subsets in complex protein digests. Cysteine-selective UVPD is mediated through 
the site-specific conjugation of reduced cysteine residues with a 351 nm active 
chromogenic Alexa Fluor 350 (AF350) maleimide tag. Only peptides containing the 
AF350 chromophore undergo photodissociation into extensive arrays of b- and y-type 
fragment ions, thus providing a facile means for differentiating cysteine-peptide targets 
from convoluting peptide backgrounds. Using this approach in addition to strategic 
proteolysis, the selective analysis of diagnostic heavy chain complementarity determining 
regions (CDRs) of single-chain antibody (scAb) fragments is demonstrated. 
 
3.2  INTRODUCTION 
Over the past several decades, tandem mass spectrometry (MS/MS) has played a 
pivotal role in expanding the depth and breadth of proteomics research.1–5 Most notably, 
                                                 
*Cotham, V. C.; Wine, Y.; Brodbelt, J. S. Anal. Chem. 2013, 85, 5577-5585. 
 V.C.C. designed all experiments and completed the labeling reactions and mass spectral analysis.    
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workflows based on bottom-up liquid chromatography tandem mass spectrometry (LC-
MS/MS) have emerged as the primary analytical technique for large-scale 
characterization of complex protein mixtures, such as those originating from whole cell 
lysates6,7 or the blood serum proteome.8,9 The vast majority of these workflows rely on 
non-selective activation methods that generate informative and comprehensive mass 
spectral datasets that are interpreted bioinformatically to enable protein identification, 
detection of post-translational modifications (PTMs), and structural elucidation.5,10 
Collision induced dissociation (CID)11,12 and more recently introduced electron-based 
dissociation (electron capture dissociation (ECD) and electron transfer dissociation 
(ETD))13–15 are arguably the most widely employed activation strategies for 
accomplishing these goals.16–18  
Despite the merits of using indiscriminate activation processes for proteomic 
analysis, the exorbitant, and often times redundant, amount of data generated by these 
methods places a substantial computational burden on bioinformatic databases used for 
spectral interpretation.10,19 This often results in long search times and high false discovery 
rates (FDRs), particularly for low resolution instruments where mass accuracy and 
resolving power cannot be exploited for improved spectral matching.20 Furthermore, 
these non-selective methods greatly reduce the ability to efficiently differentiate 
diagnostic subsets of information from a greater pool of less-informative data. One 
common approach to increase selectivity entails the use of data-dependent methods.21  
Data-dependent approaches, in which the most abundant precursor m/z values are 
excluded from repeated MS/MS interrogation, help streamline data collection but the data 
discrimination process is linked to precursor abundances rather than structure- or 
sequence-specific features. Moreover, the common use of 3 m/z precursor selection 
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windows means that MS/MS spectra may be composites of several precursors, thus 
further confounding spectral interpretation and peptide identification.   
The issues surrounding indiscriminate MS/MS methods are highlighted when 
considered in the context of current proteomic approaches for the characterization of the 
antigen-specific immunoglobulin repertoire of polyclonal serum antibodies produced 
during an immune response. The high degree of sequence homology shared between 
complex mixtures of unique high-specificity IgGs presents a particularly daunting 
analytical challenge for traditional bottom-up methods and hinges on the ability to 
sequence low abundance peptides originating from the complementarity determining 
regions (CDR1, CDR2, and CDR3) of the heavy and light chain variable domains. In 
particular, heavy chain CDR3 (CDR-H3) peptides, which contain hypervariable amino 
acid sequences caused by V(D)J gene recombination and somatic hypermutation,22,23 
serve as diagnostic molecular signatures that enable differentiation of IgGs,24,25 but 
remain difficult to analyze in the presence of more abundant homologous peptides. 
Moreover, conventional database searches, which rely on strong statistical correlations 
between experimental MS/MS spectra and those generated in silico from known protein 
sequences, are not well-suited for antibody-based applications as a result of the high 
degree of homology between IgG sequences leading to an excessively high number of 
false identifications.25  Recent efforts to overcome these challenges have focused on 
reducing sample complexity via affinity enrichment of antigen-specific IgGs in 
combination with next generation DNA sequencing to create refined variable gene 
sequence databases.25,26 Although these strategies have demonstrated improved 
deconvolution of the serum antibody response, methods that afford more discriminate 
analysis of diagnostic CDR peptides in bottom-up workflows remain desirable. 
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In the ongoing efforts to incorporate greater selectivity into mass spectrometric 
strategies, photodissociation has cultivated considerable interest as an alternative 
dissociation method due to its versatility, tunable energy deposition and potential for 
streamlining tandem MS workflows for complex mixtures.27–30 While infrared 
multiphoton photodissociation (IRMPD) has exhibited some capacity for selective 
screening, this method is largely limited to the differentiation of phosphorylated peptides 
in protein digests.31,32 Alternatively, ultraviolet photodissociation (UVPD) has 
demonstrated significant attributes as an ion activation method due to its capability for 
fast, high energy deposition and tunable dissociation behavior based on wavelength 
selection and the incorporation of appropriate chromophores. This last point has proven 
particularly effective for enhancing the selectivity of UVPD-based techniques through 
chromophore-mediated dissociation at wavelengths that are minimally absorbed by native 
peptides. For example, Julian et al. have developed a number of 266 nm UVPD methods 
that rely on the strategic attachment of a photolabile antenna to drive site-specific radical 
induced dissociation. This method has been applied to allow facile identification of 
phosphorylation sites33,34 and determination of the presence and location of cysteine 
residues.35,36 Previously, our group has demonstrated the utility of 355 nm UVPD for 
applications including the manipulation of product ion distributions for de novo 
sequencing through terminal chromophore labeling,37 as well as the identification of 
peptide cross-links via selective photodissociation of a bis-aryl hydrazone crosslinker.38  
Recently, Lemoine et al. introduced a novel photodissociation-based technique, referred 
to as photo-selected reaction monitoring (photo-SRM), which combines both traditional 
SRM with selective chromophore-mediated dissociation at visible wavelengths (473 
nm).39  Using site-specific labeling of cysteine residues they were able to show targeted 
analysis of modified cysteine-containing peptides from complex plasma protein digests.40  
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The present study incorporates both site-specific conjugation of cysteine residues 
with a commercially available thiol reactive Alexa Fluor 350 chromophore and selective 
photodissociation at 351 nm. The use of a fast repetition rate excimer laser provides a 
significant advantage over selective 355 nm UVPD methods previously reported37,38 in 
that its affords rapid activation on a timescale amenable to LC-MS/MS. Efficient and 
exclusive dissociation of Alexa Fluor 350 modified peptides is observed upon irradiation 
at 351 nm, yielding an extensive array of b and y-type ions, while unmodified precursors 
neither absorb nor dissociate. Therein, this selective strategy enables both facile 
identification of cysteine-containing peptides and effectively eliminates convoluting 
MS/MS spectra for streamlined data analysis. Following validation of this approach using 
a standard protein digest, its application is further extended to the selective analysis of the 
diagnostic third heavy chain complementarity determining region (CDR-H3) of IgG 
single-chain antibody fragments (scAbs). To accomplish this goal, a highly conserved 
cysteine residue located N-terminal to the CDR-H3 region of interest41,42 was targeted for 
site-specific labeling. Combined with the use of appropriate proteases and selective 351 
nm UVPD, high sequence coverage of diagnostic CDR-H3-containing peptides was 
observed and differentiation of IgG scAbs is accomplished. 
 
3.3 EXPERIMENTAL 
3.3.1 Materials and Reagents 
Model cysteine-containing peptides CDPGYIGSR and AGCKNFFWKTFTSC 
were purchased from American Peptide Company (Sunnyvale, CA).  Bovine serum 
albumin (BSA), iodoacetamide, glutathione and urea were obtained from Sigma Aldrich 
(St. Louis, MO). Mass spectrometry grade trypsin and sequencing grade chymotrypsin 
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were purchased from Promega (Madison, WI) and thiol-reactive Alexa Fluor 350 C5 
maleimide was obtained from Life Technologies (Grand Island, NY). Tris(2-
carboxyethyl)phosphine (TCEP) solution, Slide-A-Lyzer dialysis cassettes (10 kDa 
MWCO), and PepClean C18 spin columns were purchased from Pierce (Rockford, IL). 
All other buffer components and solvents were obtained from Fisher Scientific (Fairlawn, 
NJ). 
 
3.3.2 Single-Chain Antibody Fragment (scAb) Preparation 
Single-chain antibody fragments were prepared as previously described43 with the 
following modifications: antibody fragments were expressed as scAbs by inserting the 
scFv encoding genes of 2 anti-HA33 (HA33 (33 kDa) - part of the botulinum neurotoxin 
complex44) variants (#3 and #4) into pMopac16 vector, a pAK400 derivative45 in which 
the scFv was fused in frame to a C-terminal human kappa light chain constant domain 
and hexahistidine tag. Antibody fragments were expressed in E. coli BL21. Individual 
colonies were inoculated into 4 ml TB media with 50 μg/ml ampicillin and 2% glucose, 
and were grown overnight at 37°C. Overnight cultures were used to inoculate 400 ml of 
TB media with 50 μg/ml ampicillin and the cells were grown at 37°C until OD600 0.6 was 
reached. Cultures were transferred to 25°C and protein expression was induced with 1 
mM IPTG. After a 5 hour incubation at 25°C, cells were collected by centrifugation and 
protein was purified from the osmotic shock fraction as described previously.43,46 The 
purity of isolated scAb was verified by gel electrophoresis on a 4-20% SDS-PAGE gel 
(NuSep, Lawrenceville, GA) stained with Coomassie blue. 
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3.3.3 Cysteine Derivatization and Sample Preparation 
Disulfide bonds were reduced using a 5x molar excess of TCEP solution (500 
mM in water) for 1 hour at 55˚C in the presence of 8 M urea (in 1x PBS, pH 7.4). 
Following reduction, protein solutions were diluted 2-fold with 1x PBS to lower the urea 
concentration to 4 M immediately prior to site-selective conjugation of reduced cysteine 
residues. Alexa Fluor C5 maleimide stock solution (45 mM in water) was added at a 10x 
molar excess over the protein concentration and the reaction was allowed to proceed for 3 
hours in the dark at room temperature under gentle mixing conditions. Conjugation with 
Alexa Fluor 350 maleimide results in a mass shift of 478 Da per modified cysteine 
residue. Standard alkylation was carried out by adding iodoacetamide to a final 
concentration of 15 mM in solution and allowed to react at room temperature for 45 
minutes in the dark. Reactions were quenched with an excess of glutathione. Modified 
BSA was dialyzed overnight against 1x PBS to remove urea and excess reagent prior to 
enzymatic digestion with trypsin. Alternatively, modified scAbs were buffer exchanged 
into 100 mM Tris-HCl, 10 mM CaCl2 (pH 8) for conditions compatible with 
chymotrypsin digestion. Modified BSA and scAbs were digested overnight at 37˚C using 
a 20:1 ratio of protein to trypsin or chymotrypsin, respectively. 
 
3.3.4 Mass Spectrometry, Liquid Chromatography, and Photodissociation 
All experiments were undertaken on a Thermo Scientific Velos Pro dual-pressure 
linear ion trap mass spectrometer (San Jose, CA) outfitted with a Coherent ExciStar XeF 
excimer laser operated at 351 nm. The laser setup was similar to that previously 
described,47,48 with the exception that a quartz window was used for transmission of 351 
nm photons. Modified peptides were analyzed by direct infusion ESI-MS using a spray 
voltage of 4 kV and a heated capillary temperature of 200oC. Protein digests were 
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separated on a Dionex UltiMate 3000 RSLCnano system (Sunnyvale, CA) configured for 
on-line preconcentration using a New Objective Integrafrit trap column (3.5 cm x 100 
μm) and Picofrit nanobore analytical column with integrated emitter (15 cm x 75 μm). 
Both columns were packed in-house with 3 μm Michrom Magic C18 stationary phase 
(Auburn, CA). 1 μL of digest prepared at 1 μM in 0.1% formic acid was injected onto the 
trap column and preconcentrated with 2% acetonitrile with 0.1% formic acid at a flow 
rate of 5 μL/min for 5 minutes. For separation on the analytical column eluent A 
consisted of 0.1% formic acid in water and eluent B was 0.1% formic acid in acetonitrile. 
A linear gradient from 3% to 40% B over 70 min at 0.3 µL/min was used for all tryptic 
BSA digests. Due to the considerably greater number of peptides generated using the 
lower specificity chymotrypsin protease, scAb digests were subjected to a 120 minute 
gradient using the same conditions previously stated.  
LC-MS/MS data was collected using data-dependent acquisition in which the first 
event was the full mass scan (m/z range of 400 – 2000) followed by 10 consecutive 
isolation and activation (UVPD or CID) events of the most abundant ions detected in the 
full mass scan. For all 351 nm UVPD experiments, the qz-value was set to 0.1 to reduce 
the low mass cut-off to below m/z 150 and precursor ions were irradiated with 10 pulses 
at a repetition rate of 500 Hz using a power of 3 mJ/pulse. The qz-value was increased to 
0.25 and a normalized collision energy (NCE) of 35% was applied during a 10 ms 
activation period for all comparative CID experiments. 
 
3.3.5 Database Searching 
MassMatrix database search algorithm (version 2.4.0) was used for in silico 
interpretation of all MS/MS data.49 All LC-MS/MS RAW files generated in the Thermo 
Xcalibur software (version 2.2) were converted to the mzXML file format compatible 
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with the MassMatrix algorithm. MS/MS data for BSA digests was searched against the 
reference bovine proteome database (UniProtKB). This same database was modified to 
incorporate both scAb sequences for interpretation of MS/MS data from scAb digests. A 
precursor ion mass tolerance of ± 1.8 Da and a fragment ion tolerance of ± 0.8 Da were 
used for all searches. Oxidation of methionine (+15.9949 Da) and conjugation of cysteine 
residues with Alexa Fluor 350 maleimide in its standard (+478.1284 Da) and hydrated 
(+496.1389 Da) forms were searched as dynamic modifications and peptides consisting 
of fewer than four amino acids were filtered out. All database search results were verified 
manually. In some cases, peptides not identified by MassMatrix were manually 
interpreted based on MS/MS fragmentation and the presence of a unique reporter ion at 
m/z 296 generated by cleavage of the amide bond within the Alexa Fluor 350 maleimide 
tag. 
 
3.4 RESULTS AND DISCUSSION 
The workflow of the LC-MS/351 nm UVPD platform used in this study for the 
selective-analysis of cysteine-containing peptides is shown in Figure 3.1. In principle, 
native peptides exhibit minimal gas phase absorption near 350 nm, therefore 
incorporation of chromogenic moieties that enhance photoabsorptivity are critical for 
successful UVPD within this wavelength regime. The present study uses a fast repetition 
rate 351 nm excimer laser to achieve selective photodissociation of cysteine-containing 
peptides on a timescale amenable to chromatographic separation of complex protein 
digests. As shown in Figure 3.1, the disulfide bonds in the proteins were reduced, and the 
free cysteines were subsequently alkylated using the Alexa Fluor maleimide reagent in 
lieu of the conventional iodoacetamide utilized in most bottom-up proteomic methods.  
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The proteins were proteolyzed, and the resulting digest was analyzed by nanoLC-MS 
with UVPD as the activation mode. Only the Alexa Fluor-modified cysteine peptides 
absorb, undergo photodissociation, and give diagnostic fragmentation patterns.  
 
 
 
 
Figure 3.1 LC-MS/MS workflow based of 351 nm UVPD for the selective analysis of 
cysteine-containing peptides in complex mixtures. Proteins are subjected 
to site-specific conjugation at cysteine residues with a chromogenic Alexa 
Fluor 350 maleimide tag. Modified protein digests are separated by 
nanoLC and activated by 351 nm UVPD which promotes selective 
photodissociation of Alexa Fluor 350 modified peptides. 
 
Cysteine residues are compelling analytical targets for this study due in part to the 
intrinsically high nucleophilicity of the free sulfhydryl functionality contained in their 
side chain, making them attractive for site-specific incorporation of chromophores 
necessary for selective 351 nm activation. Furthermore, cysteines are responsible for less 
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than 1.4% of the total amino acid composition, but are present in nearly all proteins of 
well-characterized proteomes (i.e. 97% in the human proteome), making them ideal 
targets for streamlined protein identification via selective analysis of the unique cysteine 
peptide subset. Lastly, it has been shown that cysteine is a highly conserved residue 
located at the N-terminal position of CDR3 sequences of monoclonal antibody heavy 
chains. CDR-H3 sequences exhibit the greatest amino acid diversity of all hypervariable 
antibody domains and are predominantly responsible for antigen recognition. As such, 
these diagnostic regions provide a unique molecular signature by which antigen-specific 
IgGs can be identified.25 Thus, when combined with the appropriate proteases, this 
conserved cysteine residue provides a fixed target for selective chromophore-mediated 
dissociation of diagnostic CDR-H3 sequences to enable efficient characterization and 
differentiation of IgGs. As shown in the following sections, we evaluate the selectivity of 
our 351 nm UVPD platform against conventional bottom-up LC-MS/MS of protein and 
IgG digests to assess its analytical potential for streamlined proteomic and immunogenic 
analysis. 
 
3.4.1 Selective Modification and 351 nm UVPD of Model Cysteine Peptides 
The utility of the cysteine-selective UVPD strategy is highly dependent on the 
ability to efficiently conjugate cysteine residues in a protein (or protein mixture) to a 
chromophore that affords strong absorption at 351 nm. Solution phase absorbance data 
are shown in Figure 3.2 for unmodified and AF350-modified forms of the cysteine-
containing tripeptide glutathione. The low absorbance profile of unmodified glutathione 
is highly representative of native proteolytic peptides, which do not contain active 
chromophores near 350 nm. By incorporating the AF350 chromophore into the peptide 
structure via derivatization of the cysteine residue, absorption was dramatically increased 
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over a wavelength range well-suited for 351 nm activation. Although gas-phase and 
solution absorption maxima are not necessarily identical, the high absorbance from 325 
to 375 nm in solution offered a sufficiently broad range to guide our choice of Alexa 
Fluor 350 equipped with a cysteine-reactive moiety for our gas-phase study.  
 
 
 
Figure 3.2 UV/VIS absorbance curves of native and Alexa Fluor 350 maleimide 
modified glutathione (GSH) in water. 
 
Model peptides CDPGYIGSR and AGCKNFFWKTFTSC were selected to assess 
the efficiency of site-specific modification at cysteine residues with Alexa Fluor 350 
maleimide, as well as to evaluate the feasibility of promoting selective photodissociation 
at 351 nm. Reduction and subsequent derivatization of cysteine residues with the 
chromogenic AF350 tag exhibited complete conversion of peptides to their modified 
forms as demonstrated in the representative ESI spectrum shown in Figure 3.3 for AF350 
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labeled CDPGYIGSR. Although the AlexaFluor moiety contains an ionizable sulfonic 
acid group, the Alexa Fluor-modified peptides exhibited the same charge states, and 
similar distribution of charge states and ionization efficiencies as observed for 
iodoacetamide-alkylated peptides, and thus there is no evidence that the sulfonic acid 
group is deprotonated in the gas phase.   
 
 
 
Figure 3.3  ESI mass spectrum of Alexa Fluor 350 maleimide modified 
CDPGYIGSR. A mass shift of 478 Da corresponding to Alexa Fluor 350 
conjugation of the cysteine residue is denoted by (♦). 
 
Conjugation at the cysteine side chain was confirmed by both CID and UVPD, as 
shown in Figure 3.4 for AF350 modified AGCKNFFWKTFTSC. Both spectra exhibited 
abundant and identical arrays of b- and y-type fragment ions with mass shifts consistent 
with AF350-maleimide modification at both Cys3 and Cys14. The multiple sites of 
modification were further verified by consecutive losses of 80 Da from the precursor ion, 
which correspond to the sulfonic acid moieties from two separate AF350 labels. This 
characteristic loss proved effective in not only identifying conjugated peptides, but also 
determining the number of modifications along the peptide backbone. One noteworthy 
 60 
attribute of using UVPD over conventional CID for the activation of AF350-peptide 
conjugates arises from access to a lower m/z trapping limit during UVPD because the 
effectiveness of UVPD is not mediated by the rf voltage applied to the trap, as is the case 
for CID. As exemplified by the UVPD mass spectrum shown in Figure 3.4b, the 
detection of informative low mass ions, particularly a diagnostic reporter ion at m/z 296 
generated from cleavage of the amide bond within the AF350 maleimide tag provided an 
additional means to pinpoint modified cysteine peptides in mixtures and afforded greater 
confidence in subsequent peptide identifications.  
 
 
 
Figure 3.4 MS/MS spectra based on (a) CID and (b) 351 nm UVPD (10 pulses, 3 mJ) 
of AGCKNFFWKTFTSC 2+ modified at both cysteine residues with 
Alexa Fluor 350 maleimide (♦). 
 
The remarkable overlap in CID and UVPD spectra for the modified cysteine-
containing peptide (Figure 3.4) indicated similarities in the activation processes and 
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internal energy deposition; however, unlike resonant CID, which caused exclusive 
excitation of the isolated precursor, the non-resonant nature of UVPD promoted 
activation of both precursor and primary fragment ions retaining the chromogenic tag. 
This potential for secondary activation enabled greater tunability of energy deposition 
based on laser parameter selection (i.e., laser power and number of pulses). In this study, 
optimal photoactivation was accomplished using ten 5 ns laser pulses at a constant energy 
of 3 mJ per pulse. These conditions were selected based on three criteria: i) adequate 
dissociation of the precursor, ii) abundance of informative fragment ions, and iii) 
activation on a timescale comparable to conventional strategies used in LC-MS/MS 
workflows. 
To demonstrate the concept of selective 351 nm photodissociation, the peptide 
CDPGYIGSR was alkylated by either iodoacetamide (IAM) or chromogenic Alexa Flour 
350 maleimide, infused, and activated by 351 nm UVPD. The overlaid isolation spectra 
for both forms of the doubly charged peptide are shown in Figure 3.5a during the laser 
“off” state. Upon triggering the laser to deliver 10 pulses of 351 nm photons (laser “on” 
state, Figure 3.5b), the AF350-modified precursor diminished by approximately 97% of 
its initial intensity, confirming that this ion was highly responsive to photoirradiation. 
Alternatively, the IAM-alkylated precursor remained unaffected by UV irradiation. This 
point was illustrated more explicitly by comparing the behavior of each precursor ion in 
the respective single ion chronograms (SIC) during alternating laser on/laser off states 
(Figure 3.5c). The ion intensity of the IAM-alkylated precursor showed no dependence 
on the state of the laser as demonstrated by a negligible change in intensity over the 
course of the laser on/off switching experiment, whereas the ion intensity of the AF350-
modified precursor showed immediate depletion during the laser on periods. 
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Furthermore, the UVPD spectrum of the AF350-modified peptide obtained during the 
laser on state yielded diagnostic b- and y-type fragment ions (Figure 3.5d), whereas that 
of the corresponding IAM-alkylated peptide showed only the presence of the intact 
precursor (i.e. no dissociation, data not shown).  
 
 
 
Figure 3.5 Overlaid and normalized isolation spectra of Alexa Fluor 350 (♦) and IAM 
modified CDPGYIGSR 2+ under (a) laser OFF and (b) laser ON 
conditions. (c) Single ion chronograms (SIC) of the 2+ charge state of 
modified and unmodified peptide are shown under alternating laser 
ON/OFF states in 30 s intervals and (d) the UVPD spectrum of Alexa 
modified peptide during laser ON conditions. 
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3.4.2 Validation of Cysteine-Selective Strategy with Model Protein Digest 
The selective 351 nm UVPD method was extended to a considerably more 
complex tryptic protein digest to assess the feasibility of cysteine-selective analysis 
within the context of a typical LC-MS/MS based proteomic workflow. Bovine serum 
albumin (BSA) was selected as a model protein due to the significant number of cysteine 
residues (35) contained throughout the protein sequence, thus providing a large pool of 
analytical targets. LC-MS/MS analysis based on CID and 351 nm UVPD was performed 
for AF350 maleimide-conjugated tryptic BSA to compare the relative peptide populations 
identified by both MS/MS methods. The discriminatory power of selective 351 nm 
UVPD on a chromatographic timescale is illustrated by the representative UVPD spectra 
shown in Figure 3.6 of non-cysteine containing HPYFYAPELLYYANK and AF350-
modified DDPHACYSTVFDK tryptic BSA peptides, respectively. The non-cysteine 
peptide (identified by CID) exhibited no dissociation upon activation by 351 nm UVPD, 
whereas extensive sequence information was obtained for the AF350-modified peptide. 
While conventional CID yielded approximately 80% sequence coverage of BSA through 
the identification of over 70 peptides, a database search of the UVPD data returned an 
exclusive list of 24 peptides, all cysteine-containing, accounting for 42% of the BSA 
sequence and 34 of the possible 35 (97%) cysteine residues. As demonstrated in Figure 
3.7, examination of the extracted ion chromatogram (XIC) of the m/z 296 reporter ion 
provided a facile means to track cysteine-peptide elution in the resulting LC-MS/UVPD 
dataset. 
The results from the model protein study provided validation of selective 
cysteine-peptide analysis in a conventional LC-MS/MS workflow. Importantly, 351 nm 
UVPD demonstrated the potential for streamlined database searching of the cysteine-
peptide subset in a complex protein digest compared to indiscriminant CID, which 
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generated a significant number of convoluting non-cysteine peptide identifications. 
Furthermore, these results demonstrated the ability to confidently identify a protein based 
exclusively on the unique cysteine-peptide data generated by 351 nm UVPD. 
 
 
 
Figure 3.6 351 nm UVPD mass spectra of tryptic BSA peptides (a) 
HPYFYAPELLYYANK 2+ and (b) Alexa Fluor 350 conjugated 
DDPHACYSTVFDK 2+ following 351 nm photoirradiation with 10 
pulses at 3 mJ. 
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Figure 3.7 Alexa Fluor 350 maleimide modified tryptic BSA digest subjected to LC-
MS/351 nm UVPD:  (a) Base peak chromatogram and (b) extracted ion 
chromatogram (XIC) for m/z 296 reporter ion showing peaks associated 
with identified AF350 modified tryptic cysteine-containing peptides. 
 
3.4.3 Selective CDR-H3 Analysis of IgG Fragments 
To demonstrate the analytical merit of this strategy in a biological context, 
cysteine-selective 351 nm UVPD was used to facilitate selective characterization of the 
highly diagnostic hypervariable CDR-H3 sequences of single-chain antibody fragments 
(scAb). Two scAbs sharing over 97% sequence homology with identical CDR-H3 
sequences and each containing a total of six cysteine residues (Figure 3.8) were 
subjected to site-specific conjugation with AF350 maleimide. Modified scAbs were 
strategically digested with chymotrypsin due in part to the low frequency of tryptic sites  
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Figure 3.8 Sequence alignment of single-chain antibody fragments (scAbs). Sequence 
variations are highlighted in white. 
 
in the regions surrounding the CDR-H3 sequences, but more importantly due to the 
potential for generating CDR-H3 peptides containing a highly conserved cysteine residue 
in the heavy chain framework to facilitate selective photodissociation. Digests were 
subsequently analyzed by LC-MS/MS based on CID and 351 nm UVPD. Table 3.1 
provides a comparative summary of peptides identified using both activation platforms. 
As shown, the CID data resulted in over 40 peptide identifications from each scAb, 
yielding sequence coverages of 92% and 89% for scAbs #3 and #4, respectively.  
Alternatively, the 351 nm UVPD data generated selective identification of only modified 
cysteine-containing peptides, thereby reducing the amount of convoluting peptide 
information by more than 60%. With the exception of CQHFW, all cysteine-containing 
peptides identified by both MS/MS strategies were found exclusively in their modified 
forms, thereby suggesting nearly complete derivatization of cysteine residues. 
Interestingly, AF350-modified cysteine peptides YCASGGEL and CQHFW were 
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identified from the 351 nm UVPD datasets for each scAb, but were not identified from 
the corresponding CID datasets, perhaps suggesting greater sensitivity of selective UVPD 
towards AF350-modified peptides.  
 
 
Table 3.1 Summary of peptides identified by LC-MS/MS based on CID and 351 nm 
UVPD of chymotrypsin digested Alexa Fluor 350 maleimide conjugated 
scAbs. 
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UVPD also facilitated differentiation of scAbs despite their high degree of 
sequence homology and limited number of cysteine residues in areas containing sequence 
variations. This was accomplished by means of selective 351 nm activation of the unique 
scAb #3 peptide VKPGASVKLSCTASGF, as shown in Figure 3.9. We speculate that 
the corresponding scAb #4 peptide was not identified by either CID or UVPD due to 
ionization suppression resulting from sequence mutation K19T, which reduced the 
number of charge-carrying sites along the peptide backbone. Although selective UVPD 
afforded a facile approach to withdraw peptide subset information from scAb digests 
(Figure 3.10), the true impact of this method and its implications for streamlined 
antibody characterization are demonstrated by the UVPD spectrum provided in Figure 
3.10c for the chymotryptic CDR-H3 peptide YCASGGELGFPY. As shown, by targeting 
the highly conserved cysteine residue contained in the framework preceding the 
diagnostic CDR-H3 (see Figure 3.8) for site-specific conjugation, in addition to strategic 
digestion, 100% sequence coverage of the diagnostic CDR-H3 was achieved using the 
cysteine-selective LC-MS/351 nm UVPD workflow. The base peak chromatogram for 
the chymotryptic digest of Alexa Fluor 350-modified scAb #3 shows the profile of all 
eluting peptides (Figure 3.10a), and the extracted ion chromatogram (XIC) of the UVPD 
reporter ion (m/z 296) shown in Figure 3.10b allowed the elution of all of the cysteine-
peptides to be readily pinpointed within the complex mixture, thus streamlining the 
identification of key peptides of interest. The presence of excess Alexa Fluor 350 
maleimide that was not effectively removed from the sample during the dialysis or 
desalting step also generated the reporter ion at m/z 296 and is responsible for several of 
the unlabeled peaks in the XIC. 
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Figure 3.9 Sequence alignment of the first 60 amino acid residues from scAb #3 and 
scAb #4 are shown, respectively. Sequence variations are highlighted in 
red. The blue shaded region corresponds to the unique scAb #3 peptide 
identified by cysteine-selective LC-MS/MS as shown in the 351 nm 
UVPD spectrum. The presence of the Alexa Fluor 350 maleimide tag is 
indicated by (♦) and the hydrated form is shown as (♦*)    
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Figure 3.10 (a) Base peak chromatogram for a chymotrypsin digest of Alexa Fluor 
350-modified scAb #3 and (b) corresponding XIC for reporter ion at m/z 
296. Labeled peaks correspond to modified cysteine-containing peptides 
identified by 351 nm UVPD. The inset shows the full scan mass spectrum 
of the modified chymotryptic CDR-H3 peptide YCASGGELGFPY 
identified by 351 nm UVPD as shown in (c). The presence of Alexa Fluor 
350 maleimide is denoted by (♦).      
 
3.5 CONCLUSIONS 
When combined with strategic proteolysis, cysteine-selective UVPD was shown 
to be highly effective for improved characterization of the diagnostic CDR-H3 sequences 
in antibody digests. The gas-phase photoabsorptivity of native cysteine-containing 
peptides was significantly enhanced at 351 nm by means of site-specific conjugation of a 
chromogenic Alexa Fluor 350 moiety for the purpose of selective chromophore-mediated 
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UVPD. Modified cysteine peptides underwent rapid and extensive photodissociation to 
yield diagnostic sequence ions, while unmodified peptides exhibited no response upon 
photoirradiation. The use of a fast repetition rate laser facilitated cysteine-selective 
UVPD on a timescale amenable to chromatographic separation, thus allowing facile 
differentiation and streamlined data collection of the cysteine-containing peptide subset 
of complex mixtures in the context of a conventional bottom-up LC-MS/MS workflow. 
This method proved successful for the analysis of the diagnostic heavy chain 
complementarity determining regions of single-chain antibody fragments, ones 
containing a highly conserved cysteine residue located N-terminal to the CDR-H3 region.  
Ongoing work to develop a novel thiol-reactive chromogenic tag that provides the added 
advantage of cysteine-peptide enrichment in addition to selective photodissociation at 
351 nm is currently underway. We anticipate that this type of tag will further improve the 
selectivity of the workflow because the enrichment step should discriminate against 
unmodified (non-cysteine containing) peptides and alleviate both the congestion of 
digests and the chances that unmodified peptides will saturate the ESI signal. A 
complementary enrichment step should be particularly useful for the analysis of low 
abundance peptides, thus facilitating the analysis of considerably more complex 
proteomic and immunogenic samples 
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Chapter 4 
Middle-Down 193 nm UVPD for Unambiguous Antibody Identification 
and its Implications for Immunoproteomic Analysis  
 
4.1 OVERVIEW 
Mass spectrometry has emerged as a powerful tool within the growing field of 
immunoproteomics, which aims to understand antibody-mediated immunity at the 
molecular level based on the direct analysis of serological antigen-specific antibody 
repertoires. To date, these methods have relied on the use of high resolution bottom-up 
proteomic strategies that require effective sampling and characterization of low 
abundance peptides derived from the antigen binding domains of clonally unique 
antibodies within complex mixtures of highly homologous peptide backgrounds. Herein, 
we describe a method that uses restricted Lys C enzymatic digestion to increase the 
average mass of proteolytic IgG peptides (≥ 4.5 kDa), thereby enhancing the uniqueness 
of their amino acid composition and reducing the total sample complexity. When 
combined with 193 nm ultraviolet photodissociation, improved characterization of the 
antibody sequence is accomplished relative to conventional collision- and electron-based 
activation methods. Moreover, we demonstrate the utility of pairing this middle-down 
UVPD strategy with next-generation V-gene database searching for unambiguous 
differentiation of unique antibodies in mixtures, thus demonstrating its analytical 
potential for MS-based serological antibody repertoire analysis. 
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4.2  INTRODUCTION 
A potent humoral immune response hinges on a diverse and highly dynamic 
antibody repertoire that confers protection through efficient recognition and targeted 
neutralization of antigenic threats.1,2 Antibodies, which exist as either membrane-bound B 
cell receptors (BCRs) or as their secreted protein analogues, are composed of two 
identical units of paired heavy (H) and light (L) immunoglobulin (Ig) chains that are 
functionally divided into N-terminal variable domains (VH and VL) and C-terminal 
constant domains (CH and CL).3 In general, the immunoglobulin scaffold exhibits a high 
degree of sequence homology between individual antibodies, with the exception of three 
hypervariable complementarity determining regions (CDRs) that are embedded within 
the frameworks of each VH and VL domain.4 Collectively, the CDRs and their adjacent 
frameworks form a unique antigen-binding pocket that is distinct to antibodies derived 
from each clonal population of B cells.3,4 The potential for substantial sequence diversity 
within the CDRs is the product of somatic recombination and junctional diversification of 
germline gene segments that encode for these regions during B cell development.5 
Together these processes give rise to a pre-immune repertoire that is estimated to consist 
of >108 distinct antibodies in humans, thus providing the mechanism for broad antigen-
recognition that is critical for effective host defense.4,6  
Upon antigen challenge, the immune repertoire is modulated in an antigen-
specific manner through exclusive activation and clonal expansion of naïve B cells 
expressing antibodies with sufficient antigen affinity.7 Over time the repertoire undergoes 
further affinity maturation via somatic hypermutation (SHM) within the variable domains 
to generate a polyclonal antibody population that is highly specific for the target 
antigen.7,8 Currently, there is enormous interest in methods capable of unbiased 
identification and characterization of such affinity matured antibodies, particularly when 
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raised at functionally relevant levels against deleterious disease antigens, owing to their 
intrinsic therapeutic value for use as putative biomarkers and biotherapeutic agents, as 
well as to guide in vaccine development.9–11  
High-resolution mass spectrometry (MS) has emerged as a powerful tool to 
directly monitor serological antibody repertoire composition and dynamics under disease 
or vaccine-induced states.12–21  To date, these studies have relied on bottom-up proteomic 
strategies that entail enzymatic digestion with trypsin or multiple proteases and analysis 
by liquid chromatography–tandem mass spectrometry (LC-MS/MS). While such methods 
are well established for conventional proteome analysis,22 antibody repertoires present 
several formidable technical hurdles that must be overcome for successful 
immunoproteomic implementation. For example, no a priori sequence database is 
available for mass spectral interpretation since antibody genes are not directly encoded in 
the germline, but instead undergo extensive diversification and hypermutation.13,15 This 
shortcoming has been largely circumvented by recent integration of MS-based 
approaches with next-generation DNA sequencing of mature B cell Ig variable (V-gene) 
domains, or Ig-seq technology, to facilitate the construction of individualized antibody 
sequence databases.12,17–21 Despite this improvement, however, deconvolution of antibody 
repertoires from complex proteolytic mixtures remains non-trivial in the presence of 
abundant and highly homologous peptide backgrounds arising from conserved 
immunoglobulin frameworks.19 As a result, unambiguous antibody identification is 
contingent on the ability to both sample and fully characterize low abundance peptides 
originating from unique hypervariable antigen-binding domains.19 This limitation can be 
partially mitigated by reducing the complexity of the peptide population, which is often 
accomplished in proteomics through selective enrichment or depletion of certain types of 
peptides.23 Another option, termed the middle-down approach, relies on restrictive 
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enzymatic digestion to generate fewer and larger peptides than conventional trypsin 
proteolysis,24–26 and offers a compelling alternative to bottom-up methods for antibody 
repertoire analysis. Several groups have already demonstrated the merits of utilizing 
middle-down approaches for enhanced characterization of therapeutic monoclonal 
antibodies (mAbs), both in terms of peptide-level sequence coverage and detection of 
post-translational modifications (PTMs).27–31 Notably, Tsybin and co-workers showed 
that enzymatic digestion of a mixture of therapeutic mAbs with secreted aspartic acid 
protease 9 (Sap9) yielded a greater fraction of peptides that contained full-length or 
multiple hypervariable CDR sequences to improve the confidence of antibody 
identification compared to conventional bottom-up analysis.30 This study represented an 
important step towards advancing middle-down proteomics for the evaluation of 
increasingly complex antibody mixtures and motivated our interest in expanding this 
strategy for integration with more challenging V-gene database searching against an 
expanded set of closely related sequences to better assess its merits for antibody 
repertoire analysis. Moreover, the conventional activation methods used to interrogate 
these longer peptides, including both low- and high-energy collision induced dissociation 
(CID and HCD, respectively) and electron-transfer dissociation (ETD), do not 
consistently afford complete inter-residue coverage of the CDRs,30 which may lead to 
ambiguous spectral matches during repertoire analysis.19  
Recently, ultraviolet photodissociation (UVPD) has been established as a versatile 
alternative ion activation strategy that is amenable to a broad range of proteomics 
applications.32–41 In particular, our group has shown that UVPD at 193 nm offers 
considerable performance gains relative to conventional activation methods for the 
characterization of whole proteins and large polypeptides thereof on chromatographic 
timescales,29,40 thus prompting our efforts to evaluate its utility for middle-down 
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immunoproteomic analysis. Herein, we describe a high-throughput middle-down strategy 
for antibody identification and characterization that exploits the combination of restricted 
lys-C enzymatic digestion to increase the average mass of proteolytic peptides (≥ 4.5 
kDa) with the sequencing power of 193 nm UVPD. The overall workflow is illustrated in 
Figure 4.1. Unlike other less specific proteases that have been used to produce 
comparably sized peptides for middle-down antibody analysis, such as Sap9 and 
pepsin,30,31 lys-C cleaves with high selectivity at lysine side-chains to generate a 
predictable and lower complexity peptide population for streamlined bioinformatic 
interpretation. Moreover, we compare the performance of 193 nm ultraviolet 
photodissociation (UVPD) to that of more conventional collision- and electron-based 
activation methods for the sequence characterization of these large antibody peptides, 
with a particular emphasis on coverage of the diagnostic hypervariable CDR sequences. 
Finally, the utility of this method was assessed within the context of a middle-down 
immunoproteomics experiment combined with next-generation V-gene database 
searching for the analysis of a mixture of anti-influenza monoclonal antibodies. 
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Figure 4.1 Schematic representation of workflow for middle-down analysis of 
antibodies based on restricted proteolytic digestion with lys-C. Digestion 
is carried out prior to disulfide reduction and alkylation steps to promote a 
greater number of missed cleavages as a means to bias the resulting 
peptide population toward higher mass.    
 
4.3 EXPERIMENTAL 
4.3.1 Materials and Reagents 
Clinical grade Trastuzumab (Herceptin) monoclonal IgG1 used for initial method 
development was donated by Genentech. Influenza monoclonal IgGs were provided by 
the Georgiou lab (University of Texas at Austin) and were synthesized as described by 
Lee et. al.42 Proteomics-grade r-LysC was obtained from Promega (Madison, WI). LC-
MS grade solvents were obtained from EMD Millipore (Temecula, CA). All other 
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reagents and buffer components were acquired from Sigma-Aldrich (St. Louis, MO). 
Integrafrit columns (360 µm O.D. x 100 µm I.D.) and picofrit columns (360 µm O.D. x 75 
µm I.D. x 30 µm emitter tip I.D.) were purchased from New Objective (Woburn, MA). 
 
4.3.2 Sample Preparation for Middle-Down Analysis 
Intact Intact Trastuzumab and an equimolar mixture of three purified anti-
influenza IgGs previously discovered in post-vaccinated donor serum were resuspended 
in 50 mM Tris-HCl (pH 8) containing 2M urea and digested at 37°C with LysC for two 
hours using a 1:75 enzyme-to-substrate ratio. The resulting digests were diluted to a final 
urea concentration of 0.5 M in Tris-HCl and sequentially reduced in the presence of 5 
mM DTT for 30 min at 37°C and alkylated with 25 mM IAM at room temperature, in the 
dark, for 45 min. Immediately following alkylation, IgG digests were acidified with 0.5% 
formic acid and desalted on a solid phase extraction (SPE) column containing C8 resin 
(Agilent) prior to LC-MS/MS analysis. 
 
4.3.3 Liquid Chromatography and Mass Spectrometry   
Proteolytic IgG peptides were separated by reversed phase chromatography on an 
Eksigent 2D Plus nanoLC system (Redwood, CA) configured for preconcentration using 
an Integrafrit trap column (3 cm) and a picofrit analytical column (20 cm) packed in-
house with 5μm Michrom Magic C8 stationary phase (Auburn, CA). Eluent A was 0.1% 
aqueous formic acid and eluent B was 0.1% formic acid (v/v) in acetonitrile. Peptides 
were loaded onto the trap column and preconcentrated for 5 min in aqueous solvent 
containing 2% acetonitrile and 0.1% formic acid at a flow rate of 5 μL/min. For single 
IgG digests separation was carried out over 60 minutes using a linear gradient from 4-
10% eluent B over the first 5 minutes and further increased to 40% eluent B over the last 
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55 min at 0.3 μL/min. For the mixture of IgGs discovered in donor serum, separation was 
carried out over 120 min to increase the probability of sampling diagnostic peptides 
derived from the CDR regions.  
The LC system was coupled via a nano electrospray ionization source (Nanospray 
Flex ion source, Thermo Scientific) maintained at 1.8 kV to a Thermo Fisher Orbitrap 
Elite mass spectrometer (Bremen, Germany) outfitted with a 193 nm ArF excimer laser 
(Coherent ExciStar XS) to allow UVPD in the HCD cell as previously described.39,43 For 
all experiments, MS1 spectra were collected at a resolving power of 120K (at m/z 400) 
and MS2 product ion spectra were acquired for the top five most abundant precursors by 
averaging three microscans at 120K resolution. The automatic gain control (AGC) target 
for MS2 was set to 1E6 with a maximum injection time of 300 ms using a 5 m/z isolation 
width. To bias data acquisition towards larger peptides, ions 4+ and higher were selected 
for activation. Monoisotopic precursor selection and dynamic exclusion were enabled 
using a 30s exclusion window. For UVPD experiments, precursor ions were transferred 
to the HCD cell for activation and spectra were acquired using two laser pulses at 3 mJ 
per pulse. HCD was carried out using normalized collision energy (NCE) of 30% while 
ETD was performed using a reaction time of either 25 ms or 50 ms with a reagent AGC 
target of 5E5 and a maximum injection time of 100 ms. 
 
4.3.4 Data Processing 
RAW files were deconvolved using the Xtract algorithm (Thermo Fisher 
Scientific) embedded within ProSightPC 3.0 to obtain neutral monoisotopic mass 
information using a precursor ion signal-to-noise (S/N) threshold of 7 and a fragment ion 
S/N threshold of 3. All data was searched using ProSightPC 4.0 equipped with nine ion 
type (a, a+1, b, c, x, x+1, y, y-1, and z) search capabilities. Data from single IgG analyses 
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were searched against a custom database containing closely related therapeutic IgG 
sequences obtained from the DrugBank resource database (http://www.drugbank.ca/). 
UVPD data from the mixture of anti-influenza IgGs discovered in post-vaccinated donor 
serum was searched against a database consisting of 14,499 VH sequences constructed 
from next generation sequencing of VH genes from B cells of the same donor. All 
searches, with the exception of those used to identify glycoforms in trastuzumab, were 
performed in Absolute Mass mode using a 2.2 Da precursor mass window based on 
peptide monoisotopic mass and a 5 ppm product ion tolerance. Glycoform searches were 
conducted using a loose precursor window of 2000 Da and filtered based on known N-
linked glycan masses.  
 
4.4 RESULTS AND DISCUSSION 
4.4.1 In-silico Proteolysis of a Theoretical Antibody Repertoire  
The success of immunoproteomic methods for the evaluation of serological 
antibody repertoires hinges on the ability to sample and confidently identify diagnostic 
peptides arising from the antigen-binding domains of unique monoclonal antibodies. As 
demonstrated in the sequence alignment of multiple immunoglobulin heavy chain 
variable domains (VH) shown in Figure 4.2b, the heavy chain complementarity 
determining region 3 (CDR-H3) exhibits the greatest diversity in both length and amino 
acid sequence of all hypervariable antigen-binding regions. As such, this region functions 
as the primary determinant of antigen recognition and provides a unique molecular 
signature by which to differentiate IgGs. To this end, we sought to strategically exploit 
highly conserved lysine residues in adjacent frameworks (Figure 4.2) to generate 
peptides containing the full-length CDR-H3. To evaluate the occurrence of lys-C 
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proteolytic sites (K) flanking this target region, V and J gene sequence logos, as shown in 
Figure 4.2a, were prepared from IMGT germline gene sequences (www.IMGT.org). 
Based on these data, lysine represents a strong candidate cleavage site for generating 
middle-down sized CDR-H3 peptides. The relatively high number of conserved lys-C 
cleavage sites that occur in the VH sequence N-terminal to the region of interest also 
suggest that a considerable portion of the resulting peptide population will overlap with 
tryptic length distributions. While this is non-ideal from a purely middle-down method 
development perspective, it may offer an additional opportunity to strategically reduce 
sample complexity using a mass-biased partitioning approach, such as that previously 
reported by Cannon et. al.,44 to improve the sampling efficiency of CDR-H3-containing 
peptides in MS-based immunoproteomic analyses. 
Using the IgSimulator software,45 a set of artificial VH sequences were constructed 
to simulate the relative performance of trypsin and lys-C for generating suitable peptides 
for proteomic identification of the CDR-H3. Sequences were translated, filtered to 
remove any with stop codons or out-of-frame J regions, and digested in silico at each site 
C-terminal to either lysine (Lys-C) or arginine and lysine (trypsin). Other proteases do 
not consistently produce peptides spanning the CDR-H3 region and were therefore not 
considered. Figure 4.3 shows the expected mass distribution plots for the resulting 
theoretical peptides produced using each of the two proteases (lys-C and trypsin) 
assuming no missed cleavage sites. The inset table shows counts of CDR-H3-containing 
peptides from both synthetic IgSimulator VH data (used for the mass distribution plots) 
and empirical data derived from next-generation sequencing of VH genes of peripheral B 
cells obtained from post-influenza vaccinated donor serum as described elsewhere.42 The 
theoretical and empirical data demonstrate consistent shifts toward higher mass peptides 
possessing greater unique sequence information following lys-C digestion. Importantly, 
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more than 50% of the resulting CDR-H3-containing peptide population falls within an 
ideal middle-down size regime of 5-12 kDa, making this a compelling strategy for 
immunoproteomic analysis.  
 
 
 
Figure 4.2 (a) VH sequence logo constructed from IMGT germline V and J gene 
segments and (b) sequence alignment of VH sequences from multiple 
unique antibodies. Hypervariable complementarity determining regions 
(CDRs) are embedded within conserved frameworks (FRs). Lysine (K) 
and arginine (R) residues are shown in green and purple, respectively. 
Based on highly conserved cleavage sites, lys-C often generates a full-
length CDR-H3-containing peptide as indicated in red. 
 85 
 
 
Figure 4.3 CDR-H3 peptide mass distribution plots for simulated VH sequences 
generated by in-silico trypsin and Lys-C digestion. The inset table shows 
counts of theoretical CDR-H3-containing peptides following Lys-C or 
trypsin digestion of simulated (Igsim) VH sequences and empirical next-
generation sequenced VH genes of peripheral B cells obtained from post-
influenza vaccinated donor serum.  
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4.4.2 UVPD, HCD and ETD Analysis of Lys-C Digested Trastuzumab  
Based on the in silico results described above, lys-C digestion addresses the first 
of two critical variables required for deconvolution of complex antibody mixtures: the 
sampling of peptides derived from the antigen-binding regions (CDRs). The second 
involves the unambiguous characterization of these diagnostic sequences based on 
informative MS/MS spectra. Recently, UVPD has proven to outperform other 
conventional activation methods (e.g. HCD, ETD) for the characterization of proteins and 
large proteolytic peptides on chromatographic timescales owing to its fast and high 
energy deposition, which gives rise to extensive and diverse fragmentation (a, b, c, x, y, 
and z-type ions) throughout the polypeptide backbone.29,40 Thus, UVPD is a compelling 
option to address this latter variable for middle-down sized peptides produced upon lys-C 
proteolysis. 
Trastuzumab was selected as a model antibody to benchmark our middle-down 
UVPD strategy owing to its well-defined sequence, which closely reflects the theoretical 
and empirical repertoire trends described above. Peptide masses were experimentally 
biased using restricted two-hour lys-C digestion at the intact (unreduced) level to promote 
the occurrence of missed cleavages (i.e., fewer exposed lysine residues resulting from 
extensive disulfide bonding) and increase the average length of resultant peptides. 
Reduction and alkylation were carried out immediately following digestion to eliminate 
undesirable crosslinks arising from the presence of intrinsic disulfide bonds and to ensure 
the formation of readily interpretable linear peptides. The resulting mixture was then 
chromatographically separated on a reversed phase C8 column and analyzed by UVPD, 
HCD and ETD on an Orbitrap Elite mass spectrometer operated in high resolution/high 
mass accuracy mode for both precursor and product ion detection. Figure 4.4a,b 
provides comparative summaries of the peptide populations confidently identified based 
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on separate UVPD, HCD and ETD datasets. All three methods performed comparably 
with respect to peptide-level mapping of trastuzumab, yielding ≥ 97% sequence coverage 
of the heavy and light chains (Figure 4.5). These results are consistent with the 
production of a predictable peptide mixture based on selective cleavage at lysines that, on 
average, falls within a suitable middle-down size regime (≥ 4.4 kDa, Figure 4.4b) and is 
amenable to high-throughput LC-MS/MS analysis. However, while all three activation 
methods returned similar peptide-level sequence coverages as a whole, considerable 
variability was observed in the peptide identifications upon which these coverages are 
based (Figure 4.4a). On average, only 56% of peptides identified from each individual 
run were confidently identified by the other two activation methods used, despite 
exceptional run-to-run chromatographic reproducibility. Further evaluation of these 
peptide populations revealed inconsistencies in the identifications of low abundance 
peptides that contained partial or complete sequence overlap with dominant peptide 
forms, but varied based on their number of missed cleavages. For example, UVPD and 
HCD identified three overlapping forms of light chain N-terminal peptides: LC(1-39), 
LC(1-45), and LC(1-103) (where “LC” represents the light chain and the numbers in 
parentheses indicate the amino acid positions) containing up to three internal lysine sites; 
whereas ETD only returned hits to the dominant peptide LC(1-45). Many of these 
variably truncated peptides (a negative byproduct of incomplete digestion) contained 
redundant information, as evidenced by the fact that approximately 90% sequence 
coverage of the heavy and light chain was obtained based exclusively on the 29 
overlapping peptides identified by all three activation methods (Figure 4.6). While the 
majority of these overlapping peptides were present in high abundance (Figure 4.7), 
additional optimization of lys-C digestion parameters may help to limit sample dilution 
and complexity arising from undesirable peptide redundancy.   
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Figure 4.4 Comparison of UVPD, HCD and ETD for middle-down analysis of lys-C 
digested trastuzumab in terms of (a) overlap in identified peptide 
populations and (b) average peptide mass and total peptide-level sequence 
coverage obtained by each activation method. The relative E-scores for the 
29 overlapping peptides identified by all three activation methods are 
compared in (c) and ion cleavage maps obtained for an 8.2 kDa CDR-H1 
and CDR-H2-containing peptide are shown in (d). The hypervariable 
regions are shaded in gray 
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Figure 4.5 Summary of peptide-level sequence coverage of the light and heavy chain 
of trastuzumab obtained by UVPD, HCD, and ETD, respectively. 
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Figure 4.6 Summary of peptide-level sequence coverage of trastuzumab based on 
peptides identified by all three activation methods: UVPD, HCD and ETD. 
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Figure 4.7 Base peak chromatograms for consecutive injections of restricted lys-C 
digested trastuzumab demonstrating high run-to-run reproducibility. 
 
 
 
To better evaluate the performance of UVPD against HCD and ETD for the 
characterization lys-C generated trastuzumab peptides, the highest ranking spectral 
matches for each of the 29 peptides found by all three activation methods were compared 
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based on total number of matching fragment ions, percent coverage of inter-residue 
positions, and relative E-scores (Table 4.1). Note that the E-score represents the inverse 
log of the expectation value (or E-value), which is a confidence metric that describes the 
probability at which a set of fragment ions match to a given sequence by random chance 
alone. As demonstrated in Figure 4.8, UVPD consistently gives rise to a greater number 
of matched fragment ions per peptide (Figure 4.8a), an outcome attributed to the diverse 
array of fragmentation channels accessible to this high energy activation process. To 
more accurately reflect the gain in sequence-informative fragmentation obtained for each 
peptide upon UVPD, the total number of matched fragment ions was normalized to 
peptide length (Figure 4.8b). Based on these data, fragmentation per residue is enhanced 
by an average ratio of 2.3:1:1 for UVPD relative to HCD and ETD alike, allowing more 
extensive and uniform coverage of the peptide backbone that approaches single amino 
acid resolution (Figure 4.8b), as well as results in higher confidence identifications 
across the entire range of lys-C generated peptides. This latter point is illustrated in 
Figure 4.4c, which compares the relative peptide E-scores derived from the UVPD, HCD 
and ETD spectra for the 29 peptides. The relative size of the bars associated with each 
activation method scale with the confidence of the identification. With few exceptions, 
UVPD dramatically outperformed HCD and ETD with respect to peptide confidence 
across the entire mass distribution, resulting in an average E-score that roughly doubled 
that of the more conventional methods (i.e., 143 versus 74 and 77 for HCD and ETD, 
respectively). 
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Mass 
(Da) 
Chain 
(residues) 
Sequence 
E-score  
Inter-residue 
Coverage (%)  
# Matching 
Fragment Ions 
ETD HCD UVPD 
 
ETD HCD UVPD 
 
ETD HCD UVPD 
1872.91 HC (396-412) 
TTPPVLDSDGSFFLYSK 
31.9 37.8 32.9  75 88 94  14 16 36 
2125.06 LC (127-145) SGTASVVCLLNNFYPREAK 68.9 24.0 95.8 
 
94 78 100 
 
28 15 48 
2140.07 LC (189-207) HKVYACEVTHQGLSSPVTK 76.7 64.3 131.2 
 
94 83 100 
 
30 28 62 
2342.17 HC (344-363) GQPREPQVYTLPPSREEMTK 60.4 49.3 105.9 
 
79 74 89 
 
24 20 60 
2543.12 HC (374-395) GFYPSDIAVEWESNGQPENNYK 27.6 63.5 84.4 
 
57 81 95 
 
14 27 52 
2746.34 LC (184-207) ADYEKHKVYACEVTHQGLSSPVTK 95.9 96.6 168.4 
 
96 100 100 
 
39 41 82 
2954.44 HC (252-277) DTLMISRTPEVTCVVVDVSHEDPEVK 57.1 86.9 156.6 
 
76 96 100 
 
27 37 83 
3029.56 HC (1-30) EVQLVESGGGLVQPGGSLRLSCAASGFNIK 107.6 79.8 75.8 
 
83 79 90 
 
46 31 50 
3043.39 HC (418-442) SRWQQGNVFSCSVMHEALHNHYTQK 94.6 73.0 171.1 
 
96 83 96 
 
39 31 87 
3333.63 HC (222-251) SCDKTHTCPPCPAPELLGGPSVFLFPPKPK 73.9 55.1 140.9 
 
69 72 97 
 
35 30 77 
3459.79 HC (292-320) TKPREEQYNSTYRVVSVLTVLHQDWLNGK 119.6 57.6 111.0 
 
96 79 93 
 
50 33 73 
3596.68 LC (184-214) ADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 36.4 88.5 80.3 
 
63 93 77 
 
27 48 52 
3599.72 HC (413-442) LTVDKSRWQQGNVFSCSVMHEALHNHYTQK 109.6 99.4 166.1 
 
90 100 97 
 
49 51 89 
3618.70 LC (150-183) 
VDNALQSGNSQESVTEQDSKDSTYSLSSTLTL
SK 83.5 103.0 174.7  67 94 97  37 54 110 
3721.89 HC (44-76) GLEWVARIYPTNGYTRYADSVKGRFTISADTSK 120.4 90.9 134.0 
 
91 88 97 
 
52 43 77 
3786.89 HC (218-251) 
VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPK
PK 89.9 50.1 124.6  67 58 88  38 29 70 
4160.00 LC (146-183) 
VQWKVDNALQSGNSQESVTEQDSKDSTYSLS
STLTLSK 33.8 105.5 223.7  32 89 100  15 44 119 
4581.35 HC (1-43) 
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDT
YIHWVRQAPGK 115.9 95.2 193.3  79 83 93  53 46 110 
4613.22 HC (252-291) 
DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
GVEVHNAK 102.0 112.7 245.7  72 95 100  48 62 137 
4876.42 LC (1-45) 
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAV
AWYQQKPGKAPK 93.2 64.2 179.5  82 66 89  48 35 106 
4904.32 HC (292-320) TKPREEQYN*STYRVVSVLTVLHQDWLNGK 103.3 29.7 131.0 
 
96 61 89 
 
46 17 83 
5066.38 HC (292-320) TKPREEQYN**STYRVVSVLTVLHQDWLNGK 97.3 31.6 136.7 
 
93 68 89 
 
44 19 83 
5774.70 HC (292-325) 
TKPREEQYN**STYRVVSVLTVLHQDWLNGKEY
KCK 57.9 26.5 123.9  61 61 91  28 20 79 
6475.11 LC (46-103) 
LLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQ
PEDFATYYCQQHYTTPPTFGQGTK 59.1 105.1 177.4  35 65 89  29 53 113 
6558.07 HC (77-136) 
NTAYLQMNSLRAEDTAVYYCSRWGGDGFYAM
DYWGQGTLVTVSSASTKGPSVFPLAPSSK 53.0 114.2 191.2  29 81 93  26 51 125 
6712.31 HC (151-213) 
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL
YSLSSVVTVPSSSLGTQTYICNVNHKPSNTK 37.4 97.1 152.2  27 66 82  21 50 103 
7438.66 HC (226-291) 
THTCPPCPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
AK 
66.4 114.9 103.2 
 
52 77 85 
 
39 62 103 
8014.97 HC (137-213) 
STSGGTAALGCLVKDYFPEPVTVSWNSGALTS
GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
ICNVNHKPSNTK 
68.4 67.6 173.1 
 
49 41 74 
 
40 31 125 
8285.23 HC (1-76) 
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDT
YIHWVRQAPGKGLEWVARIYPTNGYTRYADSV
KGRFTISADTSK 
99.2 68.0 161.0   56 49 81   56 39 115 
  
*G0F glycoform (+1444.5339 Da)            
  
**G1F glycoform (+1606.5867 Da) 
           
 
Table 4.1 Comparison of performance metrics for 29 lys-C generated trastuzumab 
peptides identified by UVPD, HCD and ETD. Peptides are ordered by 
increasing mass and compared in terms of E-value/E-score, percent inter-
residue coverage, and total number of matching fragment ions. 
 
 94 
 
 
Figure 4.8 Histograms comparing the (a) total number of matching fragment ions, (b) 
number of fragment ions normalized to peptide length, and (c) percent 
coverage of inter-residue sites for lys-C generated trastuzumab peptides 
identified by UVPD (2 pulse, 3 mJ), HCD (30% NCE), and ETD (25 ms 
and 50 ms). 
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While the ability to obtain high confidence peptide identifications on the whole is 
compelling, a better assessment of the analytical utility of the middle-down UVPD 
strategy for high-throughput antibody identification is based on its capacity for 
comprehensive characterization of hypervariable CDR sequences that are critical for the 
differentiation of unique antibodies. Of the 29 peptides identified by all three activation 
methods, four peptides exceeding 4.8 kDa in mass were found to encompass all 
hypervariable regions of the heavy (CDR-H1, CDR-H2, and CDR-H3) and light (CDR-
L1, CDR-L2, and CDR-L3) chains of trastuzumab. Figure 4.4d shows a comparison of 
the resulting fragment ion maps for one 8.2 kDa peptide, HC(1-76), encompassing both 
the heavy chain CDR-H1 and the CDR-H2 (both shown in gray) based on high-
throughput analysis by UVPD, HCD, and ETD, respectively. As demonstrated in both the 
sequence maps (Figure 4.4d) and corresponding mass spectra (Figure 4.9), UVPD 
yielded extensive and pairwise fragmentation across the peptide backbone, giving rising 
to a rich array of product ion types (a, b, c, x, y, and z) that enabled the unambiguous 
characterization of both hypervariable regions. Alternatively, both HCD and ETD 
showed more limited fragmentation of the peptide backbone and incomplete inter-residue 
coverage of the CDR regions, resulting in lower confidence identification relative to 
UVPD (Figure 4.4d). 
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Figure 4.9 Comparative MS/MS spectra (120K at m/z 400) for the N-terminally 
derived CDR-H1 and CDR-H2-containing lys-C peptide from 
trastuzumab, HC(1-76), activated by (a) UVPD using 2 pulses at 3 mJ, (b) 
HCD using an NCE of 30%, and (c) ETD at 50 ms reaction time. (Mr of 
peptide = 8285.23 Da, 7+ charge state). The insets demonstrate the 
product ion diversity observed for each activation strategy. The sequences, 
inter-residue coverages, and E-scores are shown in Figure 2d. 
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As previously stated, the CDR-H3 is commonly used in MS-based 
immunoproteomics as a unique molecular signature by which to differentiate antibody 
clonotypes due to its nature as the most diverse hypervariable region and primary 
determinant of antigen recognition.10 Ultimately, the diagnostic value of the CDR-H3 and 
the occurrence of highly conserved lysine sites flanking this region prompted our use of 
restricted lys-C digestion to generate peptides that encompassed this entire hypervariable 
region, making it a particularly important target by which to evaluate our middle-down 
strategy. Figure 4.10 demonstrates the successful implementation of strategic lys-C 
proteolysis to generate an ideal middle-down sized CDR-H3-containing peptide (6.5 
kDa) that was readily identified using all three activation methods compared herein. 
Similar to the results obtained for the CDR-H1/CDR-H2-containing peptide described 
above, UVPD resulted in complete and pairwise coverage of the diagnostic CDR-H3 
(Figure 4.10a). HCD performed comparably to UVPD with respect to coverage 
throughout the CDR-H3 (Figure 4.10b), but yielded lower overall coverage of the 
peptide backbone (Figure 4.10e). ETD performed poorly for the characterization of this 
peptide overall; however, it still provided reasonable coverage of the CDR-H3 region 
(Figure 4.10c). Again, the extensive fragmentation afforded by UVPD allowed improved 
characterization and more confident identification of this diagnostic peptide relative to 
more conventional activation methods as evidenced by comparisons of the number of 
matched ions, the percentage of inter-residue coverage, and the peptide E-scores, all 
shown in Figure 4.10d-f. 
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Figure 4.10 MS/MS spectra (120K at m/z 400) and associated fragment ion maps for a 
full-length CDR-H3-containing Lys-C peptide (one missed cleavage) from 
trastuzumab activated by (a) UVPD using 2 pulses at 3 mJ, (b) HCD using 
an NCE of 30%, and (c) ETD at 50 ms reaction time. (Mr of peptide = 
6558.07 Da, 5+ charge state). Shown for each of the activation methods 
are (d) the total number of matched fragment ions, (e) the percent 
coverage of possible inter-residue cleavage sites, and (f) the peptide 
confidence reported in terms of the relative E-score.. 
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4.4.3 Middle-Down 193 nm UVPD of Anti-Influenza Antibody Mixture  
Owing to the superior performance of UVPD over more conventional HCD and 
ETD for the characterization of large CDR-containing peptides, as demonstrated in initial 
benchmarking experiments with trastuzumab, we next sought to evaluate the potential for 
integration of the middle-down UVPD strategy into an immunoproteomics workflow. For 
these proof-of-principle experiments a mixture of three anti-influenza monoclonal 
antibodies, previously identified in the serum repertoire of a vaccinated donor,42 was 
analyzed. In the interest of evaluating the discriminatory power of this method in an 
unbiased manner, no sequence information was provided for the antibody mixture. The 
LC-MS/UVPD data was then searched against a VH-gene database constructed from 
approximately 15,000 heavy chain sequences previously obtained by next generation 
sequencing of VH genes from peripheral B cells of the donor from which the antibody 
mixture was derived.42 The resulting peptide hits were then ranked by E-score (highest to 
lowest) using an applied E-value threshold of 1E-4, and filtered to remove multiple hits 
to the same VH sequence entry. This process ensures that only the most confident peptide 
hit for each unique VH sequence entry is reported. Hits to 47 unique VH sequences 
remained using the filtering criteria employed as summarized in the E-score distribution 
plot shown in Figure 4.11. Based on these data, hits to three unique VH entries exhibited 
markedly higher E-score values than the other 44 hits (Figure 4.11). In all cases these 
hits correspond to peptides containing complete or partial CDR-H3 sequences. A 
representative example is provided in Figure 4.12 which shows the UVPD spectrum and 
resulting fragmentation map for the highest scoring peptide match to a full-length CDR-
H3 peptide. The extensive coverage afforded by UVPD resulted in 100% coverage of the 
diagnostic hypervariable sequence allowing for unambiguous antibody identification. 
. 
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Figure 4.11  (a) Comparison of E-score distributions for top ranking peptide hits to 
unique Ig VH sequences based on LC-MS/UVPD analysis of a Lys-C 
digested anti-influenza three IgG mixture searched against a donor VH 
gene sequence database, and (b) a summary of ProSight PC search results 
for the top five highest ranking hits to unique Ig VH sequences. 
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Figure 4.12 UVPD spectrum and resulting fragmentation map for an unambiguously 
identified full-length CDR-H3 peptide (Mr = 5708.71 Da, 5+ charge state, 
Ig VH = H1-2-S) from an anti-influenza monoclonal IgG mixture searched 
against a donor VH sequence database. The hypervariable region is shaded 
in gray. 
 
4.5 CONCLUSIONS 
The middle-down workflow presented herein exploits highly conserved lysine 
residues flanking the diagnostic CDR-H3 to generate ideal middle-down sized peptides 
(3-10 kDa) that can be used to uniquely identify antibodies in mixtures. The extensive 
fragmentation afforded by 193 nm UVPD allows comprehensive sequencing of large 
CDR-H3-containing peptides for unambiguous IgG identifications. Moreover, we 
demonstrated the potential utility of integrating middle-down UVPD with Ig-seq VH 
database searching for enhanced antibody serum proteomics.    
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Chapter 5 
Characterization of Therapeutic Monoclonal Antibodies at the Subunit-
Level using Middle-Down 193 nm Ultraviolet Photodissociation
*
 
2 
5.1 OVERVIEW 
Monoclonal antibodies (mAbs) are a rapidly advancing class of therapeutic 
glycoproteins that possess wide clinical utility owing to their biocompatibility, high 
antigen specificity, and targeted immune stimulation. These therapeutic properties 
depend greatly on the composition of the immunoglobulin G (IgG) structure, both in 
terms of primary sequence and post-translational modifications (PTMs); however, large-
scale production in cell culture often results in heterogeneous mixtures that can 
profoundly affect clinical safety and efficacy. This places a high demand on analytical 
methods that afford comprehensive structural characterization of mAbs to ensure their 
stringent quality control. Here we report the use of targeted middle-down 193 nm 
ultraviolet photodissociation (UVPD) to provide detailed primary sequence analysis and 
PTM site localization of therapeutic monoclonal antibody subunits (~25 kDa) generated 
upon digestion with recombinant immunoglobulin G-degrading enzyme of Streptococcus 
pyogenes (IdeS) followed by chemical reduction. Under optimal conditions, targeted 
UVPD resulted in approximately 60% overall coverage of the IgG sequence, in addition 
to unambiguous glycosylation site localization and extensive coverage of the antigen-
binding complementarity determining regions (CDRs) in a single LC-MS/MS 
experiment. Moreover, we exploited the tunable energy deposition afforded by UVPD, as 
well as the complementary nature of UVPD and ETD to obtain deeper sequencing and 
                                                 
*Cotham, V. C.; Brodbelt, J. S. Anal. Chem. 2016, 88, 4004-4013. 
 V.C.C. designed and conducted all experiments.    
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greater overall characterization of IgG subunits. Overall, this targeted UVPD approach 
represents a promising new strategy for the comprehensive characterization of antibody-
based therapeutics.  
 
5.2  INTRODUCTION 
Since the first therapeutic monoclonal antibody (mAb) entered the clinic nearly 
three decades ago, the number of mAb-based products approved by the US Food and 
Drug Administration (FDA) and the European Medicine Agency (EMA) has increased by 
approximately 50-fold.1,2 Moreover, upwards of 300 mAb candidates and their derivatives 
are currently in the clinical development stages, making them among the most rapidly 
advancing biotherapeutic modalities in the pharmaceutical industry.2,3 The success of 
antibody-based biologics, particularly those used in oncogenic and autoimmune disease 
treatment, arise from their ability to elicit or modulate a desired immune response 
through efficient and highly specific interactions with a given target.4–8 These acute 
interactions and the resulting downstream therapeutic efficacy are regulated by mAb 
structural integrity with regard to primary sequence and the presence and abundance of 
post-translational modifications (PTMs), as well as the impact of these variables on 
higher order structure.9 Importantly, heterogeneities introduced via production in cell 
culture or during purification and storage procedures can alter pharmacokinetic 
properties, reduce therapeutic potency and in severe cases stimulate deleterious 
immunogenic responses.10,11 Such modifications include sequence mutations, differential 
glycosylation, and heavy chain C-terminal processing, as well as varying levels of 
deamidation and oxidation.12,13 Consequently, methods that facilitate detailed 
characterization of antibody primary sequence in addition to PTM identification and site 
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localization are critical to ensure mAb safety and efficacy. This objective remains 
challenging, however, due to the size (~150 kDa) and structural complexity of the 
tetrameric immunoglobulin G (IgG) scaffold from which all approved mAb therapeutics 
are derived. The IgG structure consists of two identical heavy chains (HC, ~50 kDa) and 
two identical light chains (LC, ~25 kDa) that are joined through a series of intra- and 
intermolecular disulfides.14 Each chain is further divided into variable (V) and constant 
(C) domains that are responsible for antigen-specific binding and initiation of cell-
mediated effector mechanisms, respectively.15,16  
Advances in sensitivity, resolution, and throughput have established mass 
spectrometry (MS) as the primary analytical tool used for the characterization and quality 
control (QC) of antibody therapeutics within the pharmaceutical industry.17,18 Bottom-up 
peptide mapping workflows, which involve reduction, alkylation and enzymatic digestion 
into constituent peptides followed by liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) analysis, are routinely used to monitor mAb primary sequence across all 
stages of production.19 Although well-established both in terms of peptide-level 
separations and MS/MS activation methods, bottom-up strategies tend to be labor-
intensive and suffer from limitations arising from incomplete peptide sampling and 
artifactual heterogeneities introduced via sample handling and proteolysis that can 
obscure the differentiation of manufacturing-related modifications.17,20 To circumvent 
these shortcomings, tandem-MS based methods that restrict or completely bypass 
enzymatic digestion have gained traction for mAb characterization.21–29 The latter, or top-
down approach, is particularly desirable due to the lack of sample preparation required, 
which translates to maintenance of  high structural integrity, in addition to its ability to 
provide immediate feedback on sequence fidelity and proteoform abundance based on 
intact mass measurement.30,31 However, both the size and structural complexity of IgGs 
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render high-throughput MS/MS analysis at the top-down level non-trivial using 
conventional activation methods and current state-of-the-art instrumentation.26–28,32 To 
date, electron-transfer dissociation (ETD) and electron-capture dissociation (ECD) have 
emerged as the methods of choice for top-down sequencing of mAbs due to their 
enhanced protein-level fragmentation efficiency compared to low energy, slow heating 
methods, such as collision-induced dissociation (CID).26–28 Despite this improved 
efficiency, electron-based methods are limited to the interrogation of approximately 30-
35% of the antibody structure,  due in part to the number of disulfide protected regions 
across each IgG domain.27,28 These important structural features currently preclude top-
down MS/MS analysis as a standalone method for comprehensive mAb characterization.     
Middle-down mass spectrometry has surfaced as a compelling alternative that 
combines the strengths of both bottom-up and top-down methods and mitigates their 
shortcomings. This approach generally involves restricted enzymatic digestion to 
generate large peptides (~3-20 kDa) that are amenable to high resolution LC-MS/MS 
analysis.21,24,33–35 IgG subdomain analysis is a common variation of the middle-down 
approach  accomplished via chemical or electrochemical reduction of intermolecular 
disulfides to produce free heavy chains (~50 kDa) and free light chains (~25 kDa) or in 
combination with selective cleavage near the hinge region with proteases such as papain 
or IdeS to generate three distinct ~25 kDa subunits consisting of the free light chain (Lc), 
the heavy chain variable domain (Fd), and the heavy chain Fc monomer (Fc/2).17,21–23,36–38 
While better suited for high-throughput analysis compared to their intact counterparts, 
characterization of antibody subunits remains challenging due to inherent limitations in 
the speed and sensitivity of high resolution measurements required for large (≥ 25 kDa), 
highly charged species within narrow chromatographic elution windows.39–41 Fornelli and 
co-workers addressed these issues on an Orbitrap Elite instrument by utilizing a survey 
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LC-MS run to first establish accurate mass measurements of IdeS generated IgG 
subunits, followed by subsequent targeted LC-MS/MS analyses based on broadband ETD 
of multiple highly charged precursors.22 Using this targeted approach, acquisition of a 
greater number of scans was possible to generate averaged spectra with improved signal-
to-noise, resulting in approximately 30-50% sequence coverage of IgG subunits from a 
single LC-MS/ETD run. At a slight cost in throughput, sequence coverages were 
improved to 60-70% when transients were averaged from 6-10 independent LC-MS/ETD 
runs collected with varied ETD reaction times.22 Wang et al. demonstrated only 
marginally lower sequence coverage of the Lc subunit using a single LC-MS/MS analysis 
based on broadband higher energy collisional activation (HCD).23 However, since this 
middle-down approach did not incorporate enzymatic digestion of the heavy chain, a 
direct comparison between HCD and ETD performance for the Fd and Fc/2 subunits is 
currently lacking.  
Recently, our group has demonstrated substantial performance gains in the 
characterization of intact proteins using 193 nm ultraviolet photodissociation (UVPD) 
and hybrid activation methods thereof relative to conventional collision- and electron-
based strategies.42–45 The high energy deposition afforded by 193 nm UV photoabsorption 
facilitates interrogation of nearly every inter-residue site to provide unparalleled 
identification and site localization of sequence variants and PTMs in intact proteins.42,44 
Moreover, the utility of UVPD for whole protein characterization on chromatographic 
timescales has also been demonstrated.43,45 These performance attributes make UVPD an 
ideal candidate to address the increasing demand for analytical methods that provide 
efficient and detailed characterization of antibody therapeutics to ensure product quality 
and clinical safety. Herein, we present a middle-down strategy that capitalizes on the high 
energy deposition and tunability of UV photoactivation to achieve unprecedented 
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sequence coverage of monoclonal antibody subunits within a single LC-MS/MS 
experiment. Modulation of the activation parameters, both in terms of pulse number and 
pulse energy allows for greater control over the extent of coverage of terminal and 
interior regions of the subunit sequence. By combining the information from four 
separate targeted UVPD experiments using variable laser parameters, subunit sequence 
coverages as high as 85% were achieved.     
 
5.3 EXPERIMENTAL 
5.3.1 Materials and Reagents 
Clinical grade recombinant monoclonal antibodies of the IgG1 subclass were used 
for all experiments. Trastuzumab (Herceptin) was kindly donated by Genentech. 
Adalimumab (Humira) was purchased at >97% purity from BOC Sciences (Shirley, NY). 
Lyophilized recombinant immunoglobulin G-degrading enzyme from Streptococcus 
pyogenes (IdeS/FabRICATOR, Genovis) was obtained from Bulldog Bio, Inc. 
(Portsmouth, NH). All solvents and mobile phase additives were purchased in LC-MS 
grade purity. Water, acetonitrile, urea and all other buffer components were obtained 
from Sigma-Aldrich (St. Louis, MO). Isopropyl alcohol and formic acid were purchased 
from Fisher Scientific (Fairlawn, NJ). Tris(2-carboxyethyl)phosphine (TCEP) solution 
was obtained from Pierce (Rockford, IL). 
5.3.2 IdeS Digestion and Sample Preparation 
Sample preparation was adapted from that previously described by Fornelli et al.22 
Briefly, acetone-precipitated monoclonal antibodies were resuspended at 5 μg/μL in IdeS 
cleavage buffer (50 mM sodium phosphate, 150 mM NaCl, pH 6.6)  and subjected to 
hinge-selective cleavage with one unit of IdeS per microgram of IgG at 37˚C for 30 
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minutes to produce the F(ab’)2 and Fc fragments. Following digestion, these fragments 
were denatured with 4 M urea and reduced in the presence of 30 mM TCEP for 30 
minutes at room temperature to produce the Fc/2, Lc and Fd IgG subunits (~25 kDa). To 
quench the reaction and prevent disulfide bond reformation, the sample was acidified 
with 1% formic acid (FA). Immediately prior to analysis the sample was diluted to 1 
μg/μL in 0.1% FA.  
5.3.3 Liquid Chromatography and Mass Spectrometry   
Chromatographic separation of IgG subunits was accomplished using a Dionex 
Ultimate 3000 microbore liquid chromatography system (Sunnyvale, CA) equipped with 
a Waters XBridge Protein BEH300 C4 column (2.1mm x 250 mm, 3.5 μm particle size) 
heated to 65˚C. Mobile phase A consisted of 0.1% formic acid in water, and mobile phase 
B consisted of 39.9% IPA, 60% ACN, and 0.1% formic acid. 2 μg of IgG subunit mixture 
was injected on-column and separated using a steep linear ramp from 5% B to 20% B 
over 2 minutes followed by a shallow linear gradient from 20% B to 40% B over 28 
minutes at a flow rate of 250 μL/min. The LC system was coupled via an electrospray 
ionization (ESI) source to a Thermo Fisher Orbitrap Elite mass spectrometer (Bremen, 
Germany) outfitted with a 193 nm ArF excimer laser (Coherent ExciStar XS) to allow 
UVPD in the HCD cell as previously described.42,46 For all experiments, an ESI source 
voltage of 3.75 kV, S-lens rf level of 70%, and heated capillary temperature of 350˚C 
were used. The sheath and auxiliary gas flow was maintained at 35 and 5 arbitrary units, 
respectively. The HCD collision gas pressure in the vacuum chamber containing the 
Orbitrap mass analyzer was reduced so that the change in pressure (∆p) equals 0.1 x 10-10 
(~5 mTorr) as previously described to enhance the detection of low abundance and large 
product ions.22,42 Prior to acquisition of MS/MS data, a survey LC-MS run was performed 
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to establish the chromatographic elution window and charge state distributions for each 
IgG subunit. All MS1 spectra were acquired using a mass range of m/z 400-2000 and 
resolving power of 120,000 at m/z 400. For all MS2 experiments, targeted LC-MS/MS 
programs were developed in which spectra were acquired using a mass range of m/z 205-
2000 with 240,000 resolution at m/z 400, and each FTMS scan was the result of 20 
microscans. For UVPD, an automatic gain control (AGC) target of 1.0 x 106 was used 
and the most abundant charge state was continuously activated across the elution profile 
for each subunit using either one or two 5 ns laser pulses at a range of 1 to 2.5 mJ per 
pulse. In the UVPD set-up, the laser is neither focused nor collimated. ETD data was 
acquired using a reaction time of 5 ms with a reagent AGC target of 7.5 x 105 and a 
maximum anion injection time of 50 ms. For direct comparison with UVPD under the 
same conditions, ETD activation was performed on the most abundant charge state of 
each subunit using a 20 m/z isolation window. To compare the performance of UVPD 
with more optimal ETD conditions, ETD was also carried out using multiple highly 
charged precursors via a wide isolation window (150 m/z) as described by Fornelli et al.22 
 
5.3.4 Data Processing 
MS1 spectra collected across the entire chromatographic elution profile for each 
IgG subunit were combined to generate a single averaged MS1 spectrum that was 
subsequently deconvolved using the Xtract algorithm (Thermo Fisher Scientific) with a 
S/N ratio of 3 to determine the monoisotopic mass of each subunit. For MS/MS data, all 
scans for a given precursor or range of precursors were averaged and a new Thermo 
.RAW file was generated for each subunit. The averaged UVPD spectra were 
deconvolved with Xtract to obtain monoisotopic mass information for all product ions 
with a S/N ratio of 3 or higher and then analyzed using ProSight Lite with UVPD 
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searching enabled in addition to Protein Prospector-assisted manual interpretation to 
search for 10 ion types: a, a+1, b, c, x, x+1, y, y-1, Y and z. ETD spectra were searched 
for c, z, and y-type product ions. Cleavage sites were assigned using a 10 ppm tolerance. 
 
5.4 RESULTS AND DISCUSSION 
5.4.1 Evaluation of IgG Subunit Separation and Accurate Mass Analysis 
Trastuzumab and adalimumab used in this study are two therapeutic monoclonal 
IgG1 antibodies that possess well-characterized primary sequences and post-translational 
modifications to allow for reliable benchmarking of our targeted middle-down UVPD 
strategy. As summarized in Figure 5.1, the first part of the workflow utilizes hinge-
selective digestion with IdeS, which cleaves at the conserved di-glycine motif of the 
heavy chain (Xxx-L-L-G/G-P-S-xxX), followed by reduction of inter- and intra-chain 
disulfide bonds to produce the Fc/2, Lc, and Fd antibody subunits. Complete sample 
preparation was accomplished in approximately one hour using mild reaction conditions 
previously shown to minimize processing-derived artifacts, such as oxidation and 
carbamylation that are common to lengthier bottom-up digestion procedures.22,38 The 
overlaid total ion chromatograms (TIC) shown in Figure 5.2 for IdeS digested 
trastuzumab (Figure 5.2a) and adalimumab (Figure 5.2b) demonstrate efficient 
conversion of intact IgG into the three constituent subdomains of interest. Moreover, the 
TICs demonstrate baseline resolution of the subunit mixture with high chromatographic 
reproducibility for replicate injections of the same antibody using reversed-phase C4 
separation. These criteria are critical for the integration of subunit-specific targeted 
MS/MS activation across discreet elution windows used in the second half of the 
workflow (Figure 5.1). 
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Figure 5.1 Schematic representation of sample preparation and analysis workflow. 
IgG subunits are first produced from IdeS digestion and TCEP reduction. 
High resolution LC-MS1 analysis using 120K resolution (at m/z 400) 
provides accurate mass measurements of subunits in addition to elution 
profiles and charge state distributions necessary for targeted MS/MS 
activation. 
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Figure 5.2 Stacked total ion chromatograms for triplicate LC-MS analyses of IdeS-
derived (a) trastuzumab and (b) adalimumab subunits: Fc/2, Lc, and Fd, 
respectively, with baseline chromatographic resolution. 
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Despite greater than 90% sequence identity between full length trastuzumab and 
adalimumab, the majority of the amino acid variability occurs within the antigen-binding 
complementarity determining regions (CDRs) of the Lc and Fd subdomains (Figure 5.3) 
resulting in considerable variations in both chromatographic and ESI profiles that must be 
empirically defined for respective mAbs. This was accomplished using a strategy similar 
to that described by Fornelli et al.,22 in which a high resolution LC-MS survey run was 
first performed to provide immediate feedback regarding subunit elution and charge state 
distribution. As demonstrated in Figure 5.4, MS1 acquisition at a resolving power of 
120,000 (m/z 400) affords isotopic resolution of the charge state envelope and 
monoisotopic mass determination with sub 4 ppm mass accuracy for each subunit within 
a single LC-MS experiment. High resolution accurate mass analysis also revealed the 
presence of two commonly observed post-translational modifications on the heavy chain-
derived Fc/2 subunit: N-linked glycosylation and C-terminal lysine truncation. Glycan 
microheterogeneity was observed as consecutive mass shifts consistent with either fucose 
or hexose saccharide additions. Masses corresponding to the G0, G0F, G1F and G2F 
glycoforms were identified for trastuzumab (Figure 5.4a), whereas adalimumab 
exhibited only the G0F and G1F glycovariants (Figure 5.4d). Furthermore, each Fc/2 
variant showed a conserved loss of 128 Da from the theoretical subunit mass, indicative 
of complete processing of the heavy chain C-terminal lysine. Both of these modifications 
have important implications on the regulation of cell-mediated effector functions and are 
thus essential for the complete characterization of IgG.16,47 While accurate mass 
information provides insight regarding the presence of probable structural features based 
on a priori knowledge of common mAb modifications, the MS1 data alone does not 
facilitate unambiguous localization of these modifications to specific residues.  
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Figure 5.3 Sequence alignment of trastuzumab and adalimumab Fc/2, Lc, and Fd 
subunits. Hypervariable CDRs are shown in red.   
 117 
 
 
Figure 5.4 ESI mass spectra for the Fc/2, Lc, and Fd subunits of trastuzumab (a-c) 
and adalimumab (d-f), respectively, collected at 120K resolution (at m/z 
400). The insets for the Fc/2 subdomains demonstrate the glycoform 
heterogeneity in each IgG based on accurate mass measurement. 
Trastuzumab exhibited the G0, G0F, G1F, and G2F glycoforms (a), 
whereas adalimumab exhibited the G0F and G1F variants only. The insets 
for all other subunits demonstrate the isotope distribution for the most 
abundant charge state.   
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5.4.2 Optimization of Targeted UVPD for Maximal Sequence Coverage and PTM 
Localization 
Characterization of whole proteins or large polypeptides thereof on 
chromatographic timescales has been shown to rely critically on the nominal resolving 
power and number of spectral averages acquired during activation.22,45,48 A recent study in 
our lab, which utilized 193 nm UVPD for the high-throughput interrogation of intact 
proteins, showed that optimal characterization, both in terms of the number of inter-
residue cleavages throughout the primary sequence and site localization of PTMs, was 
facilitate by the use of maximal resolving power.45 This was attributed to improved 
deconvolution of rich UVPD spectra that contain extensive arrays of highly charged 
product ions and instances of overlapping isotopic distributions that were otherwise 
obscured at lower resolution settings.45 To address the latter variable, Fornelli and co-
workers employed targeted MS/MS acquisition to maximize the number of scans 
collected during middle-down ETD analysis to generate more informative spectra with 
enhanced single-to-noise (S/N).22 For the present study, we hypothesized that combining 
these data acquisition strategies with the sequencing power of 193 nm UVPD would 
afford greater depth of characterization of therapeutic IgG subunits within the context of 
a high-throughput workflow. 
Optimization of laser parameters for UVPD in terms of pulse number and energy 
per pulse was carried out for trastuzumab with the goal of maximizing sequence coverage 
of all subunits within a single targeted LC-MS/MS experiment, in addition to obtaining 
fragmentation-level confirmation and site localization of PTMs. A limited set of test 
conditions was evaluated based on the degree of coverage, in terms of the ratio of 
observed versus total number of inter-residue positions, for a model modified protein of 
similar size (alpha casein, ~24 kDa, data not shown) and consisted of combinations of 
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one or two laser pulses with energies ranging from 1 to 2.5 mJ per pulse. To achieve the 
highest MS2 sensitivity and spectral S/N, we exploited the charge-independent nature of 
193 nm UVPD42,49 to continuously activate the most abundant charge state for each 
subunit (25+, 22+ and 24+ charge states for the Fc/2, Lc, and Fd, respectively) across the 
elution window defined by a preceding LC-MS1 survey run. Composite MS2 spectra 
generated by merging 60 to 80 microscans acquired at 240K resolution during targeted 
activation were then used to evaluate which set of laser conditions promoted optimal IgG 
characterization. 
As previously mentioned, Fc glycosylation is a key regulator of antibody effector 
functions, including but not limited to antibody-dependent cell-mediated cytotoxicity 
(ADCC) and phagocytosis (ADCP), via the modulation of IgG-Fc interactions with 
respective cell surface receptors.16 Due to its critical role in the immune response, most 
therapeutic IgGs possess a highly conserved site of N-linked glycosylation at asparagine 
297 (Asn-297) of the heavy chain, which consists of a heptasaccharide core 
(GlcNAc4Man3) that is often variably modified during protein engineering and 
bioproduction processes.50,51 Both the type and relative abundance of glycan 
microheterogeneities can have a profound effect on the pharmacological properties and 
therapeutic efficacy of mAb-based drugs. Thus an important metric by which to evaluate 
UVPD for the characterization of IgG is its ability to retain intact glycan and 
glycosylation site information. While photodissociation at 157 nm and 193 nm have 
shown improvement over collisional activation methods at preserving labile glycosidic 
bonds at the peptide level,52,53 this has yet to be investigated at the protein or subunit 
level. A representative example of UVPD performance for the characterization of the 
glycosylated Fc/2 subunit of trastuzumab is shown in Figure 1. Due to its greatest overall 
abundance in the MS1 spectrum, the 25+ charge state of the G0F glycoform (see top right 
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inset of Figure 5.5) was selected for repeated photoactivation. The resulting UVPD 
spectrum was first searched against theoretical fragment ion masses corresponding to the 
unmodified Fc/2 sequence using a strict 10 ppm mass tolerance (Figure 5.5 bottom left). 
The identification of N-terminally derived product ions (a, b, c) showed an abrupt stop at 
the Asn-61 position, which corresponds to the glycosylated residue of interest (Figure 
5.5 middle). A similar loss of matched C-terminal product ions (x, y, z) beyond Asn-61 
was also observed; albeit this loss appears less dramatic due to a lower frequency of bi-
directional fragmentation in terminally-located regions, consistent with previously 
reported UVPD results for proteins of similar size.44 It should be noted here that C-
terminal product ions were only identified when the terminal residue was removed, thus 
confirming lysine processing of the Fc/2. Upon the addition of 1444.53 Da at the Asn-61 
position to reflect the mass of the G0F glycan, 40 additional product ions were identified 
and the total sequence coverage was boosted from 50% to 62% (Figure 5.5 bottom right). 
As shown in the middle panel of Figure 5.5, consecutive a-ions allow unambiguous site 
localization of the G0F glycan and provide unequivocal evidence for the generation of 
diagnostic fragment ions that retain intact glycan information. 
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Figure 5.5 MS1 spectrum of the Fc/2 subunit of trastuzumab showing mass shifts 
consistent with glycoform microheterogeneity (top). The inset 
demonstrates consecutive saccharide additions to the core N-linked glycan 
structure. The zoomed region of the deconvolved 193 nm UVPD mass 
spectrum (middle) of the 25+ charge state of the G0F glycoform shows a 
mass shift consistent with the intact glycan structure between consecutive 
a ions. An abrupt stop in matched N-terminally derived ions allows for 
unambiguous glycan site localization (bottom).   
 
 
 
 
 122 
Once it was confirmed that Fc/2 fragmentation was not prohibitively biased by 
preferential cleavage of the glycan moiety, UVPD performance was further evaluated 
based on the total sequence coverage per subunit as a function of laser parameter 
selection (Figure 5.6). In general, two pulses of 193 nm photons yielded a greater degree 
of sequence informative fragmentation compared to single pulse activation, likely due to 
enhanced energization of the polypeptide backbone leading to more efficient 
photodissociation. With regard to energy per pulse, both the Fc/2 and Lc subunits 
exhibited improved coverage as laser power was increased, while the opposite was true 
for the Fd subdomain. This is readily demonstrated by comparing subunit sequence 
coverages obtained for individual targeted LC-MS/UVPD experiments performed using 
dual pulse activation at either 1 or 2.5 mJ per pulse. As summarized in Figure 5.6, a laser 
power of 1 mJ/pulse promoted 58%, 59% and 53% sequence coverage of the Fc/2, Lc, 
and Fd subunits, respectively. These values rose to 65% and 66% for the Fc/2 and Lc 
subunits at the higher energy setting of 2.5 mJ/pulse, whereas Fd coverage fell to 42%. 
These results likely reflect “over”-dissociation of the Fd backbone by way of enhanced 
production of secondary fragment ions or internal ions at increasingly energetic 
activation conditions. This outcome for the Fd polypeptide can be rationalized based on 
its greater length (i.e., 239 amino acids (aa) versus 210 aa and 214 aa of the Fc/2 and Lc, 
respectively) taken together with the fact that the amide backbone serves as the 
chromophore at 193 nm.54 Thus, as the length of the amino acid chain increases, the 
magnitude of the absorption cross-section also increases, resulting in more efficient 
photoactivation.  
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Figure 5.6 Sequence coverage observed as a function of laser parameter selection 
used for targeted UVPD of the most abundant precursor of the Fc/2 (25+), 
Lc (22+) and Fd (24+) subunits of trastuzumab.   
 
To explore this phenomenon in greater detail, the fragmentation information 
obtained by UVPD at each set of activation parameters was plotted as histograms 
showing the summed N-terminal (a, b, c) and C-terminal (x, y, z) product ion abundances 
arising at all inter-residue sites across the Fd backbone (Figure 5.7). Changes in 
fragmentation, both in terms of cleavage location and ion abundance support the 
hypothesis of increasing secondary dissociation at elevated laser power. Figure 5.7d is 
particularly illustrative of this point as the histogram is essentially devoid of sequence 
information from the interior of the polypeptide and instead shows bias towards smaller 
terminally-derived product ions that are expected to undergo less efficient secondary 
dissociation due to their inherently lower photoabsorption cross-sections. Conversely, 
greater access to interior regions of the Fd sequence was afforded by lowering the laser 
power to effectively modulate energy deposition in favor of the formation of large 
energetically stable primary fragment ions (Figure 5.7a-c). This strategy was particularly 
useful for obtaining sequence information in the complementarity determining regions 
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(CDRs) of the IgG variable domains, which are critical indicators of antigen-binding 
specificity and mAb therapeutic efficacy. Consequently, coverage of these highly 
diagnostic regions derived from the heavy chain was used as the final metric by which to 
evaluate UVPD performance for IgG characterization. As shown in Figure 5.7, dual 
pulse activation at both 1 mJ/pulse (Figure 5.7b) and 2 mJ/pulse (Figure 5.7c) yielded 
nearly complete fragmentation in these diagnostic regions (shown in gray), while also 
affording the greatest overall coverage of the Fd subunit. 
 Based on the criteria of total sequence coverage, PTM site localization, and CDR 
sequence confirmation, optimal characterization of IgG subunits was accomplished when 
UVPD was carried out using dual pulse activation at 2 mJ/pulse. Under these conditions, 
a single targeted LC-MS/UVPD experiment resulted in 62% sequence coverage of both 
the Fc/2 and Lc subunits of trastuzumab, and 52% coverage of the larger Fd subunit 
(Figure 5.7). Importantly, this level of characterization is comparable to that reported for 
ETD upon combining the MS/MS data from multiple runs completed at varying ETD 
reaction times,22 thus demonstrating significant gains in throughput using this targeted 
UVPD strategy. To emphasize the utility of tunable energy deposition for sequence 
characterization by UVPD, we combined the data from all four LC-MS/MS runs carried 
out using the laser conditions previously described. The resulting fragment ion maps 
shown in Figure 5.8a-c for the Fc/2 (G0F glycoform), Lc and Fd subunits of 
trastuzumab, respectively, reveal unprecedented characterization of IgG subunits owing 
to greater control over energy deposition and subsequent fragmentation. As summarized 
in Figure 5.8d, sequence coverages were dramatically increased to values above 80% for 
the Fc/2 and Lc subunits, and just under 70% for the Fd subunit. Moreover, all CDRs 
from both the light and heavy chain variable domains were fully sequenced (these regions 
are shown in gray in Figures 5.8b and 5.8c). 
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Figure 5.7 Histograms showing the summed N-terminal (a, b, c) and C-terminal (x, y, 
z) fragment ion abundances originating from cleavages at each inter-
residue position across the Fd subunit of trastuzumab as a function of 
pulse number (1 or 2 pulses) and pulse energy (nominally 1 mJ, 2 mJ, or 
2.5 mJ) used for UV photoactivation. The sequence positions 
corresponding to the CDRs are shaded in gray.   
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Figure 5.8 (a-c) Fragmentation maps for trastuzumab subunits generated from 
combining the fragment ion information obtained from four independent 
UVPD runs collected using varied laser parameters. The CDR sequences 
are shown in gray. (d) Comparison of sequence coverage obtained for a 
single LC-MS/UVPD run using fixed laser conditions versus that obtained 
from combining UVPD data from four runs collected with varied laser 
parameters. The following charge states were isolated for UVPD:  +25 for 
Fc/2, +22 for Lc, and + 24 for Fd. 
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5.4.3 Benchmarking UVPD against ETD for Subunit Sequence Characterization 
To rule out the possibility that greater sequence coverage of IgG subunits 
obtained with UVPD relative to the leading ETD-based method22 arises from differences 
in instrument performance or the acquisition parameters used, a direct comparison of 
both activation strategies was carried out on our Orbitrap system. To minimize bias, ETD 
was performed in two fashions based on the observations of Fornelli et al.22 using either: 
1) narrow 20 m/z isolation of the most abundant charge state (identical to UVPD) or 
alternatively, 2) wide 150 m/z isolation and broadband activation of multiple highly 
charged precursors. All ETD experiments were carried out using a 5 ms reaction time and 
UVPD was accomplished using previously optimized activation conditions. The lower 
complexity of ETD mass spectra, containing mainly c/z ions,  relative to the higher 
complexity of UVPD mass spectra (a, b, c, x, y, z-ions, respectively) mitigates the need 
for acquisition at 240K resolution; however, all data was collected at this resolving power 
to facilitate spectral comparisons. Performance metrics were evaluated based on the total 
number of positionally unique N-terminal and C-terminal fragments produced, as well as 
the overall sequence coverage obtained for each subunit of trastuzumab and adalimumab 
within single targeted LC-MS/MS analyses. In all cases, UVPD outperformed both 
variations of ETD as summarized in Figure 5.9. As expected, ETD exhibited improved 
fragmentation efficiency under conditions of greater charge density, such as those arising 
from simultaneous isolation and activation of multiple highly charged precursors; 
however, UVPD still produced between 25-30% more positionally unique fragment ions. 
Note that this increase does not directly correlate with changes in sequence coverage 
because N-terminal and C-terminal ion pairs arising from cleavage at the same sequence 
position were not accounted for. Collectively, these results point to enhanced conversion 
of the precursor into sequence-informative product ions by UVPD, likely due to its ability 
 128 
to better disrupt non-covalent interactions that persist in the gas phase and lead to non-
dissociative electron transfer by ETD, as previously described.55,56 Differences in the 
locations in which these MS2 events occur (i.e., UVPD in the HCD cell versus ETD in the 
linear ion trap) introduce variations in product ion transfer that may also contribute to the 
differences observed in the resulting fragment ion populations; although this effect was 
minimized through optimization of pressure conditions for improved transfer efficiencies. 
While UVPD leads to greater overall sequence informative fragmentation within a single 
experiment, the analytical merit of combining the unique information from both UVPD 
and broadband ETD was evaluated to assess the complementarity of the fragment ion 
populations produced by both activation methods. As demonstrated in the lower half of 
Figure 5.9 based on the fourth bar in the clustered bar graph, combining the sequence 
information from separate UVPD and ETD spectra yields considerable gains in coverage, 
going from 59% for UVPD (on average for the three subunits) and 46% for ETD (on 
average for the three subunits) to a net coverage of 74% for trastuzumab and similarly 
72% for adalimumab. An illustrative example of the complementary nature of these 
activation methods is demonstrated in the fragment ion maps for the Fc/2 subunit of 
trastuzumab shown in Figure 5.10. Notably, in numerous regions throughout the 
sequence, where one activation method produced sparse coverage the other yields 
considerably greater sequence information (i.e., see coverage for regions including 
residues 25-34 and 62-71 in Figure 5.10), thereby greatly extending the level of 
characterization. 
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Figure 5.9 Evaluation of unique fragment ions and sequence coverage obtained from 
single targeted LC-MS/MS analyses of trastuzumab and adalimumab 
subunits based on UVPD (20 m/z isolation, most abundant charge state), 
ETD (5 ms reaction time) using single precursor isolation (20 m/z 
isolation, the most abundant charge state), and ETD (5 ms reaction time) 
using multiple precursor isolation (150 Th isolation, high charge states). 
The most abundant charge states for trastuzumab were as follows: +25 for 
Fc/2, +22 for Lc, and +24 for Fd. The isolation range used for multiple 
precursor isolation included: +25 to +31 for Fc/2, +24 to +28 for Lc, and 
+25 to +29 for Fd. The most abundant charge states for adalimumab were 
as follows: +26 for Fc/2, +23 for Lc, and +24 for Fd. The isolation range 
used for multiple precursor isolation included: +26 to +30 for Fc/2, +25 to 
+27 for Lc, and +25 to +28 for Fd.  The fourth bar (purple) in the lower 
bar graphs shows the net sequence coverage for combined product ion 
information from UVPD and broadband ETD. 
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Figure 5.10 Fragment ion maps for the Fc/2 subunit of trastuzumab generated by a 
single LC-MS/MS experiment based on UVPD (top left) and broadband 
ETD (top right) and a composite map (bottom) generated by combining 
the fragment ion information from both experiments. 
 
Representative fragmentation spectra and associated sequence ion maps are 
shown in Figure 5.11 for UVPD, narrow isolation- and wide isolation ETD of the Fd 
subunit of trastuzumab. UVPD exhibited both the greatest overall product ion density and 
ion-type diversity, resulting in a rich array of a, b, c, x, y, and z-type ions as indicated in 
both the insets and fragment ion maps provided (Figure 5.11a). As expected, ETD 
produced predominantly c and z ions, as well as a slight secondary contribution of y-type 
ions (Figures 5.11b-c). Importantly, better coverage of the terminal regions of the Fd 
sequence by UVPD allowed improved sequencing of the N-terminally located variable 
domain CDR1 and CDR2, and similar coverage of the CDR3 compared to both variations 
of ETD; however, ETD does contribute information from several unique inter-residue 
sites, most notably in the diagnostic CDR3, which are not observed by UVPD, thus 
further emphasizing the complementary nature of these activation techniques. 
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Figure 5.11 Comparative MS/MS spectra and associated fragmentation maps for the 
Fd subunit of trastuzumab following isolation of the most abundant 
precursor ion (24+) obtained using  (a) UVPD (2 pulses, 2 mJ), and (b) 
ETD (5 ms reaction time), respectively, and (c) ETD (5 ms reaction time) 
with wide isolation (150 m/z) centered at the 27+ charge state. The insets 
demonstrate the product ion diversity observed for each activation 
strategy. The CDRs are shaded in gray. All spectra are shown as the 
combination of multiple scans collected at 240K resolution across the 
elution profile for a single targeted LC-MS/MS analysis. 
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5.5 CONCLUSIONS 
The utility of targeted middle-down 193 nm photodissociation for improved 
characterization of therapeutic monoclonal antibody subunits within an LC-MS/MS 
workflow was demonstrated. The rapid and high energy activation afforded by UVPD 
resulted in cleavage at a greater number of inter-residue positions for all subunits 
compared to ETD performed for single charge states or spanning a range of charge states, 
while also maintaining the integrity of labile modifications, as demonstrated for the Fc/2 
glycan. Collectively, this allowed confident glycosylation site localization in the Fc/2 
heavy chain constant domain and confirmation of diagnostic CDR sequences in the 
variable portions of the Lc and Fd subdomains. Moreover, a degree of control over the 
extent of secondary dissociation was demonstrated via modulation of pulse number and 
laser power used for UVPD. This can be used strategically to improve coverage or 
enhance product ion signal-to-noise from specific regions of the backbone. For example, 
if a particular modification is expected to occur near one terminus of a subunit, higher 
energy photoactivation conditions might be preferable in order to bias fragmentation 
towards the production of smaller, high intensity terminal product ions. The resulting data 
from this kind of “customized” UVPD run can be used independently or in combination 
with data from other runs performed using varied pulse conditions, or with 
complementary broadband ETD to obtain more comprehensive coverage of the IgG 
sequence, as shown in this study.  
While this work demonstrates an advantage to using UVPD over ETD for subunit 
characterization on an Orbitrap Elite mass spectrometer, we anticipate that ongoing 
development of newer generation Orbitrap platforms will continue to improve 
performance metrics for both activation methods described herein. Moreover, the use of 
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hybrid MS2 techniques, such as EThcD57,58 and ETUVPD43 may offer compelling 
advantages to further improve subunit characterization within single LC-MS/MS 
experiments via the simultaneous generation of product ions that are both complementary 
and unique to each activation type, as well as enhanced conversion of both initial 
precursors and charge-reduced precursors into diagnostic fragment ions of analytical 
value. 
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Chapter 6 
High-Throughput Bioconjugation for Enhanced 193 nm 
Photodissociation via Droplet Phase Initiated Ion/Ion Chemistry using a 
Front-end Dual Spray Reactor* 
3 
 
6.1  OVERVIEW 
Fast on-line chemical derivatization of peptides with an aromatic label for 
enhanced 193 nm ultraviolet photodissociation (UVPD) is demonstrated using a dual 
electrospray reactor implemented on the front-end of a linear ion trap (LIT) mass 
spectrometer. The reactor facilitates the intersection of protonated peptides with a second 
population of chromogenic 4-formyl-1,3-benzenedisulfonic acid (FBDSA) anions to 
promote real-time formation of ion/ion complexes at atmospheric pressure. Subsequent 
collisional activation of the ion/ion intermediate results in Schiff base formation 
generated via reaction between a primary amine in the peptide cation and the aldehyde 
moiety of the FBDSA anion. Utilizing 193 nm UVPD as the subsequent activation step in 
the MS3 workflow results in acquisition of greater primary sequence information relative 
to conventional collision induced dissociation (CID). Furthermore, Schiff base modified 
peptides exhibit on average a 20% increase in UVPD efficiency compared to their un-
modified counterparts. Due to the efficiency of covalent labeling achieved with the dual 
spray reactor, we demonstrate that this strategy can be integrated into a high-throughput 
LC-MSn workflow for rapid derivatization of peptide mixtures. 
 
                                                 
*Cotham, V. C.; Shaw, J. B.; Brodbelt, J. S. Anal. Chem. 2015, 87, 9396-9402. 
 V.C.C. designed and conducted all experiments.    
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6.2  INTRODUCTION 
 Bioconjugation techniques have long been used to extend the versatility of mass 
spectrometry (MS) for proteomic analysis.1,2 The number of reactive moieties 
incorporated into polymeric amino acid chains makes them amenable to a diverse array 
of site-selective chemistries, which have been exploited in both MS and MSn modes for 
purposes such as enhancing ionization efficiencies,3,4 incorporating isotopic labels for 
quantification,5–7 modulating fragmentation,8–10 and promoting selective dissociation.11–13 
Despite their utility, derivatization reactions are often the rate-limiting step in MS-based 
workflows since most require off-line solution phase chemistry prior to mass 
spectrometric analysis. Recently, this shortcoming has been addressed by several 
compelling strategies that utilize the mass spectrometer as a tool to facilitate rapid 
functional group derivatization analogous to that performed in bulk solution. These 
strategies apply the principles of two fundamentally distinct chemical platforms: 1) 
microdroplet chemistry14 and 2) gas phase ion/ion chemistry.15 Other approaches, 
including the use of theta capillaries and a sheath gas reaction mode, have been used to 
modulate electrospray ionization in an on-line manner via fast mixing of droplets or 
exposure of droplets to gaseous acids or bases.16–20 
MS-based microdroplet chemistry exploits the interfacial region between the ion 
source and the vacuum inlet of the mass spectrometer to promote rapid chemical 
modification during the ionization process.14,21–26 Cooks and co-workers demonstrated 
that the confined volume of a charged evaporating droplet acted as a microreactor for 
heterogeneous spray mixtures and promotes accelerated bond formation relative to bulk 
solution.23–25 The enhanced reaction kinetics were attributed to extremes in pH and 
concentration within the shrinking droplet environment, as well as increased collision 
frequencies at atmospheric pressure.23 This phenomenon was most prominent at sub-
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nanospray volumes, such as that of secondary droplets formed during reactive desorption 
electrospray ionization (rDESI).24 Strategies incorporating on-line microdroplet 
derivatization have primarily been limited to small molecule applications, with only a 
select few studies adapting these methods for peptide or protein analysis.14 These 
exceptions include the in-situ crosslinking of primary amines in single peptides with 
bis(sulfosuccinimidyl) suberate (BS3) using reactive DESI25 and online dithiothreitol 
(DTT) reduction of disulfides in intact proteins via reactive electrospray-assisted laser 
desorption/ionization (rELDI).27 Although these techniques established the feasibility of 
on-line microdroplet-assisted modification of several functionalities in polymeric amino 
acid chains, the potential for applying these methods to high-throughput proteomic 
mixtures remains largely unexplored.  
Gas phase ion/ion reactions represent the second major MS-based platform for 
on-line bioconjugation of peptides and proteins. These strategies move the chemical 
reaction step from the atmospheric pressure interface into the vacuum chamber of the 
mass spectrometer.15 Implementation of such methods requires the use of sophisticated 
instrumentation with bipolar trapping capabilities for mutual storage of populations of 
oppositely charged reagent and analyte ions.28 To date, a number of covalent chemistries 
have been used to selectively functionalize moieties of polypeptide chains in the gas 
phase, including Schiff base and NHS-ester modification of primary amines,29–31 
carbodiimide derivatization of carboxylic acids,32  as well as directed peptide bond 
formation via sulfo-NHS ester N-terminal coupling.33 Unlike analogous condensed phase 
reactions, which offer limited control over reacting species and are thus subject to 
undesirable side products, in vacuo ion/ion reactions afford fine-tuned selection of 
reactant ions and a high degree of conversion into the products of interest.15 Despite these 
merits, complete gas-phase transformation often comes at the cost of long activation 
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times (>100 ms) that are not amenable to on-line chromatographic separations, thereby 
limiting analysis to low complexity samples.   
In this Chapter we demonstrate a method that combines the principles of droplet 
phase and gas phase ion/ion chemistry to promote rapid bioconjugation using a front-end 
dual spray reactor. The reactor is designed to be readily coupled to LC platforms for 
high-throughput proteomic applications that were either not possible or unexplored using 
previously described droplet phase or gas phase strategies alone. To demonstrate the 
utility of the reactor for droplet-phase initiated ion/ion reactions, we borrow from 
covalent Schiff base chemistry that has been extensively explored in the gas phase.29,30,34,35 
We expand on this further by taking advantage of the chromophore addition at peptide N-
termini following Schiff base formation with 4-formyl-1,3-benzenedisulfonic acid 
(FBDSA) to enhance photodissociation at 193 nm.36  
 
6.3 EXPERIMENTAL 
6.3.1 Chemicals and Materials 
Model peptides KMVELVHFL, KLVANNTRL, RPPGFSPFR, ASHLGLAR, 
DRVYIHPFHLVIHN and DAEFRHDSGYQVHHQK were purchased from AnaSpec 
Inc. (Fremont, CA). SYSMEHFRWG was purchased from American Peptide Company 
(Sunnyvale, CA). DRVYIHPFHL and 4-formyl-1,3-benzenedisulfonic acid (FBDSA) 
were obtained from Sigma-Aldrich (St. Louis, MO). Peptides were used without 
purification. All other solvents were purchased from Fisher Scientific (Fairlawn, NJ). 
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6.3.2 Implementation of a Front-end Dual Spray Reactor 
Design and fabrication of the dual spray reactor mounting system was performed 
in house according to the illustration shown in Figure 6.1. The reactor was equipped with 
two electrosonic spray ionization (ESSI) sources (Prosolia Inc., Indianapolis, IN) that 
were integrated on the front-end of the mass spectrometer by way of a free-standing 
mount attached to a U-shaped rail that surrounded the MS inlet. The curved rail allowed 
for independent adjustment of the angle between the two sources in addition to the angle 
of each source relative to the axis of the mass spectrometer. Both sources were fixed to 
sliding supports that enabled adjustment of the y-dimensional distance between the 
emitter tip and the MS inlet. These supports were further mounted to a precision 1D 
translational stage for positional control in the z-direction. The first source was 
completely integrated, allowing direct control of polarity and spray voltage through the 
instrument control software. The spray voltage of the second source was supplied by an 
external 5 kV high voltage power supply (Stanford Research Systems Inc., Sunnyvale, 
CA) operated in negative polarity. Nebulizing sheath gas was introduced using an 
external nitrogen line equipped with a tee fitting and adjustable metering valve to evenly 
split the gas flow to both sources and allow manipulation of gas flow rates, respectively. 
 
 
 
Figure 6.1 (a) Aerial view of dual source reactor mounted at the front-end of a mass 
spectrometer and (b) free-standing design for facile adaptation to multiple 
instrument platforms. 
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6.3.3 Ion/Ion Chemistry, Mass Spectrometry and Photodissociation 
All experiments were conducted on a Thermo Velos Pro dual linear ion trap mass 
spectrometer (San Jose, CA) outfitted with a GAM EX5 or Coherent Excistar XS 500 Hz 
ArF excimer laser operated at 193 nm. The back flange of the mass spectrometer was 
modified to allow introduction of the laser beam coaxial to the dual cell linear ion trap 
through a CaF2 window and 2 mm stainless steel aperture, as previously described.37 In 
all experiments, peptide cations were generated by positive mode electrospray ionization 
of 5 μM peptide working solutions prepared in equal parts water and acetonitrile 
containing 0.1% formic acid and infused at rate of 1.5 μL/min. For ion/ion reactions, a 
second ion population consisting of a large excess of reagent anions was produced by 
negative mode electrospray of 1 mM FBDSA in 50:50 water/methanol at an infusion rate 
of 3 μL/min. The peptide source was positioned on axis to the inlet of the mass 
spectrometer; whereas the reagent ion source was position approximately 45 degrees off 
axis.  Complex formation was accomplished at atmospheric pressure by intersecting 
analyte sprays of opposite polarity in the reaction region prior to the capillary inlet. The 
spray voltage for the cation source was held constant at 1.75 kV, while the anion spray 
voltage was varied between -2.5 and -3 kV depending on optimal complex formation. 
Electrostatic adducts formed in the overlapping sprays were isolated and subjected to low 
energy collisional activation using a normalized collision energy (NCE) between 10-20% 
to promote loss of water and formation of the stable Schiff base imine product. Isolation 
and MS3 activation of the Schiff base was carried out using either collisional induced 
dissociation (CID) or 193 nm ultraviolet photodissociation (UVPD). MS3 experiments 
based on UVPD were performed using a single 2 mJ, 5 ns laser pulse.  A q-value of 0.125 
was used to extend the low m/z cutoff. UVPD efficiencies were calculated as previously 
described.36 
 143 
6.3.4 High-Throughput Bioconjugation on an LC Timescale 
The dual spray reactor was coupled to a Dionex Ultimate 3000 (Sunnyvale, CA) 
capillary flow system for all high-throughput bioconjugation experiments. Peptides were 
separated on an Agilent ZORBAX 300 Extend-C18 column (150 x 0.3 mm, 3.5 μm 
particle size) held at a constant temperature of 30˚C. Eluent A consisted of 0.1% formic 
acid in water and eluent B was 0.1% formic acid in acetonitrile. A linear gradient from 
3% to 35% B over 30 min at 4 μL/min was used. An auxiliary syringe method was 
programed to infuse FBDSA at a rate of 3 μL/min throughout the course of separation. 
The spray voltage for the cation and anion source was held constant at 1.75 kV and -2.5 
kV, respectively. Rapid derivatization was accomplished using an automated data-
dependent neutral loss (DDNL) MS3 program similar to that described by Gygi et al.38 
The top five most abundant ions in the full MS scan were subjected to low energy 
collisional activation (18% NCE, isolation width of 5 Th, q-value 0.15 ) for 50 ms. MS3 
UVPD (1 pulse, 2 mJ, q-value of 0.125) was triggered if a neutral loss product was 
detected at -18 Da (-18 Th, -9 Th and -6 Th to account for the 1+, 2+ and 3+ charge 
states, respectively) and was within the top 3 most abundant ions in the MS2 spectrum. 
All data was filtered such that grouped MS2 and MS3 scans were manually interrogated. 
  
6.4 RESULTS AND DISCUSSION 
Covalent modification in the gas phase has been shown to occur via stable, long-
lived electrostatic intermediates formed between polypeptide cations and bi-functional 
reagent anions.15,29,31 Within this context, bi-functionality refers to the ability of reagent 
anions to engage in stabilizing non-covalent interactions that favor complex formation 
over competing proton transfer, as well as facilitate functional group derivatization.15 Han 
and McLuckey reported the first example of gas phase bioconjugation within the confines 
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of an electrodynamic ion trap mass spectrometer using the aldehyde-containing reagent 
4-formyl-1,3-benzenedisulfonic acid (FBDSA) to covalently modify primary amines of 
peptide cations via Schiff base ion/ion chemistry.29 The resulting derivatized peptides 
were found to yield more informative fragmentation upon collisional activation compared 
to their unmodified counterparts. Similarly, gas phase FBDSA-based chemistry has been 
used to enhance collisional dissociation in the negative ion mode for charge inverted 
Schiff base modified peptides.34,35,39 These seminal studies demonstrated the feasibility of 
online ion/ion mediated bioconjugation, as well as its utility for improving the structural 
characterization of modified species. Despite the improved throughput of this online 
approach relative to orthogonal in-solution chemistry, the complex scan functions and 
average reaction times (50-1000 msec) required for formation of electrostatic 
intermediates in vacuo, followed by covalent conversion and subsequent activation to 
obtain structurally relevant information, have rendered these methods not well adapted 
for chromatographic timescales. These limitations have prompted our efforts to develop a 
streamlined approach that utilizes a front-end dual spray reactor to initiate ion/ion 
reactions in the droplet phase prior to introduction into the mass spectrometer. To 
benchmark the performance of the dual spray reactor, we employed aforementioned 
Schiff base reactions between peptide cations and FBDSA anions for comparison with 
previously reported gas phase ion/ion covalent chemistry. 
The process for dual spray assisted bioconjugation of peptides with FBDSA is 
summarized in Figure 6.2. The reactor utilizes two ESI sources biased at opposite 
polarity to simultaneously generate overlapping populations of peptide cations and 
FBDSA anions. This configuration was designed to maximize collisions between reactive 
species in the droplet, pseudo-droplet, and gas phase at the high pressure interface of the  
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Figure 6.2 Schematic summary of dual spray initiated bioconjugation of a peptide 
cation with an FBDSA anion for enhanced ultraviolet photodissociation. 
 
mass spectrometer, similar in concept to the Y-shaped reactor inlet used to merge ions 
from two independently biased sources in early ion/ion proton transfer reactions,40 or that 
used in extractive electrospray (EESI) configurations.41,42 The role of the sulfonate groups 
of FBDSA is two-fold: first, they provide acidic sites that are readily deprotonated under 
negative electrospray conditions to form 1- and 2- anions (Figure 6.3a), and secondly 
they engage in stabilizing acid-base interactions with multiply charged peptide cations to 
form charge-reduced non-covalent complexes that persist into the gas phase. This process 
is demonstrated in Figure 6.3, which compares the MS1 spectrum of the peptide 
DRVYIHPFHLVIHN before (Figure 6.3b) and after dual spray infusion with anionic 
FBDSA (Figure 6.3c). The major products in the post ion/ion reaction spectrum are 
charge-reduced relative to the unmodified peptide and arise from partial neutralization of 
multiply charged peptide cations (up to five sites of protonation) with singly and doubly 
deprotonated FBDSA anions.   This is clearly indicated by the absence of  the  5+  charge  
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Figure 6.3 (a) Negative mode ESI control spectrum for FBDSA and (b) positive 
mode ESI control spectrum for DRVYIHPFHLVIHN. (c) Dual spray 
spectrum for simultaneously infused DRVYIHPFHLVIHN (+) and 
FBDSA (-). Electrostatic DRVYIHPFHLVIHN/FBDSA complexes are 
denoted by ∆.    
 
state and attenuation of the relative abundances of the 3+ and 4+ charge states in the 
resulting dual spray spectrum. Moreover, new products are observed at m/z values 
consistent with the formation of 2+ and 3+ peptide/FBDSA complexes as indicated by a 
mass shift of +266 Da (denoted by the “∆” symbol) relative to the unmodified peptide. 
As shown in Figure 6.4, a direct relationship was observed between the magnitude of the 
anion source voltage and the relative contribution of complexes to the total ion current of 
the dual spray spectrum. The absence of peptide/FBDSA complexes when the voltage is 
 147 
set to zero (akin to ion/molecule reaction conditions), in addition to the observed shift 
towards more abundant complex formation as the anion source voltage is stepped to 
increasingly negative potentials confirms that the reaction occurs exclusively through an 
ion/ion mediated pathway. 
 
 
 
 
Figure 6.4 Anion source voltage optimization: normalized abundance of unmodified 
DRVYIHPFHLVIHN and DRVYIHPFHLVIHN/FBDSA complex as a 
function of anion source voltage.         
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An example of an optimized dual spray spectrum is shown in Figure 6.5 for 
FBDSA-reacted DRVYIHPFHLVIHN. Here, signal from the non-covalent complex 
accounts for approximately 37% of the total ion current, thus demonstrating the 
efficiency of the front-end ion/ion reaction. It should be noted that competing proton 
transfer reactions may also contribute to the observed attenuation of peptide charge state; 
however, an approach for isolating and quantifying this contribution relative to complex 
formation is beyond the scope of this work. 
 
 
 
 
 
Figure 6.5 Process for on-line modification of peptides with FBDSA using a dual 
spray reactor. (a) Electrostatic complexes are formed at atmospheric 
pressure between multiply charged peptide cations and FBDSA anions. 
These ion/ion intermediates are denoted with a “∆” superscript. (b) Low 
energy collisional activation of the intermediate ion/ion species promotes 
Schiff base formation via the concerted formation of an imine bond and 
loss of a water molecule, resulting in a chromophore-labeled Schiff base 
product (♦) with a mass shift of -18 Da relative to the electrostatic 
complex. (c) 193 nm UVPD of the labeled peptide exhibits extensive 
backbone fragmentation. 
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Following optimization of the front-end ion/ion reaction, the second step of the 
process requires isolation and gentle collisional activation of the electrostatic complex to 
promote covalent bioconjugation. This input of energy into the system is likely required 
to overcome the activation barrier necessary for nucleophilic attack of the FBDSA 
aldehyde by the free N-terminus of the peptide. Since water represents the major 
byproduct of imine formation, the dominant water loss product observed in the MS2 
spectrum (Figure 6.5b) is highly indicative of covalent Schiff base derivatization. An 
additional ion activation event results in an MS3 spectrum that confirms Schiff base 
formation (Figure 6.5c). Unlike previously reported in vacuo methods, which accomplish 
MS3 by using a second collisional activation step, we integrate 193 nm ultraviolet 
photodissociation (UVPD) as an alternative activation method to both verify Schiff base 
formation and achieve comprehensive structural characterization of resulting modified 
peptides. The use of 193 nm UVPD is strategic for several reasons: 1) UVPD can be 
accomplished in a much shorter activation period than required for CID, thus improving 
the throughput of the analysis, 2) in many cases, UVPD provides more extensive 
coverage of the peptide backbone compared to CID,43 and finally 3) N-terminal 
modification of peptides with chromogenic labels, such as FBDSA, has been shown to 
enhance UVPD efficiencies,36 thereby offering an additional metric by which to evaluate 
covalent attachment. The exceptional sequence coverage of the peptide backbone 
afforded by 193 nm UVPD is demonstrated in Figure 6.5c. The combined information 
obtained by the extensive array of complementary N- and C-terminal ions (in this case 
a/b and x/y/z, respectively) allows for unambiguous localization of Schiff base 
modification at the peptide N-terminus. This lack of ambiguity arises from the fact that 
all N-terminally derived ions exhibit a conserved mass shift of +248 Da (denoted in the 
spectrum by the addition of “♦” to the ion labels), whereas the entire set of 
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complementary C-terminal product ions remain unmodified. The differentiation of 
several isobaric leucine and isoleucine residues across the peptide backbone is also 
possible by unique v- and w-type side-chain ions produced upon UV activation. 
Moreover, the non-resonant nature of UVPD allows access to a lower m/z trapping limit, 
whereas CID suffers from a low mass cutoff (LMCO) restriction imposed by the RF 
amplitude applied to the trap. By overcoming this limitation, UVPD provides greater 
depth of coverage for high m/z (low charge) precursor ions commonly observed 
following the formation of charge-reduced peptide/FBDSA complexes during front-end 
ion/ion reactions. 
 
 
 
 
Figure 6.6 Comparison of 193 nm UVPD efficiencies before and after Schiff base 
modification of KLVANNTRL (1+). (a) MS2 UVPD mass spectrum for 
unlabeled peptide and (b) MS3 UVPD mass spectrum following on-line 
derivatization using the dual spray reactor. 
 
Previous work in our lab demonstrated enhanced 193 nm photodissociation of 
peptides containing native aromatic residues,43 as well as for those whose intrinsic 
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aromaticity was increased through N-terminal derivatization with chromogenic labels.36 
Based on these findings, we anticipated that front-end ion/ion mediated N-terminal 
modification with chromogenic FBDSA would enhance the UVPD dissociation behavior 
of peptides. To test this hypothesis, UVPD was evaluated for a series of model peptides 
in both the unmodified and FBDSA-labeled states. Notably, spectral changes were most 
prominent for peptides lacking intrinsic aromatic residues such as in the case of 
KLVANNTRL (Figure 6.6). Despite complete backbone coverage of the unmodified 
peptide, the fragment ion abundance only accounts for approximately 17% of the total ion 
intensity, therefore indicating rather poor dissociation of the singly charged precursor 
(Figure 6.6a). Alternatively, photoactivation of the Schiff base modified form of this 
peptide showed nearly 27% increase in the resulting photodissociation efficiency (Figure 
6.6b), as indicated by a significant increase in fragment ion intensity relative to the 
surviving precursor. Similar results were obtained for all peptides investigated in this 
study, with Schiff base modification accounting for an average enhancement in 
photodissociation efficiency of approximately 20% (Figure 6.7). This value is highly 
consistent with previous findings for peptides modified with SPITC and PPITC 
chromogenic N-terminal labeles.36 To verify that this change in dissociation behavior is 
the direct result of enhanced gas-phase photoabsorption as opposed to changes in the 
critical energies of the modified peptides, an energy variable collisional activation 
analysis was performed on unmodified and Schiff base labeled KLVANNTRL (1+). 
Figure 6.8 shows the normalized precursor ion intensity for both forms of 
KLVANNTRL (1+) as a function of increasing collision energy. The high degree of 
overlap in the variable CID profiles suggests that FBDSA predominantly enhances the 
photoexcitation energy, while having no appreciable impact on the critical energy of the 
peptide. Despite improved dissociation efficiency, decreased UVPD sensitivity is 
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possible for FBDSA-labeled peptides due to incomplete reaction conversion to the Schiff 
base product. 
 
 
 
 
Figure 6.7 Comparison of 193 nm UVPD efficiencies for a set of model peptides 
before and after Schiff base modification. 
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Figure 6.8 Variable energy collision analysis of unmodified and Schiff base labeled 
KLVANNTRL (1+). Normalized precursor abundances are plotted as a 
function of increasing collision energy. The dashed line represents the 
point of 50% precursor dissociation. 
 
Finally, we wanted to assess the feasibility of coupling the dual spray reactor to a 
liquid chromatograph in order to show the first example of high-throughput ion/ion 
mediated bioconjugation on a chromatographic timescale. For these proof-of-principle 
studies, a five peptide mixture was utilized to simulate the complexity of a small, single 
protein digest.  Unlike direct infusion experiments, which allow source parameters to be 
independently adjusted in order to maximize complex abundance, integration of the 
reactor into a high-throughput workflow requires using a fixed set of source parameters 
to generate sufficiently high levels of ion/ion complex for selection during automated 
data-dependent acquisition. Figure 6.9 provides a comparison of spectra for each peptide 
following LC-MS analysis of the mixture under control (Figure 6.9a-e) and dual source 
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reaction conditions (Figure 6.9f-j). In all cases, spectral differences between the samples 
arise from the presence of electrostatic complexes. Interestingly, the degree of complex 
formation appears greatest for early eluting peptides where the mobile phase composition 
is predominantly aqueous. This corresponds to larger droplet sizes on the basis of the 
higher surface tension of water relative to organic solvents, and thus more dilute droplet 
conditions. Contrary to microdroplet reaction theory, which states that accelerated rates 
of reaction are observed as droplet size decreases,24 our results point to a greater emphasis 
on stabilizing the electrostatic interactions for ion/ion mediated reactions as opposed to 
increasing the relative concentration of reactants per unit volume. Once formed and 
transferred into gas phase, the extent to which complexes are converted to covalent Schiff 
base products is highly dependent on the amount of time allotted for the reaction to 
proceed in the MS2 step via low energy collisional activation.). Alternatively, rapid 
activation at high collision energies (NCE>25%) resulted in dominant loss of FBDSA 
(data not shown). This observation indicates that covalent conversion occurs optimally 
under slow heating conditions as opposed to fast energy transfer. Efficient conversion 
within narrow elution windows is critical for compatibility with front-end separations, 
and the extent to which this conversion occurs has an immediate impact on the quality of 
subsequent UVPD spectra necessary for characterization of Schiff base labeled peptides. 
For all non-covalent complexes observed in these experiments, a reaction time of 50 ms 
combined with 18% normalized collision energy (NCE) resulted in predominant 
conversion to Schiff base products. These MS2 spectra were easily distinguished based on 
the abundance of the water loss product; whereas activation at 18% NCE was sufficiently 
high to promote some extent of backbone cleavage for unreacted peptides (data not 
shown). 
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Figure 6.9 (a-e) Control and (f-j) FBDSA-reacted LC mass spectra for each peptide 
of a five peptide mixture. For all data shown, the peptide source voltage 
was held constant at 1.75 kV. Dual source initiated ion/ion reactions were 
carried out using an anion source voltage of -2.5 kV. Note that spectra are 
shown in order of elution. 
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Figure 6.10 Data-dependent neutral loss MS3 decision tree for online derivatization 
using an LC-MS3 platform. 
 
The ability to establish a set of dual source parameters capable of promoting 
ion/ion mediated covalent derivatization for all peptides in a mixture provided confidence 
that online bioconjugation followed by fast UVPD characterization of modified peptides 
was possible using an automated LC-MSn approach. To test this strategy, a data-
dependent neutral loss MS3 (DDNLMS3) method was developed (Figure 6.10) in which 
the top five most abundant ions in the MS1 spectrum were subjected to MS2 using the 
aforementioned activation parameters. If the product ion corresponding to the neutral loss 
of water was within the top three most abundant ions in the low energy CID spectrum, a  
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Figure 6.11 Online derivatization of a peptide mixture using the dual spray reactor 
combined with an LC-MS based data-dependent neutral loss MS3 scan 
program. (a) Base peak chromatogram for the peptide mixture. (b) MS1 
scan during the elution of ASHLGLAR showing a mixture of unreacted 
peptide and peptide/FBDSA complexes (∆). The electrostatic complex is 
selected by the DDNLMS3 program to undergo (c) low energy CID (NCE 
= 18%). A neutral loss product is detected at -18 Da (♦), which triggers (d) 
193 nm UVPD of the Schiff base product.     
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subsequent 193 nm UVPD activation event was initiated. Automation of the complete 
ion/ion mediated bioconjugation process is shown via consecutive scan events in Figure  
6.11 for the peptide ASHLGLAR corresponding to the chromatographic peak at 17 
minutes of the elution profile (Figure 6.11a). The 1+ charge state of the electrostatic 
complex appears as the second most abundant ion in the MS1 spectrum (Figure 6.11b), 
allowing efficient selection during data-dependent acquisition. Collisional activation of 
the complex results in a dominant neutral loss of water (Figure 6.11c), thus triggering 
193 nm UVPD (Figure 6.11d). The array of fragment ions generated provides extensive 
structural characterization of the modified peptide. Moreover, greater than 20% 
improvement in UVPD efficiency was observed relative to the unmodified analog, thus 
showing excellent agreement of the high-throughput LC-MSn results with those obtained 
via dual source infusion set-up. 
 
6.5 CONCLUSIONS 
The development and implementation of a front-end dual electrospray reactor 
used for online ion/ion mediated bioconjugation was demonstrated for rapid Schiff base 
derivatization of peptide cations with FBDSA anions. Dual spray-assisted covalent 
chemistry was found to be highly consistent with analogous reactions performed in 
vacuo; however, by shifting the ion/ion reaction step to the interface of the mass 
spectrometer, both the throughput and adaptability of this approach was streamlined for 
integration into chromatographic workflows. Furthermore, we showed the advantage of 
utilizing fast online reactions to enhance the photodissociation efficiencies of peptides 
using 193 nm photoactivation as well as to improve the structural characterization of 
modified peptides.  
 159 
6.6 REFERENCES 
 
(1)  Hermanson, G. T. Bioconjugate Techniques; Academic Press, 2013. 
(2)  Stephanopoulos, N.; Francis, M. B. Nat. Chem. Biol. 2011, 7 (12), 876–884. 
(3)  Mirzaei, H.; Regnier, F. Anal. Chem. 2006, 78 (12), 4175–4183. 
(4)  Pashkova, A.; Moskovets, E.; Karger, B. L. Anal. Chem. 2004, 76 (15), 4550–
4557. 
(5)  Gygi, S. P.; Rist, B.; Gerber, S. A.; Turecek, F.; Gelb, M. H.; Aebersold, R. Nat. 
Biotechnol. 1999, 17 (10), 994–999. 
(6)  Wiese, S.; Reidegeld, K. A.; Meyer, H. E.; Warscheid, B. PROTEOMICS 2007, 7 
(3), 340–350. 
(7)  Ulbrich, A.; Merrill, A. E.; Hebert, A. S.; Westphall, M. S.; Keller, M. P.; Attie, 
A. D.; Coon, J. J. J. Am. Soc. Mass Spectrom. 2014, 25 (1), 6–9. 
(8)  Keough, T.; Youngquist, R. S.; Lacey, M. P. Proc. Natl. Acad. Sci. 1999, 96 (13), 
7131–7136. 
(9)  Madsen, J. A.; Brodbelt, J. S. Anal. Chem. 2009, 81 (9), 3645–3653. 
(10)  Robinson, M. R.; Madsen, J. A.; Brodbelt, J. S. Anal. Chem. 2012, 84 (5), 2433–
2439. 
(11)  Cotham, V. C.; Wine, Y.; Brodbelt, J. S. Anal. Chem. 2013, 85 (11), 5577–5585. 
(12)  Diedrich, J. K.; Julian, R. R. Anal Chem 2010, 82 (10), 4006–4014. 
(13)  Vasicek, L.; O’Brien, J. P.; Browning, K. S.; Tao, Z.; Liu, H.-W.; Brodbelt, J. S. 
Mol. Cell. Proteomics 2012, 11 (7), 1–10. 
(14)  Espy, R. D.; Wleklinski, M.; Yan, X.; Cooks, R. G. TrAC Trends Anal. Chem. 
2014, 57, 135–146. 
(15)  Prentice, B. M.; McLuckey, S. A. Chem. Commun. 2013, 49 (10), 947–965. 
(16)  Mortensen, D. N.; Williams, E. R. Anal. Chem. 2014, 86 (18), 9315–9321. 
(17)  Mortensen, D. N.; Williams, E. R. Anal. Chem. 2014. 
(18)  Fisher, C. M.; Kharlamova, A.; McLuckey, S. A. Anal. Chem. 2014, 86 (9), 
4581–4588. 
(19)  Miladinović, S. M.; Fornelli, L.; Lu, Y.; Piech, K. M.; Girault, H. H.; Tsybin, Y. 
O. Anal. Chem. 2012, 84 (11), 4647–4651. 
(20)  Kharlamova, A.; McLuckey, S. A. Anal. Chem. 2011, 83 (1), 431–439. 
(21)  Grimm, R. L.; Hodyss, R.; Beauchamp, J. L. Anal. Chem. 2006, 78 (11), 3800–
3806. 
(22)  Kim, H. I.; Kim, H.; Shin, Y. S.; Beegle, L. W.; Jang, S. S.; Neidholdt, E. L.; 
Goddard, W. A.; Heath, J. R.; Kanik, I.; Beauchamp, J. L. J. Am. Chem. Soc. 
2010, 132 (7), 2254–2263. 
(23)  Müller, T.; Badu-Tawiah, A.; Cooks, R. G. Angew. Chem. Int. Ed. 2012, 51 (47), 
11832–11835. 
(24)  Girod, M.; Moyano, E.; Campbell, D. I.; Cooks, R. G. Chem. Sci. 2011, 2 (3), 
501–510. 
(25)  Badu-Tawiah, A. K.; Li, A.; Jjunju, F. P. M.; Cooks, R. G. Angew. Chem. Int. Ed. 
2012, 51 (37), 9417–9421. 
 160 
(26)  Chen, H.; Wortmann, A.; Zhang, W.; Zenobi, R. Angew. Chem. Int. Ed. 2007, 46 
(4), 580–583. 
(27)  Peng, I. X.; Ogorzalek Loo, R. R.; Shiea, J.; Loo, J. A. Anal. Chem. 2008, 80 (18), 
6995–7003. 
(28)  Xia, Y.; McLuckey, S. A. J. Am. Soc. Mass Spectrom. 2011, 19 (2), 173–189. 
(29)  Han, H.; McLuckey, S. A. J. Am. Chem. Soc. 2009, 131 (36), 12884–12885. 
(30)  Stutzman, J. R.; Luongo, C. A.; McLuckey, S. A. J. Mass Spectrom. 2012, 47 (6), 
669–675. 
(31)  Mentinova, M.; McLuckey, S. A. J. Am. Chem. Soc. 2010, 132 (51), 18248–
18257. 
(32)  Prentice, B. M.; Gilbert, J. D.; Stutzman, J. R.; Forrest, W. P.; McLuckey, S. A. J. 
Am. Soc. Mass Spectrom. 2013, 24 (1), 30–37. 
(33)  McGee, W. M.; McLuckey, S. A. Proc. Natl. Acad. Sci. 2014, 111 (4), 1288–
1292. 
(34)  Hassell, K. M.; Stutzman, J. R.; McLuckey, S. A. Anal. Chem. 2010, 82 (5), 
1594–1597. 
(35)  Stutzman, J. R.; McLuckey, S. A. Anal. Chem. 2012, 84 (24), 10679–10685. 
(36)  Vasicek, L.; Brodbelt, J. S. Anal. Chem. 2010, 82 (22), 9441–9446. 
(37)  Gardner, M. W.; Smith, S. I.; Ledvina, A. R.; Madsen, J. A.; Coon, J. J.; 
Schwartz, J. C.; Stafford, G. C.; Brodbelt, J. S. Anal. Chem. 2009, 81 (19), 8109–
8118. 
(38)  Villén, J.; Beausoleil, S. A.; Gygi, S. P. PROTEOMICS 2008, 8 (21), 4444–4452. 
(39)  Stutzman, J. R.; Hassell, K. M.; McLuckey, S. A. Int. J. Mass Spectrom. 2012, 
312, 195–200. 
(40)  Ogorzalek Loo, R. R.; Udseth, H. R.; Smith, R. D. J. Am. Soc. Mass Spectrom. 
1992, 3 (7), 695–705. 
(41)  Chen, H.; Venter, A.; Cooks, R. G. Chem. Commun. 2006, No. 19, 2042–2044. 
(42)  Law, W. S.; Wang, R.; Hu, B.; Berchtold, C.; Meier, L.; Chen, H.; Zenobi, R. 
Anal. Chem. 2010, 82 (11), 4494–4500. 
(43)  Madsen, J. A.; Boutz, D. R.; Brodbelt, J. S. J. Proteome Res. 2010, 9 (8), 4205–
4214. 
 
 
 
 
 
 
 
 161 
Chapter 7 
Modulation of Phosphopeptide Fragmentation via Dual Spray Ion/Ion 
Reactions using a Sulfonate-Incorporating Reagent
*4 
 
7.1  OVERVIEW 
The labile nature of phosphoryl groups has presented a long-standing challenge 
for the characterization of protein phosphorylation via conventional mass spectrometry-
based bottom-up proteomics methods. Collision-induced dissociation (CID) causes 
preferential cleavage of the phospho-ester bond of peptides, particularly under conditions 
of low proton mobility, and results in the suppression of sequence-informative 
fragmentation that often prohibits phosphosite determination. In the present study, the 
fragmentation patterns of phosphopeptides are improved through ion/ion-mediated 
peptide derivatization with 4-formyl-1,3-benezenedisulfonic acid (FBDSA) anions using 
a dual spray reactor. This approach exploits the strong electrostatic interactions between 
the sulfonate moieties of FBDSA and basic sites to facilitate gas-phase bioconjugation 
and to reduce charge sequestration and increase the yield of phosphate-retaining sequence 
ions upon CID.  Moreover, comparative CID fragmentation analysis between unmodified 
phosphopeptides and those modified online with FBDSA or in solution via carbamylation 
and 4-sulfophenyl isothiocyanate (SPITC) provided evidence for sulfonate interference 
with charge-directed mechanisms that result in preferential phosphate elimination.  Our 
results indicate the prominence of charge-directed neighboring group participation 
reactions involved in phosphate neutral loss, and the implementation of ion-ion reactions 
                                                 
*Cotham, V. C.; McGee, W. M.; Brodbelt, J. S. Anal. Chem. 2016, 88, 8158-8165. 
 V.C.C. designed and conducted all experiments.    
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in a dual spray reactor set-up provides a means to disrupt the interactions by competing 
hydrogen-bonding interactions between sulfonate groups and the side-chains of basic 
residues.  
 
7.2  INTRODUCTION 
 Protein phosphorylation is a highly dynamic post-translational modification 
(PTM) that plays a central role in the signaling and regulatory machinery that mediate 
nearly all cellular processes including transcription, differentiation, cell cycle 
progression, and metabolism.1–3 These processes are controlled through the coordinated 
interplay of protein kinases and phosphatases that modulate the function of target proteins 
by transiently altering their phosphorylation states at serine, threonine and tyrosine sites.4 
Moreover, aberrant phosphorylation arising from the dysregulation of this activity has 
been linked to the onset and progression of numerous neurodegenerative, oncogenic and 
metabolic diseases.5–7 Consequently, the molecular-level characterization of protein 
phosphorylation is essential for the comprehensive understanding of complex 
mechanisms governing cell health and disease and offers critical insight for the 
development of new therapeutics. 
Mass spectrometry (MS) has emerged as the analytical method of choice for the 
identification and characterization of phosphorylated proteins on both the individual and 
global scale.8,9 However, despite exceptional speed and sensitivity, common MS-based 
approaches suffer from several key impediments arising from the intrinsic biological and 
chemical properties of phosphoproteins and their peptide constituents. For example, 
phosphorylation often occurs at substoichiometric levels that are below the sampling 
depth of most bottom-up data-dependent driven workflows.10,11 Enrichment strategies 
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such as immobilized metal affinity chromatography (IMAC) and metal oxide affinity 
chromatography (MOAC) have helped to overcome this limitation by selectively 
increasing the relative abundance of phosphorylated targets within full MS survey scans.9 
While this additional step facilitates improved detection, subsequent tandem mass 
spectrometric (MS/MS) analysis to obtain sequence and phosphosite information by 
direct fragmentation of selected phosphopeptides is often inhibited by the higher gas 
phase lability of the phospho-ester bond relative to the polypeptide backone.12 Collision-
induced dissociation (CID) remains the most established and widely utilized ion 
activation method;13 however, the slow heating mechanism that governs ion dissociation 
promotes cleavage at the most labile sites, thereby inducing preferential neutral loss of 
the phosphate group and suppression of diagnostic sequence and phosphosite-informative 
fragmentation.12,14,15 This outcome has proven particularly problematic under conditions 
of low proton mobility where hydrogen bonding interactions between basic side-chains 
and the phosphate group facilitate nearly exclusive charge-directed neutral loss of the 
phosphate.12,16  This shortcoming has prompted the use of alternative activation strategies 
that provide more informative MS/MS spectra for phosphopeptide characterization, 
including electron-driven approaches (ETD and ECD),17,18 higher-energy collisional 
activation (HCD),19 ultraviolet photodissociation (UVPD),20–23 and several combinations 
thereof (i.e., ETcaD,24 EThcD,25 ETUVPD26).  
In addition to alternative activation methods, chemical and enzymatic strategies 
that modify the intrinsic properties of phosphopeptides to make them more suitable for 
MS/MS interrogation have also been reported, albeit at the cost of more extensive sample 
preparation and experimental complexity. Approaches based on β-elimination of 
phosphoryl groups from phosphoserine and phosphothreonine residues followed by 
Michael addition with a nucleophilic reactant have been used in a diversity of protein 
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phosphorylation studies.27–32 The purpose of this type of strategy is generally two-fold: 1) 
removal of the CID labile phosphate group to generate more informative MS/MS spectra 
and 2) incorporation of novel chemistry that can be exploited for streamlined 
phosphopeptide analysis.28,31–33 Despite these merits, one major drawback to β-
elimination-based approaches arises from their lack of selectivity toward phosphotyrosine 
residues.34 Other strategies aimed at eliminating or minimizing the hydrogen bonding 
interactions that lead to preferential phosphate cleavage have also shown success for 
generating more informative CID spectra with the added benefit of being universally 
applicable to all phosphopeptide types (S/T/Y).35–38 This has been accomplished via 
selective derivatization of either the phosphate moiety35,36 or basic side-chains of the 
peptide,37 or alternatively by the complete enzymatic removal of basic residues.38 
Recently, we described a method for the high-throughput bioconjugation of 
peptide cations via pseudo-droplet phase initiated ion/ion reactions using a front-end dual 
spray reactor.39 This previous work relied on well-characterized gas-phase ion/ion-
mediated covalent chemistry using 4-formyl-1,3-benzenedisulfonic acid (FBDSA) 
anions40–42 to both facilitate rapid derivatization on a timescale compatible with 
chromatographic separations and to increase the intrinsic photoabsorption cross-section 
of peptides for enhanced photodissociation at 193 nm.39 Herein, we demonstrate that this 
same chemistry can also be leveraged to modulate the collisional dissociation behavior of 
basic phosphopeptides in real time for improved sequence coverage and phosphosite 
localization relative to their unmodified counterparts. In a manner similar to the removal 
or selective derivatization of basic sites, this method relies on the preferential formation 
of noncovalent interactions between the sulfonate moieties of FBDSA and the basic sites 
within the peptide to overcome or partially disrupt the mechanisms leading to preferential 
phosphate loss by collisional activation. 
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7.3 EXPERIMENTAL 
7.3.1 Chemicals and Materials 
Phosphopeptides RQpSVELHSPQSLPR, GGGPApTPKKAKKL, and 
KKALRRQEpTVDAL were purchased from AnaSpec Inc. (Fremont, CA).   
RRLIEDAEpYAARG-NH2 was purchased from American Peptide Company 
(Sunnyvale, CA). 4-formyl-1,3-benzenedisulfonic acid (FBDSA), 4-sulfophenyl 
isothiocyanate (SPITC), urea and all other solvents were obtained from Sigma-Aldrich 
(St. Louis, MO). Peptides and reagents were used without further purification. 
7.3.2 Solution Phase N-Terminal Derivatization  
Aliquots of phosphopeptides lacking internal lysine residues were subjected to N-
terminal derivatization via 4-sulfophenyl isothiocyanate (SPITC) and carbamylation in 
the presence of excess urea. SPITC modification was accomplished by reacting 20 μL of 
stock solution (1 mg of SPITC in 100 μL of 1x PBS, pH 7.4) with 10 nmol of peptide for 
30 minutes at 55°C. Carbamylation reactions were carried out via incubation with 8 M 
urea in 50 mM Tris-HCl (pH 8) at 80°C for 4 h. N-terminally labeled peptides were then 
desalted on C18 spin columns (Life Technologies, Grand Island, NY), evaporated to 
dryness and resuspended in 50:50 water/methanol for infusion. 
7.3.3 Mass Spectrometry and Front-end Ion/Ion Reactions 
All experiments were conducted on a Thermo Scientific Velos Pro dual linear ion 
trap mass spectrometer (San Jose, CA) equipped with a front-end dual spray reactor as 
previously described.39 Briefly, the reactor was equipped with two electrospray ionization 
(ESI) sources (Prosolia Inc., Indianapolis, IN) mounted on a U-shaped railing system that 
surrounded the front-end of the mass spectrometer. The first source was fully integrated 
to allow for direct control of spray voltage and polarity in the Thermo Tune Plus control 
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software, whereas the spray voltage of the second source was supplied via an external 5 
kV dual polarity high voltage power supply (Stanford Research Systems Inc., Sunnyvale, 
CA). 
For standard infusion experiments, the dual spray reactor was operated in single 
source mode in a manner comparable to conventional ESI. Phosphopeptide cations were 
generated by positive mode electrospray ionization of 5 μM working solutions infused at 
rate of 1.5 μL/min using a spray voltage of 1.5 kV. Alternatively, ion/ion reactions were 
carried out using dual source mode, during which the second source was simultaneously 
operated to generate a second population of reagent anions via negative mode ESI of 2 
mM FBDSA prepared in 50:50 water/methanol infused at a rate of 3 μL/min. 
Electrostatic ion/ion complexes were formed at or near atmospheric pressure in the region 
of spray overlap prior to the inlet of the mass spectrometer. Anion source voltage was 
varied between -2.0 and -2.75 kV to achieve optimal complex formation and spray 
stability. Schiff base reactions were performed by collisionally activating the electrostatic 
phosphopeptide/FBDSA complexes with low normalized collision energy (NCE = 10-
18%) to overcome the activation barrier for imine formation. Covalent Schiff base 
products were then isolated and subjected to MS3 collision-induced dissociation (CID) to 
generate diagnostic product ions using 20-30% NCE and a q-value of 0.25. 
 
7.4 RESULTS AND DISCUSSION 
Gas-phase ion/ion-mediated Schiff base derivatization with 4-formyl-1,3-
benezenedisulfonic acid (FBDSA) is an established method for rapid covalent 
transformation of peptides within the context of a tandem mass spectrometry-based 
experiment.39–43 This chemistry proceeds via the formation of long-lived electrostatic 
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complexes arising from noncovalent interactions between the sulfonate moieties of 
FBDSA reagent anions and protonated sites of peptide cations.40 Subsequent collisional 
activation of these ion/ion intermediates promotes nucleophilic attack on the FBDSA 
aldehyde by an unprotonated primary amine in the substrate peptide, resulting in 
concerted dehydration and imine bond formation.40 Although well-defined for 
unmodified substrates, no studies to date have explored this chemistry with peptides 
containing labile post-translational modifications. Thus, we sought to evaluate both the 
feasibility and analytical utility of gas-phase derivatization with FBDSA for a series of 
phosphorylated peptides containing modified serine, threonine, and tyrosine residues. We 
hypothesized that this Schiff base reaction could provide a means to modulate hydrogen-
bonding interactions in phosphopeptides and minimize phosphate cleavage, and at the 
same time allow implementation of this method in an on-line fashion via a dual spray 
reactor set-up.  
Peptides that contain multiple basic sites pose a particularly difficult challenge for 
conventional CID-based characterization owing to the immobilization of charges caused 
by the presence of multiple basic residues that sequester ionizing protons. Previous 
mechanistic studies indicate that the protonated basic residues form strong hydrogen 
bonding interactions with the phosphate group.16 This consequently lowers the energy 
barrier for charge-directed mechanisms that lead to preferential neutral loss of phosphate 
and suppression of sequence-informative fragmentation upon collisional activation, thus 
further exacerbating the phosphate loss problem prevalent for MS/MS analysis of 
phosphopeptides.16 An illustrative example of this phenomenon is shown in the CID 
product ion spectrum of doubly charged KKALRRQEpTVDAL (Figure 7.1). The 
uninformative loss of H3PO4 from the precursor accounts for approximately 80% of the 
total product ion signal, while the remaining 20% arises from the b82+ through b122+ ions 
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split between their phosphate retained and neutral loss forms. All diagnostic product ions 
contain the N-terminus, which is consistent with proton sequestration at basic arginine 
(R) or lysine (K) side-chains that occur near the N-terminal region of the peptide. As 
underscored by this example, the impediments associated with charge-immobilization 
make this a compelling gas-phase environment in which to probe the effects of FBDSA 
incorporation on phosphopeptide fragmentation.   
 
 
Figure 7.1 CID product ion spectrum of the 2+ charge state of 
KKALRRQEpTVDAL. Neutral loss of phosphate is indicated by “-P” in 
the product ion label. 
 
7.4.1 Dual Spray Reactor-Initiated Schiff Base Bioconjugation of Phosphopeptides 
The formation of long-lived phosphopeptide/FBDSA complexes was 
accomplished in real-time using a front-end dual spray reactor as previously described.39 
Briefly, the reactor utilized two oppositely biased ESI sources to simultaneously generate 
overlapping populations of phosphopeptide cations and FBDSA anions in the high 
pressure region prior to the inlet of the mass spectrometer. The anionic reagent of 
interest, FBDSA, is negatively charged and thus has the potential to cause neutralization 
of peptides during formation of ion-ion complexes. To ensure successful detection of 
400 600 800 1000 1200 1400 1600 1800
m/z
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
b12
2+
b11
2+
b12
2+-P
b10
2+
b9
2+
b8
2+
[M+2H-NH3]
2+
[M+2H-P]2+
b11
2+-P
b9
2+-P
K K A L R R Q E pT V D A L2+ 
 169 
ion/ion complexes in the positive mode, the phosphopeptide substrates each contained at 
least two positive charge-bearing residues (i.e., arginine or lysine). This process is 
demonstrated in Figure 7.2, which compares the MS1 spectrum of 
KKALRRQEpTVDAL before (Figure 7.2a) and after (Figure 7.2b) interaction with 
FBDSA anions. Two highly abundant ions consistent with the 1+ and 2+ charge states of 
the charge-reduced KKALRRQEpTVDAL/FBDSA complex (denoted by the addition of 
“∆” in the label) are observed exclusively in the post-reaction spectrum at m/z 1874 and 
937, respectively. Together the complexed species account for approximately 60% of the 
total analyte signal, thus demonstrating high ion/ion reaction efficiency in the region of 
overlap between the dual sprays prior to transmission into the mass spectrometer. These 
results suggest that the presence of phosphorylated side-chains do not have a prohibitive 
effect on FBDSA binding despite possible competition with the phosphate moiety to form 
stabilizing noncovalent interactions with the protonated basic sites of the peptide.16,44 
 Once formed, ion/ion complexes were isolated in the linear ion trap and subjected 
to low energy CID to initiate covalent conversion to products, as demonstrated for the 
doubly charged complex of KKALRRQEpTVDAL/FBDSA (Figure 7.2c). Unlike 
collisional activation of the unreacted phosphopeptide, which is dominated by phosphate 
neutral loss (Figure 7.1), the most energetically favored pathway of the electrostatic 
complex results in dehydration with complete retention of the phosphate group and 
formation of the covalent Schiff base product. This is reflected by the single product ion 
observed in the MS2 spectrum which is 18 Da lower in mass from the precursor (Figure 
S2c), which is consistent with dehydration that occurs upon imine bond formation. The 
Schiff base product is confirmed via an additional collisional activation step (MS3) 
(Figure 7.2d). Collectively, these results demonstrate the ability to covalently modify 
phosphopeptides in the gas-phase while preserving the integrity of the labile phosphosite.   
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Figure 7.2 Process for online modification of phosphopeptides with FBDSA using a 
dual spray reactor. ESI spectra for (a) unreacted and (b) dual source 
reacted KKALRRQEpTVDAL. Charge-reduced electrostatic complexes 
are formed at atmospheric pressure between multiply charges 
phosphopeptide cations and FBDSA reagent anions (denoted by the “∆” 
subscript), and transferred and mass analyzed in the linear ion trap. (c) 
Low-energy collisional activation of these ion/ion intermediates promotes 
concomitant imine bond formation and dehydration to form a covalent 
Schiff base product (♦). (d) CID of the resulting Schiff base 
phosphopeptide results in sequence-informative fragmentation.   
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7.4.2 CID of Unmodified versus FBDSA-Modified Phosphopeptides 
As described above and shown in Figure 7.1, the product ion spectrum of doubly 
charged KKALRRQEpTVDAL illustrates the poor performance of CID under proton 
immobilized conditions; however, a marked improvement in fragmentation is observed 
following derivatization with FBDSA (Figure 7.2d). This is reflected in part by a 65% 
decrease in product ion signal comprised of non-sequence phosphate neutral loss from the 
precursor. Suppression of this preferential cleavage is accompanied by a concomitant 
gain in both the number and relative abundance of diagnostic fragment ions, resulting in 
an increase in sequence coverage from 42% to 92%. A small subset of product ions 
containing the phosphothreonine residue exhibit phosphate loss; however, in each case 
the relative abundance of these ions is lower than that of their corresponding phosphate-
retaining forms. Furthermore, the emergence of y-ions and singly charged b
♦
-ions is 
consistent with greater proton mobility across the peptide backbone. 
This dramatic change in fragmentation behavior upon incorporation of FBDSA is 
proposed to arise from the disruption and displacement of hydrogen bonding interactions 
between the phosphate group and basic sites of the peptide that lead to selective 
phosphate cleavage by CID. This hypothesis is supported by the lower pKa of sulfonate 
moieties in FBDSA relative to the phosphate group,44 as well as previous reports 
describing the gas-phase stability of acid-base interactions between sulfonate moieties 
and basic side-chains of peptides.43,45 Consequently, the strength of these interactions, and 
by effect the degree of change in subsequent fragmentation, should exhibit a dependence 
on the gas-phase basicity of the interacting side-chains. To explore this further, the 
relative change in fragmentation following FBDSA derivatization was evaluated for the 
arginine-containing peptide, RRLIEDAEpYAARG-NH2, and the lysine-containing 
peptide, GGGPApTPKKAKKL. 
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A comparison of the CID product ion spectra for the 2+ charge state of 
RRLIEDAEpYAARG-NH2 before and after gas-phase derivatization is shown in Figure 
7.3. Collisional activation of the underivatized peptide promotes dominant neutral loss of 
phosphate and ammonia with limited product ion signal arising from cleavage at six of 
the twelve amide bonds of the peptide backbone (Figure 7.3a). Resulting low abundance 
sequence ions are derived from both termini of the peptide and in all cases are singly 
charged, which indicates protonation of both the N- and C-terminally located arginine 
residues. This distribution is likely more energetically favorable than protonation of the 
two adjacent N-terminal arginines due to coulombic repulsion of side-chains. Despite low 
overall abundance, the b6 and y7 ions originating from cleavage C-terminal to the aspartic 
acid residue are more abundant than the other b/y fragment ions, an outcome consistent 
with the aspartic acid effect commonly observed under conditions of low proton 
mobility.46,47 As demonstrated in Figure 7.3b, conversion of peptide 
RRLIEDAEpYAARG-NH2 to its Schiff base analogue profoundly alters its 
fragmentation. The resulting CID spectrum shows complete suppression of selective 
phosphate cleavage and instead displays extensive pairwise fragmentation across the 
peptide backbone, resulting in 92% coverage of the b-ion series and 75% coverage of the 
y-ion series. Moreover, the collective lack of evidence for charge-directed loss of 
phosphate or enhanced cleavage C-terminal to aspartic acid is highly indicative of greater 
proton mobility following FBDSA derivatization. 
The effect of FBDSA incorporation on the fragmentation of 
GGGPApTPKKAKKL is expected to be less pronounced than that of 
RRLIEDAEpYAARG-NH2 owing to the lower gas-phase basicity of lysine side-chains 
relative to arginine and thus resultant weaker acid-basic interactions with FBDSA. The 
CID spectra of the underivatized and FBDSA-modified peptide are shown in Figure 7.4.  
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Figure 7.3 CID product ion mass spectra of RRLIEDAEpYAARG-NH2 (2+) before 
and after Schiff base modification: (a) MS2 CID mass spectrum of 
unlabeled peptide and (b) MS3 CID mass spectrum following online dual 
spray reactor-initiated derivatization. The addition of “♦” to the label 
indicates covalent FBDSA Schiff base modification and “-P” indicates 
loss of phosphate. 
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Figure 7.4 CID product ion mass spectra of GGGPApTPKKAKKL (2+) before and 
after Schiff base modification: (a) MS2 CID mass spectrum of unlabeled 
peptide and (b) MS3 CID mass spectrum following online dual spray 
reactor-initiated derivatization. The addition of “♦” to the label indicates 
covalent FBDSA Schiff base modification and “-P” indicates loss of 
phosphate. Ions shown in blue arise from lysine modification, while those 
shown in black may arise from either lysine or N-terminally labeled 
species. 
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The magnitude of the overall change in MS/MS patterns before and after derivatization 
generally agrees with this expectation about the impact of the basic side-chains. Notably, 
the dominance of phosphate neutral loss from the precursor suggests the unimpeded 
formation of hydrogen bonding interactions that facilitate charge-directed phosphate 
cleavage pathways. Differences also arise due to the fact that the ε-amino group of the 
lysine side-chain serves as a substrate for covalent FBDSA attachment. As a result, the 
location of the addition of the benzene disulfonic acid group is distributed across multiple 
reactive sites. This is reflected in the greater spectral complexity of the CID 
fragmentation spectrum of FBDSA-labeled GGGPApTPKKAKKL 2+, which exhibits 
contributions of product ions arising from various modified forms of the peptide 
(isomers) (Figure 7.4b). Despite these differences, enhanced fragmentation is still 
observed for the FBDSA modified peptide as demonstrated by more complete coverage 
of the peptide backbone. Additionally, the enhanced formation of the y7 ion 
corresponding to N-terminal to proline cleavage is consistent with greater proton mobility 
following incorporation of FBDSA.47,48 
The percent reduction in phosphate neutral loss from the precursor before and 
after derivatization provides a useful metric by which to evaluate the successful 
suppression of charge-directed mechanisms that facilitate selective phosphate cleavage. 
This data is summarized in Figure 7.5 for four representative singly and doubly charged 
phosphopeptide/FBDSA complexes generated by front-end ion/ion reactions and 
subsequently converted to their Schiff base modified forms. Substantial improvements in 
phosphate retention were observed in all cases following FBDSA incorporation; 
however, this effect was most pronounced for doubly protonated arginine-containing 
peptides for which the uninformative phosphate-loss pathways plummeted. This result 
further supports the hypothesis that the strength of the interaction between the sulfonate 
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groups of FBDSA and the basic-side chains of the peptide has a direct impact on the 
observed change in fragmentation of FBDSA-labeled phosphopeptides.  
 
 
 
Figure 7.5 Percent of total product ion abundance arising from neutral loss of 
phosphate from the precursor ion of unmodified and Schiff based-labeled 
phosphopeptides subjected to CID. 
 
 
7.4.3 Exploring the Role of the Sulfonate Moiety 
In an effort to gain greater insight into the mechanistic role of the sulfonate 
moiety during collision-induced dissociation, the fragmentation behavior of unmodified 
and FBDSA-derivatized RRLIEDAEpYAARG-NH2 and RQpSVELHSPQSLPR was 
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compared to that of their carbamylated and SPITC-modified analogues prepared in 
solution. Carbamylation converts primary amines of peptides (in this case the N-terminal 
amine) to less basic carbamate functionalities that are not expected to interact strongly 
with the basic side-chains of the peptide, thus serving as an experimental control for N-
terminal modification (Figure 7.6b). Alternatively, the SPITC reagent introduces a 
mono-sulfonated phenyl group at the N-terminus of the peptide that more closely 
resembles FBDSA (Figure 7.6a), albeit appended via a rather different pathway (Figure 
7.6c). As demonstrated in Figure 7.7, both reactions are very efficient, and the charge 
state distributions of the resulting peptides are shifted to lower values (i.e. enhancement 
of 2+, diminishment of 3+) relative to the unmodified peptide, consistent with removal of 
the N-terminal protonation site. As expected, this shift is greatest for the SPITC-modified 
peptide due to the fixed negative charge of the sulfonate moiety. 
Energy variable collisional activated dissociation was carried out on the doubly 
charged precursors for all forms of two representative phosphopeptides, 
RRLIEDAEpYAARG-NH2 (Figure 7.8a) and RQpSVELHSPQSLPR (Figure 7.8b), to 
evaluate their dissociation thresholds, one measure of stability in the gas phase. In both 
cases, the survival curves for precursors arising from sulfonate-bearing peptides exhibit a 
shift toward lower collisional energies relative to unmodified precursors, whereas the 
carbamylated species show nearly perfect overlap with the dissociation curves of the 
unmodified peptides. Such variations in fragmentation efficiency curves as a function of 
collision energy have been purported to reflect the degree of charge sequestration, 
essentially indicating the energy required for proton mobilization.47 As such, the 
fragmentation efficiency curves in Figure 7.8 suggest greater stabilization of the 
unmodified and carbamylated peptides (lower proton mobility) relative to the sulfonate-
bearing peptides. The trends observed from the energy-variable CID curves correlate 
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closely with the resulting fragmentation patterns; the unmodified (Figure 7.8c) and 
carbamylated (Figure 7.8d) peptides exhibit extensive phosphate loss, in contrast to 
enhanced backbone cleavages and production of ample diagnostic sequence ions with 
phosphate retention for the FBDSA-modified peptides (Figure 7.8e). The relative 
abundances of informative sequence ion were similarly enhanced relative to preferential 
phosphate loss ions for the SPITC-derivatized peptides; however, selective cleavage of 
sulfanilic acid from the SPITC label via cleavage of the labile C-N bond of the 
thiocarbamoyl group biased the resulting fragmentation pattern (Figure 7.9).  
 
 
 
Figure 7.6 Reaction scheme for N-terminal (a) Schiff base derivatization with 
FBDSA, (b) carbamylation, and (c) 4-sulfophenyl isothiocyanate (SPITC) 
derivatization of a peptide. 
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Figure 7.7 MS1 spectra of RQpSVELHSPQSLPR prior to (a) and after (b) 
carbamylation, (c) SPITC derivatization, and (d) ion/ion reaction with 
FBDSA.       
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Figure 7.8 Variable energy CID analysis of unmodified and N-terminally 
carbamylated, SPITC- and FBDSA-modified (a) RRLIEDAEpYAARG-
NH2 (2+) and (b) RQpSVELHSPQSLPR (2+). Normalized precursor 
abundances are plotted as a function of increasing collision energy. The 
CID product ion spectra are shown for RQpSVELHSPQSLPR (2+) in the 
following states: (c) unmodified, (d) carbamylated (*), and (e) FBDSA 
Schiff base modified (♦). The addition of “-P” to the label indicates loss of 
phosphate. 
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Figure 7.9 CID product ion spectrum of SPITC modified RQpSVELHSPQSLPR 2+. 
The abundant product ion a m/z 878 corresponds to sulfanilic acid 
cleavage from the SPITC tag. A modified b1 ion results from the Edmund 
degradation process shown in the inset. 
 
Based on the empirical observations made herein, two competing routes for the 
collision-induced dissociation of FBDSA-derivatized phosphopeptides are proposed as 
variations of the charge-directed SN2 reaction pathway previously described by Reid and 
co-workers (Figure 7.10a).16 The first pathway gives rise to preferential acid-base 
interactions between a sulfonate moiety of FBDSA and a protonated basic side-chain in 
the peptide allowing enhanced formation of sequence-informative product ions (Figure 
7.10b). However, these acid-base interactions compete with hydrogen-bonding between 
the phosphate group and basic side-chains that facilitate selective phosphate neutral loss 
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(Figure 7.10c). Our preliminary results point to the gas-phase basicity of the side-chains 
as a primary determinant of the dominant dissociation pathway following FBDSA 
incorporation. 
 
 
 
Figure 7.10 (a) Proposed mechanism for charge-directed neutral loss of phosphate for 
an unmodified phosphopeptide. Proposed competing dissociation 
pathways for FBDSA-labeled phosphopeptides with (b) and without (c) 
sulfonate-modulated suppression of charge-directed neutral loss of 
phosphate. 
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7.5 CONCLUSIONS 
This work represents the first demonstration of ion/ion-mediated bioconjugation 
of peptides bearing one of the most common types of post-translational modifications, 
phosphorylation, in the gas-phase. Electrostatic phosphopeptide/FBDSA complexes were 
shown to undergo facile collision-induced conversion to covalent products with complete 
preservation of phosphosite integrity. The resulting FBDSA-derivatized phosphopeptides 
exhibited suppressed phosphate elimination that is the dominant process of conventional 
protonated phosphopeptides along with concomitant enhancement in the formation of 
sequence-informative product ions. The sulfonate moieties introduced upon FBDSA-
incorporation are critical to this observed change in fragmentation behavior, as validated 
through comparative fragmentation analysis with other charge-site mediating 
modifications (i.e. carbamylation and thiocarbamoylation). Our results provide additional 
experimental evidence for charge-directed neighboring group participation reactions 
involved in phosphate neutral loss,16 which appear to be disrupted by competing 
hydrogen-bonding interactions between sulfonate groups and the side-chains of basic 
residues. This was further supported by the relative change in phosphate neutral loss 
observed depending on the gas-phase basicity of the side-chains present, with the greatest 
changes observed for FBDSA-labeled phosphopeptides containing arginine residues. This 
suggests that the relative strengths of the hydrogen-bonding interactions play an 
important role in subsequent fragmentation of the peptides upon CID.   
The use of a front-end dual spray reactor to facilitate the ion/ion reaction step 
allows this method to be widely adaptable to nearly all mass spectrometer platforms, 
making it a viable option for phosphopeptide analysis when conventional CID-based 
characterization yields ambiguous sequence and phosphosite information. Moreover, 
previous demonstrations of reactor compatibility with high-throughput chromatographic 
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workflows39 hint at the potential utility of dual source integration into phosphoproteomic 
analysis.  
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Chapter 8 
Conclusions 
 
8.1 SUMMARY OF CHAPTERS 
Tremendous advances in instrumentation and ion activation methods have 
established mass spectrometry as an essential analytical tool for the structural 
characterization of therapeutic antibodies, and have led to its increasing role in new 
frontiers related to vaccine development and antibody-based biomarker and drug 
discovery. Nevertheless, there remain opportunities for extending the versatility of 
tandem mass spectrometric approaches that are anticipated to have important 
biotechnological implications, both with respect to elevating quality control standards 
and as a means to more effectively evaluated antibody-mediated immunity and leverage 
its therapeutic potential. The work presented in this dissertation sought to advance mass 
spectrometry-based antibody analysis using several variations of ultraviolet 
photodissociation (UVPD) to either enhance selectivity for regions of diagnostic value in 
the context of IgG mixtures or to facilitate more detailed structural characterization in the 
interest of improving quality control. 
Using site-specific derivatization, strategic proteolysis, and chromophore-
mediated 351 nm UVPD, as described in Chapter 3, a method was developed to 
streamline the identification of unique antibodies in mixtures by enhancing selectivity for 
their diagnostic antigen-binding CDR-H3 regions. As demonstrate in the amino acid 
frequency plot shown in Figure 8.1, the highly conserve cysteine residue adjacent to the 
heavy chain CDR-H3 serves as an ideal analytical target for site-directed tagging with 
thiol-selective AlexaFluor 350 maleimide. Tailoring enzymatic digestion to include the 
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modified cysteine residue and adjacent CDR-H3 region allowed facile discrimination of 
these peptides within a high-throughput 351 nm UVPD workflow. 
 
 
Figure 8.1 Sequence logo demonstrating the amino acid frequencies at the C-terminal 
portion of framework 3 and the N-terminal region of CDR-H3 of the IgG 
heavy chain based on IMGT reference genes (www.imgt.org).  
 
Lys-C proteolysis combined with 193 nm UVPD was utilized in Chapter 4 to 
enhance the characterization of monoclonal antibodies. While restricted digestion with 
Lys-C effectively reduced sample complexity to facilitate more efficient sampling of the 
resulting IgG peptide population, the greatest merit of this method resulted from the 
generation of peptides spanning the entire length of the CDR-H3 region. The sequencing 
power of 193 nm UVPD was then exploited to comprehensively characterize these 
diagnostic peptides, often yielding 100% coverage of the CDR-H3 sequence and 
affording more confident peptide spectral matching compared to collision- and electron-
based methods. As a simple, but informative test to evaluate the potential utility of this 
strategy for proteomic analysis of antibody mixtures, a sample containing several 
unknown anti-influenza monoclonal antibodies discovered in the serum repertoire of a 
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post-vaccinated donor was subjected to Lys-C digestion and analyzed by middle-down 
193 nm UVPD. The resulting MS/MS data was searched against a database constructed 
by next-generation sequencing of V-genes from donor B cells. The searches resulted in 
unambiguous antibody identification. 
 The utility of 193 nm UVPD for the characterization of antibody subunits was 
demonstrated in Chapter 5. The tunable nature of energy deposition by UVPD afforded a 
degree of control over which regions of the subunit sequence could be interrogated in 
great detail, which is not generally observed for more conventional activation methods. 
Moreover, UVPD yielded up to 60% coverage of the IgG sequence within a single 
targeted LC-MS/MS run while also maintaining the integrity of the labile N-linked 
glycosylation site. Collectively, this allowed confident glycosylation site localization in 
the Fc/2 heavy chain constant domain and confirmation of the antigen-binding CDR 
sequences in the variable portions of the Lc and Fd subunits. 
A frontend dual spray reactor was developed and implemented in Chapter 6 for 
the high-throughput bioconjugation of peptides. While not employed directly for the 
analysis of antibodies, this method affords a rapid and universal means for enhancing 
primary sequence characterization of peptides when paired with 193 nm UVPD and was 
shown to be readily implemented into an automated LC-MSn workflow. 
The dual source method was further extended in Chapter 7 for the improved 
characterization of phosphopeptides. Gas-phase derivatization of phosphopeptides with 
4-formyl-1,3-benzenedisulfonic acid (FBDSA) resulted in suppressed phosphate 
elimination during collisional activation in addition to a concomitant enhancement in 
sequence-informative product ion formation. Further interrogation of this change in 
dissociation behavior following derivatization revealed the critical role of sulfonate 
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interference with charge-directed phosphate neutral loss mechanisms that typically 
govern the fragmentation of phosphopeptides.     
 
8.2 FUTURE DIRECTIONS 
Perhaps the most intriguing implications of the methods developed in this 
dissertation arise from the potential merits of adapting UVPD-based strategies to advance 
proteomic analysis of serological antibody repertoires. While the scope of the initial 
evaluations described in Chapters 3 and 4 were limited to low-complexity samples, they 
provide compelling evidence for the utility of UVPD for differentiating clonally unique 
antibodies in complex mixtures.   
Owing to the fast and extensive fragmentation afforded by 193 nm UVPD, as well 
as the ability to generate full length CDR-H3 peptides using restricted Lys-C digestion 
that are readily adaptable to front-end separations, the middle-down approach described 
in Chapter 4 likely holds the greatest potential for improving serum immunoproteomics. 
As a logical next step, this method should be evaluated for complex serum antibody 
repertoires in combination with Ig-seq V-gene database searching. Although this 
approach many not achieve the same sensitivity or depth as established bottom-up 
methods, it is anticipated to provide complementary antibody identifications of much 
higher confidence.  
To further improve this method and increase its sensitivity for CDR-H3 peptides, 
one can envision coupling restricted Lys-C digestion with thiol-selective enrichment prior 
to LC-MS/UVPD analysis as illustrated in Figure 8.2. This method would take advantage 
of the highly conserved cysteine residue located N-terminal to the CDR-H3 region 
(Figure 8.1) in a similar manner to the selective tagging strategy described in Chapter 3. 
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Selective pull-downs on thiol capture resins should dramatically reduce sample 
complexity while also increasing the relative abundance of Lys-C CDR-H3 peptides for 
improved detection.   
 
 
 
 
Figure 8.2 Proposed selective enrichment workflow for Lys-C generated CDR-H3 
peptides.   
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